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Abstract 
Osteoarthritis (OA) is a degenerative disease of synovial joints with an 
inflammatory component, which affects humans and companion animals, including 
horses. Current pharmacotherapy for OA is associated with deleterious side effects. 
Therefore, plant-derived products with anti-inflammatory properties may provide 
safer natural alternatives. The project aimed to use in vitro models of equine 
cartilage to test the hypothesis that plant-derived extracts would reduce inflammation 
and degradation in an explant model of early OA. 
The anti-inflammatory polyphenol, curcumin, significantly reduced 
interleukin-l beta (lL-l (3)-stimulated glycosaminoglycan, matrix metalloproteinase-3 
and prostaglandin E2 release in the explant model. Using a cocktail of plant extracts 
illustrated how different effects were observed depending on the solvent used to 
dissolve the raw material. Chondrocyte monolayers were used to determine that 
counteraction of IL-l f3-stimulated effects in the explant model occurred at non-
cytotoxic concentrations. 
The explant model was adapted for proteomic studies of the cartilage 
secretome. Several proteins involved in matrix function and degradation were 
identified. This adaptation may further our understanding of the processes in the 
early OA explant model and may facilitate studying the effects of anti-inflammatory 
compounds on the secretome. 
A concurrent field trial showed that the plant extract cocktail did not 
significantly improve mobility in horses with chronic hindlimb stiffuess. However, it 
illustrated the need for practical, more objective markers to help select animals of 
similar disease status and determine effects in the joints. Therefore, the proteomic 
study highlighted the potential for in vitro models to support field trials by 
identifying in vivo biomarkers for diagnosing early OA and assessing therapeutic 
responses. 
In conclusion, in vitro models of equine cartilage have considerable potential 
for assessing the ability of plant extracts to target inflammatory pathways and 
catabolic mediators in OA. The data presented suggests that nutritional intervention 
using plant-derived extracts with putative anti-inflammatory properties may support 
equine joint health. 
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CHAPTER 1. INTRODUCTION 
Osteoarthritis (OA) is a disease of the articulating joint, associated with degeneration 
of the articular cartilage and pathological changes in the surrounding tissues (Brandt 
et al., 2006). It has considerable welfare and economic consequences for both 
human and companion animals through increased pain, lack of mobility, reduced 
athletic performance and the cost of medical therapy. This chapter will introduce the 
main anatomical structures involved in OA, the pathology of the disease referring to 
literature from a variety of species including the horse, current medicinal therapy and 
alternative nutraceutical therapies. Current in vivo and in vitro models of OA will 
then be discussed before the aims of the thesis are stated. 
1.1. Articular Cartilage 
In the healthy vertebrate, articular cartilage covers the ends of the long bones of 
synovial joints. It is a mechanically resilient connective tissue that enables smooth 
articulation and load bearing whilst protecting the underlying bone during movement 
(Kuettner, 1992). Articular cartilage is an avascular, aneural and alymphatic tissue 
mainly consisting of a tough extracellular matrix (ECM). Chondrocytes are the sole 
cell type present in the articular cartilage and are interspersed within the matrix 
(figure 1) forming between 1-10% of total tissue volume, depending on joint location 
and species (Stockwell, 1971; Carney and Muir, 1988; Hunziker et al., 2002). 
Figure 1. Haemotoxylin and eosin stained cross section of healthy equine 
articular cartilage 
Cartilage taken from the left metacarpophalangeal joint of a young pony for this 
thesis. A. Photograph of a cross section of articular cartilage showing chondrocytes 
embedded within the lacunae of the matrix x200. B. represents a higher 
magnification (x400) of the box in A. 
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The ECM of articular cartilage is composed of collagens, predominantly collagen 
type II, which strengthen the matrix and restrain the osmotic swelling pressure 
caused by the hydrophilic aggregating proteoglycans (aggrecan), thereby giving 
cartilage viscoelasticity and allowing it to withstand compressive force (Kuettner, 
1992; Li et al., 2005). This ability to hydrate and resist compressive force is aided 
by sulphated glycosaminoglycans (GAGs), such as chondroitin sulphate and to a 
lesser extent keratan sulphate. Sulphated GAGs, together with non-sulphated GAGs 
such as hyaluronan, attach to their specific domains on the aggrecan molecule to 
form the aggregates (Watanabe et al., 1998). See figure 2 for a representative 
diagram of the synovial joint and the structures within the cartilage. 
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Figure 2. Structure of the synovial joint and the articular cartilage 
Diagram highlights the main components of the articular cartilage extracellullar 
matrix; type 11 collagen and aggregating proteog/ycans. Enlarged box identifies the 
individual components that make proteoglycans. Reproduced from Goggs ef al. 
(2005) with permission of the authors. 
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In addition to the aggregating proteoglycans, the ECM also contains small non-
aggregating proteoglycans known as small leucine-rich repeat proteoglycans 
(SLRPs). The SLRPs include decorin, biglycan, fibromodulin and lumican. Their 
core proteins allow for interaction with various collagen and growth factors in the 
ECM. Consequently, they are involved in regulating fibrillar collagen formation 
(F ont et al., 1998), strengthening the linkage of collagen to other cartilage 
macromolecules (Wiberg et al., 2003), limiting access of proteolytic enzymes to the 
cleavage site on the collagen molecule (Sztrolovics et al., 1999; Geng et al., 2006) 
and modulating chondrocyte metabolism via regulating growth factor availability 
(Hildebrand et al., 1994). Within the ECM, there are also glycoproteins which bind 
the structure together and participate in cell-matrix and/or matrix-matrix interactions, 
such as link protein, fibronectin and cartilage oligomeric matrix protein (COMP) 
(Hardingham, 1979; Rosenberg et ai., 1998; Roughley, 2001; Di Cesare et ai., 2002). 
As cartilage ages, the composition and structure of the ECM components change. In 
humans and dogs ageing is thought to decrease the swelling capacity of cartilage 
through a reduction in proteoglycan size, as well as losing the ability to withstand 
and recover from compression through increased levels of keratan sulphate and 
hyaluronan and loss of chondroitin sulphate (Bayliss and Ali, 1978; Inerot et al., 
1978). With respect to equine cartilage, it is thought that the foal is born with 
biochemically uniform articular cartilage which adapts to weight bearing during the 
first months postpartum by decreasing water, DNA and GAG content and increasing 
collagen content (Brama et al., 2000b). This collagen network remains stable as the 
horse ages, although non-enzymatic glycation increases (Brama et al., 1999). 
Increased non-enzymatic glycation results in the production of advanced glycation 
end products (AGE) in the collagen which is known to increase collagen stiffness 
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(Verzijl et al., 2002). In addition, the changes in the proteoglycan size seen in canine 
and human cartilage also occurs (Platt et al., 1998). Thus, as cartilage ages, it 
becomes more brittle and less elastic. 
Chondrocyte interactions with the ECM are mediated by the presence of 
transmembrane-receptors and proteoglycans, namely integrins and NG2 on their 
primary cilia which are involved in the signalling processes required for ECM 
synthesis and maintenance (McGlashan et al., 2006). Consequently, normal cartilage 
matrix turnover is governed by the chondrocytes, the rate of which is determined by 
various stimuli. For example, growth factors such as insulin-like growth factor 
(IGF)-II can stimulate deoxyribonucleic acid (DNA) and GAG synthesis in adult 
equine cartilage in vitro via their mitogenic effects on the chondrocytes (Henson et 
al., 1997; Davenport-Goodall et al., 2004). In contrast, cytokines such as 
interleukin-l beta ( I L - l ~ ) ) can contribute to cartilage degeneration by decreasing 
GAG synthesis by the chondrocytes (lkebe et al., 1986). Growth factors and 
cytokines can regulate each other to maintain the homeostasis of ECM turnover. For 
example, IL-l ~ ~ can increase IGF-I secretion and IGF-l receptor production 
(Matsumoto et al., 1994), thereby promoting cartilage anabolism. IGF-I can also up-
regulate the production of IL-l receptor (lL-1 R)-II, which acts as a decoy receptor 
for IL-Ialpha (IL-In) and I L - l ~ ~ (Wang et al., 2003), to regulate IL-I-mediated 
catabolism. However, IL-l ~ ~ can also increase IGF-l binding protein (IGFBP)-3 
which modulates IGF-l activity (Olney et al., 1995). Thus, the cytokines and growth 
factors regulate each other to govern cartilage turnover. 
Various intracellular and extracellular proteinases are thought to facilitate cartilage 
depletion, notably the matrix metalloproteinases (MMPs) which degrade ECM 
proteins such as collagen, and the ADAMTSs (A Disintegrin and MetaIIoproteinase 
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with ThromboSpondin motifs) which primarily degrade aggrecan (Cawston et aI., 
1999). The MMPs identified to date are grouped according to their substrate 
specificity, e.g. the collagenases MMP-l, MMP-8, MMP- 13 and MMP-18, which 
degrade collagen. However, these substrate targets often overlap meaning that 
together they can degrade a variety of ECM proteins (Stemlicht and Werb, 2001). 
This substrate diversity is illustrated in figure 3 
ICOLLAGENASES 
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Figure 3. Schematic illustration of the substrate diversity of groups of known 
matrix metalloproteinases (MMPs) 
The brown structure represents an extracellular matrix (ECM) containing a selection 
of labelled components which form the substrates for many MMP groups as 
highlighted by the arrows (Clutterbuck et aI. , 2010). 
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Similarly, ADAMTS enzymes are grouped according to their main substrates. For 
example, the hyalectanases: ADAMTS-l, ADAMTS-4, ADAMTS-5, ADAMTS-8, 
ADAMTS-9, ADAMTS-15 and ADAMTS-20 that cleave the hyalectan (hyaluronan-
binding proteoglycan) aggrecan, and the procollagen N-propeptidases: ADAMTS-2, 
ADAMTS-3 and ADAMTS-14, that cleave the amino peptides of type I, type II and 
type III procollagens (Jones and Riley, 2005). ADAMTS-7 and ADAMTS-12 
specifically associate with and degrade COMP (Liu et al., 2006a; Liu et al., 2006b). 
Although several ADAMTS enzymes can degrade aggrecan, it is also degraded by a 
variety of MMPs including MMP-l, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, 
MMP-I0, MMP-13 and membrane type (MT)-MMPI (Fosang et al., 1991a; Fosang 
et al., 1992; Fosang et al., 1994; Fosang et al., 1996; Fosang et al., 1998). Similarly, 
some ADAMTSs also degrade ECM substrates other than aggrecan, such as biglycan 
and COMP (Dickinson et al., 2003; Melching et al., 2006). 
The chondrocytes also synthesise the endogenous inhibitors of these proteases, the 
tissue inhibitors ofmetalloproteinases (TIMPs). TIMPs exist in dynamic equilibrium 
with MMPs to allow for natural processes such as growth and remodelling (Joronen 
et al., 2000), thereby maintaining the homeostasis of the articular cartilage ECM. 
Cartilage homeostasis is altered with age and exercise. Transforming growth factor-
~ ~ ( T G F - ~ ) ) messenger ribonucleic acid (mRNA) production by the articular 
chondrocytes of immature foals increases until around seven months to one year old, 
when expression declines concomitantly with a decreased responsiveness of the 
chondrocytes to T G F - ~ ~ and reduced proteoglycan synthesis (Iqbal et al., 2000; 
Nixon et al., 2000). Thus, although the anabolic ability of the chondrocytes 
increases as the horse develops, once maturity is reached, this capacity is slowly 
reduced. 
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In young horses, regular low impact exercise, such as that achieved by foals kept out 
on pasture, is necessary for normal joint development (van de Lest et a/., 2002). 
Low level exercise postpartum stimulates the chondrocytes to synthesise a 
heterogeneous ECM, providing a stable collagen framework for later life, when 
collagen turnover decreases (Brama et a/., 2000b). Strenuous exercise, however, is 
associated with lesion development in the articular cartilage and loosening of the 
collagen network in young Thoroughbred horses (Brama et a/., 2000a). A 24-month 
training programme of young Standardbred trotters showed that increasing exercise 
intensity increased collagen degradation and reduced COMP release due to reduced 
synthesis of matrix proteins (Skioldebrand et a/., 2006). Thus, excessive loading on 
joints along with ageing can cause disruption to the homeostasis of the ECM, by 
reducing the anabolic capacity of the chondrocytes and increasing catabolic mediator 
production. 
1.2. Osteoarthritis 
OA is a degenerative disease involving degradation of the articular cartilage along 
with osteophyte formation, thickening of the subchondral bone plate and 
inflammation of synovium (Martel-Pelletier, 2004). It is thought that all the joint 
components can contribute to the development of the disease, namely the articular 
cartilage, the synovium, and subchondral bone (Samuels et a/., 2008). In addition, 
the joint ligaments, peri-articular muscle and surrounding nerves can play 
contributory roles (Brandt et at., 2006). Figure 4 shows photographs of the structural 
differences between a healthy articular joint and those in various stages of disease 
progressIon. 
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Figure 4. Equine metacarpophalangeal joints in health and disease 
A is representative of a normal articular joint surface. The cartilage is 
macroscopically healthy, featuring smooth articular surfaces with even colouring 
and free of irregularities. The synovial fluid is pale and transparent and the 
synovium is not inflamed. B, C and D are examples of unhealthy cartilage. B shows 
a patchy and irregular articular surface. The hole in the cartilage highlights a 
subchondral bone cyst. C depicts wear lines on the articular surface. The dark area 
reveals an underlying subchondral bone cyst and the synovium is thickened. D 
shows severe OA, with catastrophic cartilage degeneration exposing the subchondral 
bone. The synovium is thickened and inflamed with thick yellow synovial fluid. 
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Unlike in normal cartilage where the chondrocytes are maintained in a pre-
hypertrophic state, OA chondrocytes lose their phenotype, becoming hypertrophic, 
expressing type X collagen and eventually undergoing apoptosis (programmed cell 
death) (Sandell and Aigner, 2001). Although OA chondrocytes have increased 
expression of both anabolic and catabolic matrix genes (Aigner et al., 2006), their 
catabolic ability outweighs their anabolic capacity, resulting in cartilage loss. This 
is attributed to zonal variation in matrix synthesis, with chondrocytes in the damaged 
upper zone of cartilage down-regulating matrix gene expression whilst those in the 
intact middle and deep zones show hyperactive matrix synthesis (Aigner and Dudhia, 
1997). Consequently, increased synthesis in some zones cannot compensate for 
reduced synthesis in other zones, which, coupled with increased catabolism, results 
in cartilage loss. Thus, as OA progresses from mild to severe, there is a decrease in 
genes coding for transcription of collagen, failure to maintain the proteoglycan 
matrix and reduced ability of the chondrocytes to regulate apoptosis. 
Osteoarthritic cartilage has been shown to have a higher proportion of apoptotic 
chondrocytes than normal cartilage (Blanco et al., 1998). These apoptotic 
chondrocytes are associated with decreased proteoglycan content in human cartilage 
(Hashimoto et al., 1998). Similarly, osteoarthritic equine articular cartilage has 
increasing numbers of apoptotic chondrocytes with higher histopathological 
degeneration scores as measured by both the terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick-end labelling (TUNEL) assay (Kim et al., 
2003) and active caspase-3 immunohistochemistry (Thomas et al., 2007). Caspases, 
notably caspase-3, are cysteine proteases involved in mediating nitric oxide (NO) 
induced chondrocyte apoptosis, being located in areas where progressive cartilage 
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degradation is occurring (Matsuo et al., 2001). Caspases are also involved in the 
activation of the proteolytic MMPs. 
Several proteolytic enzyme groups have been identified in OA cartilage, including 
collagenases, MMP-l, MMP-8 and MMP-13; gelatinases, MMP-2 and MMP-9; 
stromelysins, MMP-3, MMP-I0 and MMP-l1; membrane type MTI-MMP, and 
aggrecanases ADAMTS-4 and ADAMTS-5 (Goldring, 2000). The roles of 
ADAMTS-4 and ADAMTS-5 in OA are well established (Bayliss et al., 2001; 
Moulharat et al., 2004; Stanton et al., 2005) but there has been some debate as to 
which is of greater importance (Huang and Wu, 2008). However, a recent study 
using normal and OA equine joints has suggested that both aggrecanases are 
important but in different joint structures, with ADAMTS-4 being produced by the 
chondrocytes in the cartilage and ADAMTS-5 by the synoviocytes in the synovium 
in the presence of elevated TNF -a (Kamm et al., 2010). 
Although the ADAMTSs and MMPs are the main focus for OA-treatment, another 
member of the matrixin family to which these enzymes belong, ADAM (a disintegrin 
and metalloproteinase)-8, has been identified as a potential target. ADAM-8 cleaves 
fibronectin, generating fibronectin fragments (Zack et al., 2009), The proteolytic 
release of matrix protein fragments, such as fibronectin, can contribute to the 
pathogenesis of OA by up-regulating and activating MMPs (Homandberg and Hui, 
1996; Forsyth et al., 2002) and aggrecanases (Stanton et al., 2002), as well as 
suppressing proteoglycan synthesis (Xie et al., 1993). In addition to this, there is 
also less intact fibronectin, which is known to inhibit ADAMTS-4 activity 
(Hashimoto et al., 2004). The exacerbation of matrix destruction by fibronectin 
fragments is attributed to the activation of various signalling pathways, which 
amplify the inflammatory response via stimulating chondrocyte chemokine and 
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cytokine release (Pulai et al., 2005). Thus, inflammation plays a critical role in OA 
pathology. 
1.3. Inflammation and Osteoarthritis 
Although OA is defined as a non-inflammatory arthropathy, inflammation has a role 
in its pathogenesis (Hedbom and Hauselmann, 2002). Trauma to the components of 
the synovial joint, such as the synovium, articular cartilage and subchondral bone can 
initiate the production of many inflammatory and destructive mediators (figure 5). 
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Figure 5. Molecules and structures involved in osteoarthritis of the articular 
joint 
Pro-inflammatory cytokines interleukin-l beta (IL-lfJ) and tumour necrosis factor-
alpha (TNF-a) can arrive at the synovium from the circulation, or be produced by 
the synoviocytes, chondrocytes and subchondral bone tissue in response to trauma or 
inflammation. Production of reactive oxygen species (ROS), matrix 
metalloproteinases (MMPs) and prostaglandin E2 (PGE2) promotes inflammation 
and cartilage extracellular matrix (ECM) degradation. At the same time ECM 
synthesis by the chondrocytes is reduced, chondrocytes die by apoptosis and serine 
proteases aid the conversion of plasminogen to plasmin, which activates latent MMP 
(adaptedfrom Goodrich and Nixon (2006)) . 
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Therefore, it can be seen that inflammation and cartilage destruction are intricately 
linked, and that pro-inflammatory cytokines, prostaglandins, neuropeptides and 
reactive oxygen species (ROS) oxidation contribute to the development and 
progression of OA. 
1.3.i. Pro-inflammatory Cytokines 
A cytokine is a small protein released by cells that affects cellular interaction, 
communication and behaviour. Certain cytokines promote inflammation and as such 
they are termed pro-inflammatory cytokines (Dinarello, 2000). IL-l ~ ~ is a well-
documented pro-inflammatory cytokine that has been found in the synovial fluid of 
horses with clinical OA (Morris et al., 1990). IL-I ~ ~ is significantly up-regulated in 
normal cartilage obtained from joints with osteoarthritic lesions compared to 
cartilage from healthy joints (Weaver et al., 2006). This correlates with in vivo 
findings in the human field where IL-l ~ ~ and TNF -a are significantly up-regulated in 
the synovial fluid of patients with early OA (Benito et al., 2005). In vitro, the 
addition of pro-inflammatory cytokines such as IL-I ~ ~ and TNF -a to equine 
chondrocytes and synovial fibroblasts stimulates the expression of MMPs and 
cyclooxygenase (COX)-2 which promote inflammation through prostaglandin 
production (Richardson and Dodge, 2000; Tung et al., 2002). I L - l ~ ~ and TNF-a are 
commonly cited in the literature as being involved in cartilage degradation, however, 
there are many other cytokines which are thought to contribute to the progression of 
OA. For example, cytokines such as IL-17 synergise with other cytokines such as 
IL-I, TNF-a, oncostatin M (OSM) and IL-6 to cause collagen degradation (Koshy et 
al., 2002), as well as enhancing inflammation and destruction independently ofTNF-
a (Koenders et al., 2006). 
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Transcription factors are intricately involved in up-regulating cytokines as well as 
mediating their effects. TNF-a inhibits link protein and collagen type II gene 
expression in chondrocytes via the nuclear factor-KB (NF-KB) and MEK1/2 
pathways (Seguin and Bernier, 2003). I L - l ~ ~ also stimulates the NF-KB pathway as 
well as the activator protein-l (AP-l) pathway causing the down-regulation of 
collagen II and aggrecan expression and increased expression of MMPs (Martin et 
al., 2005). In fact NF-KB has been described as the link between inflammation and 
joint hyperplasia in arthritis (Miagkov et al., 1998). Thus, in an inflammatory state, 
cytokine activity can activate transcription factors, which can reduce cartilage 
synthesis as well as promoting cartilage degeneration by increasing MMP 
expression. In addition, chondrocytes cultured with I L - l ~ , , show increased apoptosis 
in comparison to controls (Heraud et al., 2000). Thus cytokines not only contribute 
to inflammation-associated cartilage degeneration, but they also reduce the reparative 
capacity of the chondrocytes by decreasing synthesis of appropriate matrix proteins 
and increasing cell death. 
1.3.ii. Prostaglandins 
Prostaglandins are eicosanoid lipid mediators that are involved in numerous 
homeostatic biological functions and inflammation (Funk, 2001). They are produced 
from the COX oxidation of arachidonic acid from cell membrane phospholipids 
(figure 6). 
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Figure 6. Prostaglandin synthesis pathway 
The release of arachidonic acid from membrane phospholipids and its conversion to 
prostaglandins occurs by a sequence of enzymatic reactions involving soluble (s) or 
cytoplasmic (c) phospholipase A2 (PLA JJ and cyclooxygenase (COX)-l or -2. Constitutive 
enzymes are shown in green, inducible enzymes are in red, red and green together show 
enzymes that are both constitutive and inducible and specific receptors are in blue. The 
resulting prostaglandin H2 (PGHJJ is converted by specific prostaglandin synthases into 
various prostaglandins. Prostaglandin h (PGIJJ is converted by PGI synthase (PGIS) and 
acts via the IP receptor. Prostaglandin D2 (PGDJJ is generated by hematopoietic and/or 
lipocaline PGD2 synthases (H-PGDS, L-PGDS) where it either reacts with the DP 1 or DP2 
receptor, or is dehydrated to form prostaglandin J2 (PGJJJ, which can be further converted 
to PGJ2 derivatives such as 15-deoxy-delta(12,14)PGJ2 (15-ilPGJJJ . Prostaglandin E2 
(PGEJJ is derived from PGE synthases (PGESs), either cytosolic (c)PGES, microsomal 
(m)PGES-1 , or mPGES-2. PGE2 can either interact with various EP receptors (1-4) or 
become dehydrated to form prostaglandin A2 (PGAJJ. Prostaglandin F2a (PGF2aJ is formed 
from PGF synthase (PGFS) and reacts with the FP receptor. Thromboxane A synthase 
(TxAS) converts PGH2 into thromboxane A2 (TxA JJ which interacts with the TP receptor 
(Stichtenoth et al. , 2001; Goldring and Berenbaum, 2004; Kojima et al., 2004; Sampey et 
al., 2005; Scher and Pillinger, 2005; Komoto et ai. , 2006; Maicas et al. , 2010). 
17 
The constitutively expressed COX-l isoform is involved in the production of 
thromboxane A2 (TxA2), prostaglandin h (PGh) and prostaglandin E2 (PGE2) in 
normal physiological processes, whereas the inducible COX-2 isoform releases 
proteases, prostaglandins and other inflammatory mediators in response to various 
stimuli, leading to further inflammation and pain (Steinmeyer, 2000). However, it is 
now known that both COX isoforms are involved in pathological and non-
pathological processes such as arthritis and ulcer healing (Iniguez et at., 1998; 
Brzozowski et at., 2001), which has changed the classical view of the COX-l being 
purely a housekeeping enzyme and COX-2 an inflammatory enzyme. 
PGE2 is the major eicosanoid involved in the pathogenesis of OA. It is found in 
increased levels in the synovial fluid from degenerative joints compared to normal 
joints in humans (Sahap Atik, 1990) and horses (Gibson et at., 1996). In vitro, PGE2 
is produced in significantly higher amounts by OA chondrocytes compared to normal 
chondrocytes, both alone and in response to IL-l ~ ~ stimulation (Jacques et at., 1999). 
In addition, synovial COX-2-derived PGE2 is associated with increased cartilage 
degradation in response to IL-l ~ - t r e a t e d d synovium and cartilage co-cultures (Hardy 
et at., 2002). PGE2 is thought to mediate this degradation via the EP4 receptor to 
increase MMP-13 and AOAMTS-5 levels (Attur et at., 2008). It also contributes to 
the inflammatory pain associated with OA via sensitising peripheral nerve endings 
(Schaible and Schmidt, 1988). Therefore, PGE2 contributes to both inflammatory 
processes and cartilage destruction in OA, as well as contributing to the pain 
associated with the disease. 
Other prostaglandins, such as prostaglandin 02 (PG02) are also found in OA 
cartilage, and are produced by chondrocytes in response to IL-l ~ ~ (Zayed et at., 
2008b). However, their presence can be associated with an anti-inflammatory/ anti-
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catabolic response. For example, PGD2 reduces MMP-l and MMP-13 production by 
IL-l ~ - s t i m u l a t e d d chondrocytes via the DP 1 receptor (Zayed et a/., 2008a). 15-
deoxy-Delta prostaglandin h ( l 5 - ~ P G h ) ) is derived from PGh which itself is a 
dehydration product of PGD2 (Scher and Pill inger, 2005). 1 5 - ~ P G h h has been 
shown to block IL-l ~ - i n d u c e d d COX-2 expression in human synovial fibroblasts 
(Farrajota et a/., 2005), thereby suggesting it is a prostaglandin with anti-
inflammatory and anti-degradative properties. 
I.3.m. Substance P and Derived Factors 
Substance P is a neuropeptide involved in the perception of pain (nociception) and 
inflammation. It is released from peripheral nerve endings in response to various 
inflammatory mediators such as prostacyclin and pro-inflammatory cytokines 
(Hingtgen and Vasko, 1994; Malcangio et a/., 1996). Substance P can also be 
released from inflammatory cells such as eosinophils and macrophages (Aliakbari et 
at., 1987; Bost et at., 1992). 
In addition, osteoarthritic synovial fibroblasts cultured in vitro have been shown to 
release substance P into the joint cavity in response to T G F - ~ ~ and basic fibroblast 
growth factor (bFGF) (Inoue et a/., 2001). Thereby suggesting that substance P can 
be released from a variety of sources into tissues where it contributes to the 
inflammatory process. 
Substance P causes local extravasation and vasodilation (Lembeck and Holzer, 
1979), as well as having a role in the chemo-attraction of neutrophils to the site of 
release (Perretti et at., 1993). In addition, substance P also potentiates the release of 
inflammatory mediators such as cytokines, oxygen (02) radicals and arachidonic acid 
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derivatives, thus amplifying the inflammatory response (Brain, 1997; O'Connor et 
al., 2004). 
Both substance P and PGE2 have been found in higher concentrations in the synovial 
fluid of osteoarthritic joints in horses classified as being lame for over one month, 
compared to normal joints in horses with no history of lameness (Kirker-Head et al., 
2000). From clinical assessments of lame horses correlating inflammatory mediators 
in the synovial fluid with clinical joint pain, it has been suggested that substance P is 
associated with joint pain whereas PGE2 reflects joint pathology, though it is 
implicated in the induction of pain (de Grauw et al., 2006). Numerous other synovial 
derived neuropeptides such as corticotropin-releasing factor, urocortin and 
vasoactive intestinal peptide are also implicated in OA and have recently been 
reviewed (Sutton et al., 2009). 
1.3.iv. Reactive Oxygen Species 
ROS include NO, superoxide anion and their derivative radicals, peroxynitrite 
(ONOO-) and hydrogen peroxide (H202), and they have been postulated as 
contributors to cartilage homeostasis due to their involvement in intracellular 
signalling pathways and in modulating gene expression (Henrotin et al., 2003a). 
ROS have even been shown to exert anti-inflammatory activity by down-regulating 
expression of inflammatory genes by chondrocytes (Mathy-Hartert et al., 2003). 
However, ROS are molecules that can oxidise and damage, all classes of 
biomolecules (Cheeseman and Slater, 1993), hence their implication in degenerative 
diseases. They are also able to activate signalling cascades and transcription factors 
which up-regulate MMP expression (Nelson et al., 2006) and mediate apoptosis (Del 
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Carlo and Loeser, 2002), thus contributing to cartilage degeneration. In support of 
this, ROS activity has been found in the synovial fluid of horses with joint disease, 
i.e. those undergoing arthroscopic surgery for traumatic joint injury or those with 
osteochondritis dessicans (OCD) (cracking of the articular cartilage due to the failure 
of the subchondral bone to form properly) (Dimock et al., 2000). 
Superoxide anion has been shown to mediate I L - l ~ - i n d u c e d d NF-KB activation in 
bovine chondrocytes (Mendes et al., 2003), which leads to the up-regulation of 
several catabolic genes as previously explained. The catabolic actions of NO include 
MMP activation (Murrell et al., 1995) chondrocyte apoptosis due to caspase 
activation and reduced proteoglycan synthesis (Taskiran et al., 1994). However, NO 
also has a protective effect. NO has been shown to prevent apoptosis by inhibiting 
caspase-3 activation (Kim et al., 1997), as well as protecting cells from oxidative 
damage and enhancing proteoglycan synthesis under hypoxic conditions (Matsushita 
et al., 2004). NO also increases the synthesis of hyaluronan which can remove 
superoxide anion ROS (Hashimoto et al., 2006). NO can also be anti-inflammatory 
as it can reduce PGE2 production by IL-l ~ - s t i m u l a t e d d chondrocytes (Henrotin et al., 
1998). Therefore, it is thought that at low levels NO has an anti-catabolic effect but 
that this becomes catabolic as production persists. 
1.4. Inflammation and Predisposing Factors to Osteoarthritis 
There are many proposed risk factors for the development of OA including genetic 
factors, mechanical stress, trauma and damage to the articular cartilage and! or 
subchondral bone (Muraoka et al., 2007). Ageing is also a factor, as it is thought to 
reduce the ability of chondrocytes within cartilage to respond appropriately to 
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mechanical and oxidative stresses (Loeser, 2009). In horses, links have been drawn 
between excessive loading of joints during strenuous exercise regimens and cartilage 
degeneration (Murray et al., 1999). Thus, the athletic nature of the horse and the 
performance sports for which it is used mean that it is in a high risk category for 
developing the condition. Consequently OA is observed in racehorses (Fubini et al., 
1999), team-roping horses (Dabareiner et al., 2005), Warmbloods (Penell et al., 
2005) and Arabians (Malone et al., 2003). However, certain risk factors associated 
with OA such as ageing (Cantley et al., 1999) and conformation (Clegg et al., 2001), 
indicate that the disease also impacts on non-performance horses. 
Poor anatomical conformation, for example joint malalignment, can cause uneven 
loading over the joint surface, which predisposes the joint to inflammation. It has 
been shown that, IL-P, TNF-a, MMP-3 and fibronectin are up-regulated in canine 
articular cartilage two weeks after impact damage (Pickvance et al., 1993). Although 
this effect is transient, increased pressure or repetitive loading on the joint in 
performance horses and in those with poor conformation, may sustain this 
inflammatory response. In addition, a single impact load increased GAG loss and 
caspase-9-induced cell death in equine cartilage explants in vitro (Huser and Davies, 
2006; Huser et al., 2006). Therefore, repeated, excessive or abnormal forces on 
articular cartilage can stimulate both inflammatory and degradative processes 
involved in the development of OA. 
Thus, many inflammatory mediators are involved in the development and 
progression ofOA, as well as the clinical manifestation of pain. Consequently, there 
are a variety of drugs are used to alleviate these symptoms. 
22 
1.5. Conventional Medical Therapy 
In principle, the ideal therapeutic agent would target multiple processes of OA, i.e 
reducing inflammation and catabolism, whilst promoting cell survival and matrix 
anabolism to aid repair, in the three main joint structures: the cartilage, synovium and 
subchondral bone (Qvist et al., 2008). Such an agent may be termed a 
chondroprotective, i.e. a substance that protects the articular cartilage during the 
process of OA, or a disease modifying OA drug (DMOAD), i.e. a substance that can 
change the course of a disease process (Verbruggen, 2006). However, no safe and 
effective DMOADs have been developed by the pharmaceutical industry to date (Le 
Graverand-Gastineau, 2010). 
Current therapeutic drugs used in the treatment of OA in humans and companion 
animals only reduce the clinical signs, i.e. inflammation and pain (Trumble, 2005; 
Qvist et al., 2008). These anti-inflammatory and analgesic drugs serve to alleviate 
patient discomfort, and may indirectly improve joint function via improving mobility 
and muscle tone to support the joint. Popular classes of drugs in conventional 
medical therapy include the nonsteroidal anti-inflammatory drugs (NSAIDs) and 
glucocorticoids. 
I.S.i. Nonsteroidal Anti-inflammatory Drugs 
NSAIDs are widely used in the treatment of human and veterinary OA. They 
prevent prostaglandin synthesis by inhibiting the COX enzymes that catalyse their 
production (Meade et al., 1993). They have also been shown to protect against 
chondrocyte cell death (Mukherjee et al., 2001b). 
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The anti-inflammatory effects ofNSAIDs have been attributed to COX-2 inhibition. 
NSAIDs targeting COX-1 and non-specific NSAIDs targeting both isforms are 
thought to cause gastrointestinal ulceration (Wolfe et al., 1999; Bombardier et al., 
2000). Thus, COX-2 inhibitors were developed to reduce the risk of adverse gastric 
side effects (Lazzaroni and Bianchi Porro, 2004). However, in humans, adverse 
cardiovascular and nephrotoxic side effects have been associated with the use of 
COX-2 inhibitors (Mukherjee et al., 2001a; Fletcher et al., 2006). Also, COX-2 has 
been shown to be important in resolving inflammation by synthesising anti-
inflammatory prostaglandins (Gilroy et al., 1999). Therefore, complete COX-l and! 
or COX-2 inhibition can be damaging. 
In the equine veterinary field, there are a variety of NSAIDs used to treat OA 
including phenylbutazone, flunixin, ketaprofen, naproxen and carprofen, all of which 
display differing degrees of analgesia and reduction of inflammation (Goodrich and 
Nixon, 2006). However, despite their beneficial effects, they are non-selective 
NSAIDs, therefore it is unsurprising many of these NSAIDs have been associated 
with gastric ulceration and colitis in horses (Andrews and McConnico, 2009). 
Although this topic is controversial (Fennell and Franklin, 2009), gastrointestinal 
toxicity of NSAIDs has been reported in many animal species (Radi and Khan, 
2006). 
NSAIDs have been reported to have an inhibitory effect on normal cartilage turnover 
in vitro. For example, phenylbutazone treatment of healthy equine articular cartilage 
explants reduced proteoglycan loss (Jolly et al., 1995), and proteoglycan synthesis 
(Beluche et al., 2001). This may be detrimental to normal joint health as well as 
prolonging healing in damaged cartilage. It has been demonstrated in vitro that 
neither phenylbutazone nor flunixin show any inhibitory activity against MMP-2 and 
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MMP-9 (Clegg et al., 1998) and that some NSAIDs may promote latent MMP-9 and 
MMP-l production by inhibiting regulatory PGE2 (Ito et al., 1995; Takahashi et al., 
1997). Therefore, although NSAIDs may reduce pain and inflammation in the joint, 
they can have potentially undesirable side effects. 
There are now more specific NSAIDs on the market, known as coxibs, which 
selectively inhibit COX-2 rather than COX-I, thereby reducing the risk of these side 
effects. In a recent study in horses, firocoxib, was found to have comparable clinical 
efficacy with phenylbutazone in horses with naturally occurring OA, and neither 
treatment showed any signs of toxicity over the relatively short study duration 
(Doucet et al., 2008). It may be that no adverse side effects are observed when either 
selective or non-selective NSAIDs are administered at the correct dosage for 
relatively short periods. However, a recent survey on 1,403 horse owners and 
trainers in the USA conducted by the animal healthcare company, Merial Ltd, found 
that 82% used NSAIDs without consulting their veterinarian, and 8% used the 
incorrect dosage (Anon, 2009). Consequently, there is stilI potential for adverse side 
effects with these drugs. This warrants research into chondroprotective agents for 
either prevention of OA to avert the need for NSAID therapy or as adjuncts to 
NSAID therapy in animals with established OA to help repair the cartilage as the 
inflammation decreases. 
I.S.ii. Glucocorticoids 
Glucocorticoids, also known as corticosteroids, are commonly used in the treatment 
of inflammatory diseases due to their anti-inflammatory capabilities. 
Glucocorticoids bind to cytoplasmic glucocorticoid receptors which can down-
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regulate inflammatory genes and up-regulate anti-inflammatory genes (Adcock et al., 
2004). Their main effects are thought to be mediated through interactions between 
the glucocorticoid receptors and the transcription factors NF -1d3 and AP-l preventing 
them from binding to inflammatory genes and promoting the inflammatory process 
(Barnes and Karin, 1997). In addition, glucocorticoids can also increase IKBa 
inhibitory protein which traps NF-KB in an inactive complex (Auphan et al., 1995). 
Thus, glucocorticoids exert their anti-inflammatory effects via decreasing cytokine 
expression. 
Current glucocorticoids used In the treatment of equine OA include 
methylprednisolone acetate, betamethasone acetate, triamicinolane acetonide, 
isoflupredone and flumethasone (Goodrich and Nixon, 2006). Most glucocorticoids 
are administered intra-articularly in order to deliver the drug directly to the site of 
inflammation thereby reducing the dosage required. Intra-articular glucocorticoid 
injections have also been shown to suppress TNF-a release from blood monocytes 
for at least four days post injection (Steer et al., 1998). Thus, it can be seen that 
glucocorticoids are effective anti-inflammatory drugs and, as such, seem an 
appropriate choice for OA therapy. 
However, as with NSAIDs, there have been concerns over the other effects that 
glucocorticoids may exert. Glucocorticoids may contribute to cartilage depletion as 
indicated by increased aggrecan turnover and reduced collagen synthesis in the 
synovial fluid after three intra-articular methylprednisolone acetate injections given 
to healthy horses over 13 weeks (Robion et al., 2001). Similarly, intra-articular 
triamicinolane acetonide increased aggrecan turnover and collagen type I and II 
cleavage whilst increasing collagen synthesis in injected and untreated contra-lateral 
joints, indicating systemic negative effects of glucocorticoid administration on 
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cartilage metabolism (Celeste et ai., 2005). This cartilage cleavage was attributed to 
the glucocorticoid inducing proteoglycan release into the synovial fluid rather than 
via MMP activity. Reports on the effects of glucocorticoids on MMP activity are 
mixed. A study using the synovium of human patients with OA found that 
glucocorticoids did not alter the expression of MMP-I, MMP-3, TIMP-I or TIMP-2 
(Young et ai., 2001). Whereas, glucocorticoid treatment of equine chondrocytes was 
found to reduce expression of MMP-I, MMP-3, MMP-13 and TIMP-I (Richardson 
and Dodge, 2003). However, several differences may account for this contradiction. 
Firstly, the reaction of the synovium to cytokines may be different to that of the 
chondrocyte. Secondly, the equine study used healthy chondrocytes stimulated with 
cytokines to replicate the diseased state unlike the human study, which used actual 
diseased tissue. The study also used recombinant human cytokines rather than 
equine specific ones. These factors may account for the differences between results. 
However, work seems to suggest that glucocorticoids do exert a suppressive effect on 
MMPs and TIMPs by reducing their expression and activity in cytokine treated 
chondrocytes in vitro (Sadowski and Steinmeyer, 2002). Despite reducing MMP 
activity, there is also a decrease in proteoglycan concentrations of explants treated 
with dexamethasone (Stove et ai., 2002). Thus, the effects of glucocorticoids on 
joint health may not all be beneficial. In addition, glucocorticoid use has been 
tenuously linked to the development of laminitis in horses via several potential 
pathways including glucose metabolism, insulin resistance, vasospasm and apoptosis 
(French et ai., 2000; Bailey and Elliott, 2007). 
Although glucocorticoids are effective anti-inflammatories, neither they nor NSAIDs 
promote cartilage matrix synthesis. Consequently, natural food derived products, 
termed nutraceuticals, are being investigated for their chondroprotective ability as 
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potentially safer joint health supportive products, to replace or use alongside existing 
anti-inflammatory and analgesic pharmacotherapy. 
1.6. Nutraceuticals 
The term 'nutraceutical' IS a portmanteau of the words 'nutrition' and 
'pharmaceutical', that was coined by Stephen De Felice to give an identity to the 
vague nomenclatural area of foods with medical benefits (De Felice, 1995; Brower, 
1998). A nutraceutical is defined as a food (or part of a food) that provides medical 
or health benefits, including the prevention and/ or treatment of a disease. Thus the 
aiding in the prevention and! or treatment of disease is what distinguishes 
nutraceuticals from functional foods and dietary supplements, which simply provide 
the body with substances needed for healthy survival (Kalra, 2003). There are 
several issues surrounding the nutraceutical and dietary supplement industry from 
concerns about bioavailability, supraphysiological dosing levels, negative 
interactions with prescription drugs, increased risk of toxicity and harmful 
interactions with other foods, to issues surrounding undeclared substances on 
packaging and the variability in content of the active ingredient in the manufactured 
product (Ridinger, 2007; Sadovsky et al., 2008). In light of this, there is a 
recognised need for greater regulation by legislative bodies on a global scale to 
ensure product quality, accurate labelling and health claims (Goggs et al., 2005; 
Gulati and Berry Ottaway, 2006; Kaushik and Kaushik, 2010; Pandey et al., 2010). 
Despite these issues, nutraceuticals have great potential and consequently are a 
popular area of research, especially in terms of chondroprotection. Two of the most 
common nutraceuticals marketed as chondroprotective agents on the human and 
veterinary market are glucosamine and chondroitin sulphate. 
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1.6.i. Glucosamine 
Glucosamine is a constitutive amino sugar of the GAGs found in the joint. Thus, its 
exogenous administration is thought to have a beneficial effect on cartilage 
regeneration in the joint (Bassleer et al., 1998a). However, treatment of mouse 
chondrocyte cultures with glucosamine has shown that glucosamine does not 
stimulate chondroitin sulphate synthesis (Mroz and Silbert, 2003). Work with human 
chondrocyte cultures has also shown that glucose competitively inhibits exogenous 
glucosamine (Mroz and Silbert, 2004). Subsequent work with bovine chondrocytes 
has supported these findings by showing that glucosamine does not increase GAG 
synthesis (Qu et al., 2006). Glucosamine is thought to inhibit NF-KB activation and 
the expression of COX-2, thereby preventing the synthesis of pro-inflammatory 
mediators and cartilage destruction (Largo et al., 2003). Thus, it appears that 
glucosamine may exert its effects through preventing catabolic mediators rather than 
promoting cartilage anabolism. This is supported by the fact that both anabolic and 
catabolic genes are down-regulated in response to glucosamine treatment in human 
osteoarthritic cartilage explants (Uitterlinden et al., 2006). 
With regard to equine in vitro work, glucosamine is also not thought to have an 
anabolic effect, as it does not significantly increase GAG synthesis in equine 
cartilage explants, with or without IL-l a (Dechant et al., 2005). However, in terms 
of catabolism, glucosamine hydrochloride (HC\) at 25mg/ml has been shown to 
reduce NO production, proteoglycan release and MMP activity in equine cartilage 
explants stimulated with either lipopolysaccharide (LPS) or recombinant human IL-
l P (Fenton et al., 2000). A subsequent study found that glucosamine HC} (1.5-
50mM) had no effects on MMPs activated by culturing cartilage explants in LPS, but 
concentrations of25mM and 50mM reduced MMP-l, -3, and -13 mRNA expression 
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in LPS-stimulated chondrocytes rather than inhibiting their activity (Byron et al., 
2003). Therefore, the reduced MMP activity may be attributed to less MMPs being 
available for activation rather than the glucosamine directly inhibiting activated 
MMPs. However, these studies found beneficial effects at relatively high 
glucosamine concentrations. Pharmokinetic studies with horses have shown that 
serum and plasma glucosamine Hel concentrations following oral administration are 
roughly 1 )lglml (-6)lM) with maximum synovial fluid concentrations reaching only 
about 10% of serum/ plasma levels (Laverty et al., 2005; Meulyzer et al., 2008). 
Thus, physiologically achievable concentrations in the joint are roughly 0.1 )lg/ml or 
0.6)lM. Although one study reported a maximum plasma concentration of 10.6)lg/ml 
following oral glucosamine Hel (Ou et al., 2004), this in theory would mean 
1.06)lg/ml glucosamine in the synovial fluid. An equine model of LPS-induced joint 
inflammation has suggested that glucosamine accumulates in inflamed joints, as 
opposed to non-inflamed joints, achieving maximal synovial fluid concentrations of 
roughly 0.42)lg/ml (2.36JlM) and 0.09Jlg/ml (0. 19J1M) respectively following 
nasogastric administration of 20mg/kg glucosamine Hel to horses (Meulyzer et al., 
2009). However, despite this, these values are still considerably lower than those 
tested in chondrocytes and explants in vitro as previously mentioned. A more recent 
study found that physiologically relevant concentrations between 0.1 and 20Jlg/ml 
had no effect on MMP-13 production by IL-I-stimulated chondrocyte and 
synoviocyte cultures, but significantly reduced mPGES production by chondrocytes 
and both mPGES and PGE2 production by synoviocytes (Byron et al., 2008). Thus, 
the effects of glucosamine may be primarily anti-inflammatory and act on other cells 
found in the joint not just the chondrocytes. It should be mentioned here that the 
experimental model of equine joint inflammation described earlier found that despite 
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increased glucosamine accumulation in the inflamed joints, no effect was seen on 
standard synovial fluid parameters of inflammation- namely white blood cell counts 
and total protein analysis (Meulyzer et al., 2009). However, this does not necessarily 
mean there was no anti-inflammatory effect as no other indicators of inflammation 
were studied, such as PGE2 or pro-inflammatory cytokine levels. 
Glucosamine has received much attention in human medicine, but clinical trial 
results have often been conflicting and compromised by poor, biased study designs 
(Barclay et al., 1998; Vlad et al., 2007). In horses, oral glucosamine 
supplementation for walked or lunged horses did not significantly alter serum 
markers of joint and bone metabolism, namely keratan sulphate and osteocalcin, a 
non-collagenous protein secreted by osteoblasts (Fenton et al., 1999). Similarly, oral 
glucosamine HCI given to Standardbred horses in race training did not significantly 
alter serum concentrations of keratan sulphate, osteocalcin or pyridinoline crosslinks 
of type I collagen (Caron et al., 2002). These results suggest that, in the horse, 
glucosamine does not influence cartilage and bone metabolism. 
The lack of effects in vivo could be due to the fact that it is difficult to achieve the 
concentrations that prove effective in vitro. The bioavailability of glucosamine HCI 
administered at clinically relevant doses to horses via nasogastric intubation is poor 
(-5.9%) and, although it can enter synovial fluid, transport into the joint cavity from 
the circulation is inefficient, resulting in concentrations 500 times lower than those 
reported to have chondroprotective effects in vitro (Laverty et al., 2005). In addition, 
there is considerable variation in glucosamine content in commercial equine joint 
supplements. One study found that nine out of the 23 supplements tested failed to 
meet the label claims (Oke et al., 2006). Therefore, poor bioavailability as well as 
poor quality supplements and varying recommended dosages means that it is 
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un surprising that in vivo results haven't reflected the initial success seen in 
chondrocyte cultures. However, the aforementioned glucosamine trials used 
exercising healthy horses and assessed markers of bone and cartilage metabolism. If, 
as in vitro results suggest, glucosamine has a greater influence on inflammation 
rather than catabolism or anabolism of cartilage and bone, then studying the 
expression and production of inflammatory mediators around the joints in healthy 
and early OA horses may be more beneficial. 
Past trials in humans and animals have generally concluded that glucosamine is well 
tolerated and is safe for long term use (Anderson et al., 2005; Hathcock and Shao, 
2007). Despite this, there have been concerns of glucosamine toxicity towards 
chondrocytes in vitro. One study reported impaired chondrocyte metabolism and a 
loss in cell viability in response to glucosamine at 6.Smg/ml (de Mattei et al., 2002), 
whereas another observed cell death at IOmg/ml, although Smg/ml was the next 
lowest concentration tested (Mello et al., 2004). However, as previously mentioned, 
these concentrations are not likely to be achieved in the joint in vivo following oral 
glucosamine administration, therefore these risks are probably minimal. 
1.6.ii. Chondroitin Sulphate 
Chondroitin sulphate is an orally administered GAG naturally present in cartilage. It 
is a much larger molecule than glucosamine and its large molecular weight has raised 
queries regarding its absorption via the gastrointestinal tract. However, it is available 
in both a normal, 16.9 kilo Dalton (kDa), form and a low molecular weight, 8.0kDa, 
form which when fed to horses at 3g per day, were shown to have a bioavailability of 
32.2% and 22% respectively, with both these forms being absorbed to a greater 
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extent than glucosamine administered at 125mg/kg (Du et al., 2004). Thus, the 
bioavailability of orally administered chondroitin sulphate appears to be adequate, 
though whether the biological activity of chondroitin sulphate is retained through the 
digestive process remains to be determined. 
Unlike glucosamine, chondroitin sulphate has shown less consistent results in vitro. 
In equine articular cartilage explants, glucosamine (1 mg/ml) reduced LPS-induced 
NO production relative to controls, and at 0.5mg/ml reduced PGE2 levels compared 
to controls, whereas chondroitin sulphate at 0.25mg/ml and 0.5mg/ml failed to 
produce any effects (Orth et al., 2002). Similarly, I L - l ~ - i n d u c e d d mRNA levels of 
MMP-13 and aggrecanase-l in equine chondrocyte pellet cultures were significantly 
reduced by glucosamine (IOllg/ml) but no effect was seen in samples treated with 
chondroitin sulphate at concentrations of 5-50llg/ml (Neil et al., 2005). In contrast to 
this, another study which extracted RNA from bovine cartilage explants after 
culturing, showed that chondroitin sulphate (20llg/ml) decreased IL-l ~ - m e d i a t e d d
MMP-13, and aggrecanase 1 and 2 gene expression (Chan et al., 2005a). However, 
these studies examined catabolic mediators of cartilage degradation, whereas the 
chondroprotective properties of chondroitin sulphate may be more attributed to 
promoting cartilage anabolism. For example, chondroitin sulphate has been shown 
to counteract the effects of IL-l ~ ~ on human articular chondrocytes during the first 16 
days of culture by reversing IL-I ~ - s t i m u l a t e d d suppression of proteoglycan and type 
II collagen synthesis (at concentrations of 500-1000llg/ml and 100-1 OOOllg/ml 
respectively) whilst decreasing PGE2 production (500-1000Ilg/ml) (Bassleer et al., 
1998b). Thus, it may be that chondroitin sulphate is capable of exerting both an anti-
catabolic and pro-anabolic effect, in addition to anti-inflammatory effects, or that it 
exerts species-specific effects. Whichever the case, live animal studies have 
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indicated that a combination of chondroitin sulphate and glucosamine may be more 
effective (Hanson et al., 1997; Canapp et al., 1999). 
1.6.iii. Glucosamine and Chondroitin Sulphate Combined 
Studies examining the effects of chondroitin sulphate and glucosamine on cartilage 
explants have found that using a combination of the two substances has a more 
beneficial effect on cartilage than either agent alone in live animal models and in 
vitro explants (Lippiello et al., 2000; Orth et al., 2002; Homandberg et al., 2006) 
Studies with bovine cartilage explants found that chondroitin SUlphate and 
glucosamine (1 Ollg/ml and 201lg/ml respectively) together, effectively suppressed the 
IL-l p-induced expression of inflammatory and proteolytic genes including NF-KB, 
COX-2 and MMP-13, whilst up-regulating TIMP-3 expression, implying that the 
combination of agents has anti-inflammatory and anti-catabolic properties (Chan et 
al., 2006). Thus, in vitro results using a combination of chondroitin sulphate and 
glucosamine have been promising. 
There are few in vivo equine studies examining the effects of combined chondroitin 
sulphate and glucosamine, and they have produced conflicting results. Daily oral 
supplementation for 26 days with glucosamine (lO.8g) and chondroitin sulphate 
(3.6g) did not improve lameness score, stride length, carpal circumference, carpal 
flexion or synovial fluid protein levels in horses with chemically induced synovitis 
and degenerative joint disease compared to untreated controls (White et al., 1994). 
Whereas horses given 9-12g of a combined glucosamine HClI chondroitin sulphate 
compound (Cosequin) twice a day for 6 weeks showed significant improvements in 
stride length, lameness grade and flexion test 2 weeks after the compound began to 
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be administered, though there was no further improvement after 4 weeks (Hanson et 
al., 1997). An eight year study of 10 working show jumpers/ hunters found that oral 
supplementation with glucosamine and chondroitin sulphate (lOg/day) reduced the 
mean number of distal tarsal joint injections per year from 1. ito 0.85, and increased 
the time interval between injections from 6.8 months to 9.98 months to maintain 
soundness (Rodgers, 2006). The differences between criteria used to assess 
improvement in horses, limitations with regard to blinding, the use of appropriate 
controls, small study numbers and limited if any statistical analysis make 
comparative analysis difficult between these studies. However, despite this, the 
basic data from the in vivo trials combined with in vitro work provide encouraging 
evidence of the chondroprotective ability of glucosamine and es. 
There is still much scepticism on the ability of these agents either alone or 10 
combination to act as chondroprotective agents in vivo, with bioavailability being 
one of the main criticisms (Ramey, 2005). However, the in vitro results with these 
agents on chondrocytes and in explant models, along with some basic in vivo trial 
data have been too effective to dismiss them and their potential role in the treatment 
of osteoarthritic conditions. Therefore, carefully designed trials on the efficacy and 
safety of these substances are needed to clarify their role as chondroprotective agents 
in the horse. 
1.7. Plant Derived Nutraceuticals 
Plant derived substances with anti-inflammatory properties are being investigated for 
their potential in the treatment of a range of human and veterinary diseases including 
OA. Ethnoveterinary medicine uses indigenous knowledge on animal health and can 
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be used to identify plants with potential therapeutic properties. This area has 
received so much interest that national data banks have been set up to record and 
preserve this information (Viegi et al., 2003). 
A review of ethnoveterinary medicines used for horses in Trinidad and British 
Columbia found a variety of plants were added in powdered form to horse feed for 
the treatment of arthritis and sore joints (Lans et al., 2006), see table 1. 
Scientific Name Common Name Plant Part Use 
Arctium lappa Burdock root Arthritis 
Capsicum sp Cayenne fruits Joint pain 
Curcuma longa Turmeric rhizome Arthritis 
Equisetum arvense Horsetail aerial parts Arthritis 
Filipendula ulmaria Meadowsweet whole plant Arthritis 
Glycyrrhiza glabra Liquorice root Arthritis 
Harpagophytum procumbens Devils Claw root Arthritis 
Lavendula sp Lavender flowers Arthritis 
Salix alba White Willow bark Arthritis 
Scutellaria baicalensis Baical Skullcap aerial parts, leaves Arthritis 
Scutellaria lateriflora Skullcap aerial parts, leaves Pain 
Si/ybum marianum Milk Thistle seed Arthritis 
Table 1. Plant remedies used in British Columbia for the treatment of arthritis 
and joint pain in horses adapted from Lans et al. (2006) 
Many plant extracts have been investigated for their beneficial anti-inflammatory 
properties and anti-degradative properties in a variety of cell types, including 
chondrocytes. For example, the green tea polyphenol, epigallocatechin gallate 
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(EGCG), from the leaves of Camellia sinensis inhibits I L - l ~ - i n d u c e d d mRNA 
expression and enzyme activity of MMP-l and MMP-13 in human chondrocytes 
(Ahmed et al., 2004). Pre-treatment of chondrocytes with pomegranate extract 
inhibits the IL-l ~ - i n d u c e d d increase in MMP-l, MMP-3 and MMP-13 production 
(Ahmed et al., 2005). Resveratrol from red grapes reduces IL-l ~ - s t i m u l a t e d d MMP-
3, MMP-9 and COX-2 expression, as well as chondrocyte apoptosis (Shakibaei et al., 
2008). The flavanoid, nobiletin, from Citrus depressa suppresses COX-2 mRNA 
expression but not COX-I, similar to the coxib drugs, as well as increasing TIMP-l 
production in synovial fibroblasts (Lin et al., 2003). Thus, some extracts can exert 
multiple anti-inflammatory and anti-degradative effects on cartilage in vitro. 
The anti-catabolic activities of plant extracts on cartilage can be accompanied by 
pro-anabolic effects. For example, avocado/soybean unsaponifiables (ASU) can 
restore aggrecan synthesis in IL-l ~ - s t i m u l a t e d d human OA chondrocytes, whilst 
concurrently inhibiting MMP-3 production (Henrotin et al., 2003b). Some extracts 
may be more beneficial in combination as shown by a recent study combining ASU 
and EGCG which reduced COX-2 expression and PGE2 production in I L - l ~ ~
stimulated equine chondrocytes (Heinecke et al., 2010). In addition, the combination 
of resveratrol and the polyphenol curcumin, derived from turmeric, has been shown 
to reduce MMP-3, MMP-9 and COX-2 production by IL-l ~ - s t i m u l a t e d d chondrocytes 
(Csaki et al., 2009). Many of these plant extracts exert their anti-inflammatory 
actions through blocking the translocation and activation of the transcription factors, 
primarily NF-KB (Singh et al., 2002; Ahmed et al., 2004; Ahmed et al., 2005; Gabay 
et al., 2008; Csaki et al., 2009). Figure 7 summarises the modulatory actions of 
some known plant extracts on the NF-KB pathway. 
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Figure 7. Areas for nutritional modulation of the nuclear factor-kappa B (NF-
KB) pathway in arthritis 
Activation of the NF-KB pathway is initiated by cytokines, such as IL-1 p, binding to 
their receptors on the cell membrane. This starts an intracellular signal 
transduction cascade, numbered as follows,' 1. Activation of cytoplasmic lKBa 
kinases (IKK)-a, IKK-[J, and IKK-y. 2. Phosphorylation of inactive lKBa (the 
inhibitory unit of the NF-kB (P65/p50) complex). 3. Dissociation and degradation of 
lKBa to release the active NF-KB p50/p65 heterodimer. 4. Translocation of NF-KB to 
the nucleus. 5. Binding of NF-KB and DNA to activate inflammatory, degradative 
and apoptotic gene production (Roman-Bias and Jimenez, 2006,' Shakibaei et al., 
2007,' Csaki et al. , 2009). Inhibitory effects of various plants extracts have been 
measured at these stages (indicated by a blue line). A = avocado/soybean 
unsaponijiables, C = curcumin, E = epigallocatechin gallate, N = nobile tin, P = 
pomegranate extract, R = resveratrol. 
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Some of these extracts have been tested in horses and were found to have disease-
modifying properties. For example, oral ASU treatment of horses with 
experimentally induced OA significantly reduced the severity of articular cartilage 
erosion and synovial haemorrhage whilst significantly increasing GAG synthesis, 
compared with placebo-treated horses, although it had no effect on signs of pain or 
lameness (Kawcak et al., 2007). Therefore, there are many known plant-derived 
extracts with potential joint supportive properties, and probably many more as yet 
undiscovered. However, their modes of actions and beneficial effects must be 
established in in vitro and in vivo models of OA before the widespread acceptance of 
the scientific community. 
1.B. Current Models o/Osteoarthritis 
l.S.i. In Vivo Models 
Pain in OA only manifests after the involvement of other joint structures with a nerve 
supply such as the synovium (Brandt, 1989), thus cartilage degeneration is often 
advanced before it is clinically diagnosed. Therefore, animal models have been 
developed to study OA at earlier stages and monitor disease progression. Many 
animal species are currently used in OA research including; laboratory animals: 
mice, rats, guinea pigs, rabbits; farm animals: sheep, goats; and companion animals: 
dogs, cats, horses. Animal OA models roughly fall into five categories; firstly, 
spontaneous OA, which naturally occurs in the knee joints of animals, such as guinea 
pigs and dogs, and has a similar pathogenesis to human OA (Miller and Lust, 1979; 
Bendele and Hulman, 1988). Secondly, the surgical creation of joint instability, for 
example anterior cruciate ligament transection (ACL T) in dogs (Pond and Nuki, 
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1973), meniscal tear model in rats (Janusz et aI. , 2002), and collateral ligament 
transection in horses (Simmons et aI. , 1999). Thirdly, the surgical replication of joint 
trauma, for example the canine groove model (Marijnissen et aI. , 2002), and carpal 
chip fragmentation in horses (Kawcak et aI. , 2008). Fourthly, injection into the joint, 
for example papain (Bentley, 1971), sodium mono-iodoacetate (Gustafson et aI. , 
1992) and collagenase (van der Kraan et aI. , 1990). The final category is the knock-
out model which deletes certain genes in mice resulting in the development of OA-
like degenerative joint disease. For example the deletion of the gene that codes type 
IX collagen (Fassler et aI. , 1994), or the double deletion of biglycan and 
fibromodulin (Ameye et aI. , 2002). Some commonly used animal models of OA are 
summarised in figure 8. 
SPONTANEOUS 
OA 
Figure 8. Commonly used animal models of osteoarthritis 
ACLT = anterior cruciate ligament transaction; OA = osteoarthritis. 
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All these models cause different characteristics of OA and differ in their similarities 
with the human condition. For example, aggrecan content of cartilage from dogs 
with spontaneous OA decreased by 50-40% (similar to human OA) whereas it 
increased by 26% in cartilage from ACLT-induced OA (Liu et ai., 2003). In 
addition, some models such as the partial medial meniscectomised guinea pig model, 
produce rapid and severe cartilage degeneration which may limit their use for testing 
therapeutic agents (Bendele, 1987). The merits and limitations of each model must 
therefore be carefully considered when designing experiments and translating the 
results. In addition, there are obvious welfare issues with using live animal models 
in terms of pain, debilitation and euthanasia. Therefore, the development of 
alternative in vitro models of OA have been encouraged to reduce, refine and replace 
the use of animals in research. 
I.S.ii.ln Vitro Models 
All in vitro culture systems are simplified models of an in vivo milieu (Stewart et ai., 
2000). In vitro models, are often used as a preliminary step before in vivo testing, 
especially in determining safe concentrations of test substances (Pearson, 1986). In 
vitro testing has numerous benefits in that it can standardise experimental conditions, 
reduce costs, increase sample numbers, lessen variability through the elimination of 
systemic factors and limit animal suffering (Finn and Giardino, 2003). However, 
metabolites and toxic products can accumulate in in vitro cultures, and the relative 
simplicity of in vitro systems compared to the complex interactions occurring in an 
organism, limits their use (Finn and Giardino, 2003). 
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With regard to in vitro models of cartilage and OA, there are numerous models 
available. Isolated chondrocytes can be grown in high density, stationary 
mono layers or in roller bottles where they form mono layers and multilayers, to 
examine morphology and responses to external stimuli at a cellular level (Kuettner et 
al., 1982). However, this system is very different from the in vivo situation, where 
chondrocytes reside either singly or in pairs throughout the cartilage matrix. In the 
monolayer system chondrocytes can lose their phenotypic stability after several 
weeks, as they express more type I collagen and less collagen type II (Benya et al., 
1978). In addition, the morphology of monolayer chondrocytes changes from 
spherical to flattened, fibroblast-like cells after about a week in culture (Grundmann 
et al., 1980). Consequently, more appropriate scaffolds for chondrocyte culture have 
been investigated, notably on alginate beads or within agarose gels. 
Chondrocytes grown in alginate beads (either in a semi-solid gel or encapsulated 
within hollow beads) maintain their spherical morphology as opposed to the typical 
fibroblast-like morphology of monolayer chondrocytes (Guo et al., 1989). 
Chondrocytes that have de-differentiated in monolayer culture will re-differentiate 
back to their chondrocyte phenotype after culturing on alginate beads for two weeks 
(Lemare et al., 1998) or after a week in agarose gels (Benya and Shaffer, 1982). In 
addition, adult bovine articular chondrocytes remain phenotypically stable for up to 
eight months when grown on alginate beads, expressing collagen type II and 
aggrecan (Hauselmann et al., 1994). Chondrocytes grown in mono layers lose their 
responsiveness to IL-l p over time, for example reduced NO production that is non-
detectable by passage six (Blanco et al., 1995), and reduced MMP-9 production by 
passage two, which can be restored by culture in alginate (Lemare et al., 1998). 
Interestingly, 02 tension is also thought to be important for restoring and maintaining 
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the chondrocyte phenotype alongside alginate. Although the aforementioned studies 
showed re-differentiation of chondrocytes in alginate beads under standard culture 
conditions, other studies have shown re-differentiation only when cultured in alginate 
at low 02 tension (5%), as opposed to standard normoxic levels (20-21% 02) 
(Murphy and Sambanis, 2001; Domm et al., 2002). Thus, it appears low 02 and a 
three-dimensional (3-D) culture system are important for maintaining the 
chondrocyte phenotype. Thus, alginate beads are useful for long-term chondrocyte 
culture studies, and are of value when studying chondrocyte responses to 
inflammatory mediators. 
In contrast to isolated cell models, the cartilage explant model maintains the 
chondrocytes in their native matrix. Although chondrocytes in cartilage explants 
maintain their phenotypic stability, they have lower basal expressions of matrix 
proteins than are found in vivo (Stewart et al., 2000). Despite this, explant models 
are often used to study the synthesis and turnover of ECM molecules (Carney et al., 
1985; Campbell et al., 1989). The explant model has a variety of uses. It can use 
arthritic and non-arthritic cartilage from age matched controls for comparative 
studies on matrix composition and change (Malemud et al., 1995). However, the 
often unknown aetiology of OA and individual variation, for example in weight and 
inflammatory response, can make comparisons between individuals difficult. 
Therefore, another adaptation of the model is to use healthy cartilage stimulated with 
various stimuli, alone or in combination, to induce changes typical of OA. This 
enables cartilage from the same donor to be used for controls and treatments alike, 
thereby reducing variation, and allowing the effects of different stimuli to be 
evaluated. Thus, explant models can provide more precise and scientifically robust 
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studies of cartilage in a constant environment, removing many of the confounding 
factors associated with live animal work. 
The stimulus used to induce degradation in the explant model can determine the 
nature of OA being studied. For example, the addition of a single cytokine such as 
IL-I ~ ~ to human cartilage explants increases gene expression of degradative enzymes 
and inflammatory mediators, whilst reducing collagen type II expression (Sandell et 
al., 2008). Collagen type II gene expression is significantly lower in cartilage from 
early OA patients compared to late OA patients (Aigner et al., 2006), thereby 
suggesting that the IL-I ~ - s t i m u l a t e d d explant culture system represents a model of 
early OA. 
Other explant systems have used combinations of cytokines to induce cartilage 
degradation, in terms of GAG and/ or collagen loss, at lower concentrations than 
each cytokine alone. This has been done with various combinations, such as IL-1 ~ ~
and TNF -(1 in bovine nasal explants (Saklatvala, 1986), IL-I ~ ~ and OSM in feline 
articular cartilage (Gabriel et al., 2010), IL-17 with either OSM, IL-l (1 or TNF -(1 in 
bovine nasal cartilage (Koshy et al., 2002). In contrast to the relatively rapid loss of 
GAGs from explants in culture, collagen degradation is often observed after 2 weeks 
of explant culture with combined cytokines (Koshy et al., 2002; Gabriel et al., 2010). 
However, the combination of cytokines with the plasma serine protease, activated 
protein-C, has been shown to induce collagen loss within 4 days (Garvican et al., 
2010), thereby highlighting the flexibility of the model. Despite this, the 
aforementioned explant models do not take into account the biomechanical forces 
present in the joint in vivo. Therefore, mechanical compression can be applied to 
explants in culture to represent joint injury through overloading. Injurious 
compression to cartilage explants reduces the tensile strength of the collagen 
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network, increases chondrocyte death and causes a prolonged increase in 
proteoglycan turnover (Quinn et ai., 1998). It also stimulates inflammatory 
pathways by inducing COX-2 and mPGES-l expression and protein synthesis 
(Gosset et ai., 2006). To create a more complex model studying the interactions 
between mechanical forces and degradative pathways, injured cartilage explants can 
be cultured with TNF -u and IL-l ~ ~ to cause a synergistic increase in GAG loss 
(Patwari et ai., 2003). 
Cartilage explants can be studied in conjunction with cell culture, or explants of 
other joint structures to examine the effects of different joint components. For 
example, co-culturing cartilage explants with synoviocytes has suggested that the 
synoviocytes exert a protective effect over IL-l ~ ~ mediated cartilage degradation 
(Gregg et ai., 2006). Culturing cartilage explants with subchondral bone (either 
attached to the cartilage or as separate explants) has been shown to increase 
chondrocyte survival compared to cartilage alone (Am in et ai., 2009). Therefore, 
there are a variety of in vitro chondrocyte and cartilage explant culture models for 
studying healthy and naturally diseased joint structures, as well as inducing cartilage 
changes typical of OA in normal cartilage. 
1.9. Aims and Objectives 
The aim of this thesis was to develop in vitro models of equine cartilage to 
investigate the anti-inflammatory and anti-degradative effects of plant extracts in 
order to assess the potential of using nutritional intervention to support joint health in 
equine OA. 
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In order to achieve the specific aims and objectives of this project, it was necessary 
to establish and test in vitro models of equine cartilage using a series of downstream 
biochemical assays. The models included monolayer cultures of primary 
chondrocytes for cytotoxicity testing and refinement of the well-established explant 
system for biochemical assays. A significant amount oftime and effort was involved 
in developing and evolving the models in order to achieve reliability and consistency. 
Once the models were developed, it created the opportunity to perform hypothesis 
driven research, which resulted in the experimental chapters. The model needed to 
be validated and therefore the well-studied anti-inflammatory phytochemical agent, 
curcumin, and the NSAID, carpro fen , were employed to test the in vitro models 
before studying combination products developed by W AL THAM® and by third 
parties. 
An unexpected benefit of the developmental phase of this study was the opportunity 
to exploit the refined explant model for proteomic studies of the cartilage secretome 
in collaboration with Bruker Daltonics in Coventry. 
Although not stated in the original proposal, the opportunity arose to conduct an in 
vivo field based study at Redwings Horse Sanctuary in Norfolk to gain experience in 
the area of field trial work by evaluating the combination products tested in vitro. 
This highlighted the limitations and complexities of field trial work and emphasised 
the importance of not over-interpreting in vitro work. 
One of the anticipated outcomes was that the results of the in vivo field trial and the 
proteomics work would help direct future research in the area of selection and testing 
new botanical extracts for supporting joint health. 
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CHAPTER 2. DEVELOPING A CARTILAGE MODEL OF 
EARLY OSTEOARTHRITIS FOR TESTING PLANT 
EXTRACTS 
2.1. Introduction 
The chondrocyte is a highly specialised cell that synthesises components of the 
cartilage ECM. Within the matrix, chondrocytes are sparsely distributed, making up 
less than 10% of the ECM tissue volume (Carney and Muir, 1988). In vitro, 
chondrocytes grown in low density monolayer cultures begin to de-differentiate into 
fibroblast-like cells and synthesise collagen type I instead of type II, thus changing 
their phenotype (Muller et al., 1977; von der Mark et al., 1977). Cartilage explant 
models allow the study of cartilage in vitro without causing this de-differentiation, 
and although the mRNA expression of cartilage matrix components; pro-collagen 
type II, aggrecan and fibronectin, are down-regulated, this is thought to be as a 
consequence of removing biomechanical stimuli (Stewart et al., 2000). Explants 
support viable cells and can respond to the addition of exogenous inflammatory 
cytokines and/or mechanical compression by exhibiting a dose-dependent release of 
cartilage GAGs from the ECM (Ratcliffe et al., 1986; Patwari et al., 2003; DiMicco 
et al., 2004). GAG depletion of cartilage occurs in OA, thus, by adding these 
exogenous stimuli alone or in combination, the cartilage explant model can be 
adapted to create in vitro models of OA. 
Although many studies have examined explants taken from osteoarthritic patients 
(Shuckett and Malemud, 1988; Billinghurst et al., 1997), the differing (and 
sometimes unknown) aetiologies, duration of disease and status of disease 
progression can vary widely between subjects. Cartilage cultured in vitro from 
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osteoarthritic patients is thought to be less vital, in terms of increased catabolism and 
decreased anabolism, compared to normal cartilage shortly after collection (Lafeber 
et al., 1992). This suggests that the properties of the explant model will be greatly 
affected by the disease status of the tissue. However, the response of cartilage 
explants to exogenous stimuli in vitro enables the utilisation of cartilage from 
patients with no clinical signs of joint pathology. Thus, apparently "healthy" 
cartilage from multiple donors can be stimulated at the same time to enable 
comparisons of potential treatments at a similar disease stage. Although this may not 
be identical, it at least allows for some control on the variability that is inherent with 
clinical patient samples. In addition, the model enables the investigation of the 
effects of various stimuli, such as cytokines and mechanical compression (Patwari et 
al., 2003), both alone and in combination, to determine their individual effects on 
normal cartilage, whereas the multi-factorial aetiology of OA can make comparisons 
between patients difficult. Consequently, the cartilage explant model is a well-
established in vitro model for examining cartilage under various culture conditions. 
The aim of the studies in this chapter was to develop an in vitro explant model, 
stimulated with an inflammatory mediator to mimic the structural changes in early 
OA for future studies testing plant extracts for potential anti-catabolic and anti-
inflammatory effects. The pro-inflammatory cytokines IL-1 ~ ~ and TNF -a were tested 
in the model to induce cartilage degeneration indicative of OA, as they have been 
found in the synovial fluid of osteoarthritic equine joints (Morris et al., 1990; 
Billinghurst et al., 1995). Once the stimulus was determined, the anti-inflammatory 
phytochemical, curcumin, was used to test the model. A combination of colorimetric 
assays, immunoassays and western blotting were used to quantify various 
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degradation products, inflammatory mediators and catabolic enzymes in the explant 
culture medium in response to inflammatory stimuli and plant extracts. 
Due to the developmental nature of this chapter, the general methods are described 
first, then each of the studies charting the chronological development of the model 
are described in tum with the results and improvements for each study to show how 
the model developed. This is followed by a general discussion of the chapter. 
2.2. General Materials and Methods 
Tissue Collection 
Full depth, macroscopically normal articular cartilage samples as determined by 
observation of a smooth intact cartilage surface, clear viscous synovial fluid and a 
non-inflamed synovium, were obtained from weight-bearing regions of the 
metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints (unless 
otherwise stated) of horses of mixed breed, age and sex. Cartilage shavings were 
aseptically harvested into low glucose Dulbecco's modified Eagle's medium 
(DMEM; HyClone, Thermo Fisher Scientific) containing 4% penicillin/streptomycin 
(Sigma-Aldrich) before washing in phosphate-buffered saline (PBS) containing 10% 
penicillin/streptomycin for 20 minutes. Cartilage samples from each animal were 
kept separate throughout the studies. 
Cartilage Histology 
Histological samples of articular cartilage were taken from each joint to ensure that 
macroscopic identification of a healthy joint was supported by microscopic evidence. 
Cartilage was fixed in neutral buffered formalin for a minimum of 24 hours. Fixed 
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samples were processed overnight and embedded in paraffin. The blocks were 
sectioned at 51lm, mounted onto non-coated glass slides and left to dry. Tissue 
sections were then subjected to haematoxylin and eosin (H & E) staining. In brief, 
sections were de-waxed in Histo-Clear (National Diagnostics) for 30 minutes, 
followed by rehydration in a graded series of ethanol baths (100%, 95%, and 70%). 
Slides were washed in distilled water and stained with haematoxylin for 4 minutes. 
Slides were then washed in distilled water, dipped in 1 % industrial methylated spirit 
(lMS), washed in distilled water, dipped in ammoniated water and washed in 
distilled water. Tissue sections were then counterstained with eosin for 5 minutes. 
After thorough washing with distilled water, the sections were dehydrated in another 
series of graded ethanol baths (70%, 95%, and 100%). Sections were cleared in 
Histo-Clear, then Xylene (Thermo Fisher Scientific) for 5 minutes before mounting 
in DPX (Fluka) and leaving to set. Stained sections were photographed at X200 
using an inverted microscope (Leica DM5000B) fitted with a digital camera (Leica 
DFC350FX) and Leica Application Suite software. Sections were examined for 
irregularities in the articular surface. 
Some examples of joints and histology are shown in figure 9. A joint designated as 
suitable for collection via macroscopic and histological evidence are shown in figure 
9.A, whereas cartilage not suitable are shown in figure 9.B. 
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Figure 9. Selection of metacarpophalangeal joint cartilage for the explant model 
A. Photographs and histology slide of healthy cartilage as determined by 
observation of a smooth intact cartilage surface, clear viscous synovial fluid and a 
non-inflamed synovium. B. Photographs of unsuitable joints and haematoxylin and 
eosin stained tissue section of damaged articular cartilage. Criteria for exclusion 
included wear lines, fissures or irregularities on the articular surface, red synovial 
fluid, and! or subchondral bone cysts. 
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Cartilage Explant Preparation 
For all studies, full depth cartilage shavings were cut into 3mm discs using a biopsy 
punch. Three discs per well from the same animal were placed in 24-well plates 
containing Iml of culture medium (serum-free, low glucose DMEM supplemented 
with 2% penicillin/streptomycin) and allowed to equilibrate overnight at 37°C under 
5% C02. The following day, before the studies began, the overnight culture media 
were removed. 
2.3. Study 1. Human Cytokine Selection/or the Model 
This initial study sought to determine the appropriate inflammatory stimulus for the 
model as determined by the GAG assay, which quantitates the levels of sulphated 
GAGs in the media and explants. The study was carried out using human 
recombinant cytokines: I L - l ~ ~ and TNF-a, due to their known ability to induce 
cartilage degradation through proteoglycan breakdown (Pratta et al., 1989). 
2.3.1. Materials and Methods 
Cartilage was collected from the MCP and MTP joints of one horse. Explants were 
prepared as previously described. 
Study Design 
Overnight culture medium was removed and replaced with fresh culture medium 
containing the treatments (1 ml total volume per well). Treatments included; 
recombinant human IL-l ~ ~ (Roche Diagnostics; O.5ng/ml, 10ng/ml, and 25ng/ml), 
52 
recombinant TNF-a (Roche Diagnostics; 0.5ng/ml, lOng/ml, and 25ng/ml), and a 
combination of IL-IP and TNF-a (lOng/ml each). Each treatment was repeated in 
triplicate. Explants were incubated for five days at 37°C and 5% C02, after which 
time, media and explants were placed in separate 1.5ml microcentrifuge tubes and 
stored in a freezer at -20°C until ready to assay. 
Glycosaminoglycan Assay 
For evaluation of matrix GAG release, cartilage discs were digested in 1 ml papain 
buffer (O.IM sodium phosphate buffer, 5mM N-acetyl cysteine, 5mM 
Ethylenediaminetetraacetic acid (EDTA)) containing 1.5mg/ml papain (Sigma-
Aldrich) for 16 hours. Papain-digested cartilage and their corresponding 
supernatants were assayed in 96-well plates using the dimethylmethylene blue 
(DMMB; Sigma-Aldrich) method as described by (Farndale et al., 1982). The assay 
is colorimetric and quantifies sulphated GAGs in suspension through the dye 
molecules associating with the sulphate, causing a shift in absorption as the dye turns 
from blue to pink. In brief, each sample was diluted in duplicate in distilled water to 
a volume of 40111 per well. Although dilutions varied to ensure that the samples were 
read from the middle of the standard curve for accuracy, they were approximately 
1:5 for media samples and 1 :40 for digested cartilage. Shark chondroitin sulphate 
(Sigma-Aldrich) in papain buffer was used to prepare standards (0 - 70Ilg/ml). 
DMMB solution was prepared (16mg 1,9-DMMB in 1 litre of water containing 3.04g 
glycine, 2.37g sodium chloride, 95ml O.lM hydrochloric acid, pH3) and added to 
each well (200Ill/well). Plates were immediately read on a plate reader (Multiskan 
Ascent, Thermo LabSystems) and assayed using Ascent Software (version 2.6, 
Thermo LabSystems). Total GAG release was obtained from a spectrophotometric 
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reading of the digested cartilage and its corresponding supernatant at 540nm. 
Percentage of GAG release from the total GAG content of the explants was 
calculated by dividing the supernatant value from the total GAG release for each 
well. 
Statistical Analysis 
Percentage GAG release data from each treatment in triplicate were combined and a 
one-way between-groups ANOV A was conducted to test for a statistically significant 
difference at the p<0.05 level. Post hoc comparisons using the Tukey test were 
conducted with GraphPad Instat (version 3.05, GraphPad Software Inc.) to determine 
where the differences among the groups occurred. Data were plotted using 
GraphPad Prism (version 4, GraphPad Software Inc.). Values are reported as means 
of three replicates per treatment from one horse ± standard error of the means (SEM). 
2.3.2. Results 
Control explants released a mean percentage of 11.92 ± 0.82% GAG over 5 days 
(figure 10). Recombinant human IL-IP significantly increased GAG release 
compared to controls at 0.5ng/ml (29.18 ± 3.79%, p<O.OOI), lOng/ml (32.30 ± 
2.58%, p<O.OOl) and 25ng/ml (31.55 ± 0.69%, p<O.OOl). TNF-a significantly 
increased GAG release, compared to controls, at 25ng/ml (22.78 ± 2.07%, p<0.05). 
IL-IP and TNF-a combined (lOng/ml each) resulted in a mean GAG release of29.77 
± 3.23%, which was significantly higher than controls (p<O.OOl). 
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Figure 10. Percentage of glycosaminoglycans (GAGs) released from cartilage 
explants after 5 days, in response to recombinant human interleu kin-l beta (I L-
1 P), tumour necrosis factor-alpha (TNF -a), or in combination 
Graphs give mean values collatedfi-om replicate wells (3 replicates per trealment) 
and bars represent standard error of the means (SEM) . Significance compared to 
control explants is shown by * (p <O.05) and *** (p <O.OOJ). 
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2.3.3. Discussion 
The aim of this study was to assess the degradative capacity of human IL-l p and 
TNF-a, alone and in combination, in the equine cartilage explant model, and to 
determine which cytokine (individually or in combination) was the most effective 
catabolic stimulus for the model as indicated by a GAG assay. The pro-
inflammatory cytokine, IL-l p, causes increased release of cartilage degrading MMPs 
from chondrocytes (Mort et al., 1993). In agreement with this, the present study 
showed that human IL-l p effectively stimulated GAG release from equine cartilage 
explants. This finding concurs with several other studies reporting that human IL-l p 
is an effective inducer of cartilage degradation in explants from a variety of species 
including human, (Mort et al., 1993), bovine (Smith et al., 1989) and equine (Bird et 
al., 1997). 
TNF-a inhibits cartilage proteoglycan synthesis and is thought to mediate many of its 
effects on cartilage through the production of NO (Saklatvala, 1986; Goodstone and 
Hardingham, 2002). As well as reducing cartilage anabolism, TNF -a also has 
catabolic effects, being capable of inducing focal loss of cartilage in OA (Westacott 
et al., 2000). In the cartilage explant model, human TNF-a produced a significant 
increase in GAG release from the explants at a concentration of 2Sng/ml. This is 
lower than some previous reports in other species where increased GAG release 
compared to control was not seen until seen at 100ng/ml TNF-a in bovine MCP 
cartilage explants (Gilbert et al., 2004). However, other studies have found 
concentrations as low as 10ng/ml TNF -a can increase proteoglycan degradation in 
cartilage explants (Pratta et al., 1989) and meniscal explants (Voigt et al., 2009). 
The high variation in levels ofTNF-a receptors within joints and between individuals 
(Westacott et al., 2000), may account for differences between studies. This may also 
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explain the lack of significance at concentrations under 2Sng/ml seen in the present 
study. Thus, further studies with larger numbers of animals may be needed to 
account for the individual variation in response to TNF-a.. 
Due to the complex nature of OA, it was decided that a combination of the two 
cytokines should also be investigated. The involvement of the two cytokines in OA 
is evident from the combined use of receptor antagonists to IL-l ~ ~ and TNF -a. to 
reduce collagen type II cleavage and GAG release from human OA cartilage explants 
(Kobayashi et al., 200S). The combination of I L - l ~ ~ and TNF-a. (lOng/ml each) 
significantly increased GAG release compared to control. Combining cytokines has 
been shown to have a greater effect on GAG release than either cytokine alone. For 
example, in bovine nasal explants, TNF-a. alone (2ng/ml) caused approximately 30% 
GAG release, IL-17 alone (O.Sng/ml) caused approximately 3S% GAG release, 
whereas a combination of the two (2ng/ml + O.Sng/ml) combined caused 
approximately 65% GAG release (Koshy et al., 2002). However, the current study 
showed that, in terms of GAG release, there was no advantage of using two 
cytokines in the model. Therefore, in the interests of economy, IL-l ~ ~ alone was 
selected for the model as it effectively increased GAG release at all the 
concentrations tested. 
However, this study only provided preliminary results from one horse; therefore, a 
further study was required with larger numbers of animals to determine the reliability 
of IL-l ~ ~ to consistently increase GAG release from explants. 
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2.4. Study 2. Determination o/Optimal Human IL-IP Dose Ranges 
The initial study established that IL-I ~ ~ was an effective inducer of cartilage 
degradation in the model as indicated by the GAG assay. Thus, I L - I ~ ~ was selected 
for the model, but to optimize the stimulus and check that results were consistent 
with the previous study, cartilage explants from multiple horses were subjected to a 
range of human recombinant IL-I ~ ~ concentrations. 
2.4.1. Materials and Methods 
Cartilage from eight horses was used for the study. Each treatment was repeated in 
triplicate per horse, but not all horses were used for all treatments due to space 
constrictions on the plate, which resulted in different n numbers (where n = 
individual horses) for the various treatments. Control wells (n=8) contained Iml of 
DMEM supplemented with 2% penicillin/streptomycin. Recombinant human IL-l ~ ~
was diluted in the control medium to the following concentrations and added to each 
of the three wells per horse; O.5nglml (n=4), lOng/ml (n=5), 17ng/ml (n=3), 25ng/ml 
(n=4). Explants were then placed in an incubator at 37°C and 5% C02 for five days. 
Culture supernatants were placed into individual microcentrifuge tubes and stored in 
a freezer at -20°C before undergoing a GAG assay as previously described (page 53). 
Statistical Analysis 
Percentage GAG release data from each treatment in triplicate were combined for 
each horse and a one-way between-groups ANOV A was conducted to test for a 
statistically significant difference at the p<O.05 level. Data from all horses, except 
horse G which did not respond to IL-I ~ ~ treatment, were then combined and analysed 
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with a one-way ANOV A. Post hoc compansons usmg the Tukey test were 
conducted to determine where the differences among the treatment groups occurred. 
Values are reported as means of three replicates per treatment from seven horses ± 
SEM. 
2.4.2. Results 
Upon analysing the results from individual horses, it could be seen that cartilage 
from one horse (horse G) did not respond to the addition o f I L - l ~ ~ (figure 11). It was 
decided that data from this animal should be excluded from the analysis as it was a 
non-responder and would skew the data when combined with the other horses. 
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Figure It. Percentage of glycosaminoglycans (GAGs) released from 
recombinant human interleukin-l beta (IL-l p)-stimulated cartilage explants 
from a non-responder (horse G) after 5 days 
Graphs give mean values collated from replicate wells (3 replicates per treatment) 
and bars represent standard error of the means (SEM). No significant differences 
between control and /L-J p-treated ex plants were found 
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Due to the omission of horse G from the results, the final number of horses included 
was n=7, although not all horses received all doses of the cytokine due to space 
restrictions on the plates. At all the concentrations tested, IL-1 ~ ~ significantly 
increased GAG release compared to controls (figure 12). 
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Figure 12. Percentage of glycosaminoglycans (GAGs) released from cartilage 
explants after 5 days, in response to recombinant human interleukin-l beta (IL-
IP) 
Graphs give mean values collated from replicate wells (3 replicates per horse per 
treatment) and bars represent standard error of the means (SEM). Significance 
compared to control ex plants is shown by ** (p<O.OJ) and *** (p<O.OOJ). 
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Control explants from the seven horses released a mean percentage GAG release of 
10.35 ± 0.80% over five days. GAG release was significantly increased from 
controls by the addition of recombinant human IL-l B at 0.5ng/ml (19.42 ± 2.23%, 
n=4, p<O.Ol), lOng/ml (28.39 ± 2.22%, n=5, p<O.OOl), 17ng/ml (27.61 ± 3.08%, 
n=3,p<0.001) and 25ng/ml (35.93 ± 2.57%, n=4,p<0.001). 
2.4.3. Discussion 
In agreement with the prevIous study, recombinant human IL-l B significantly 
increased GAG release at all concentrations tested compared to controls in a larger 
number of horses. Thus, it was decided that IL-l B was a suitable stimulus for the 
model. With regard to consistency, the percentage GAG data in this study using 
multiple horses was within 5% ofthe values reported in the previous study using one 
horse for 10ng/ml and 25ng/ml IL-1 B. However, there was larger variance of about 
10% for O.Sng/ml IL-l B, which affirms why it was important to test the variability in 
response to IL-1 B with multiple horses. Similar to the previous study, IL-1 B 
(10ng/ml) produced an increase in GAG release which was significant at the p<O.OO 1 
level. This concurs with several other studies that have used human IL-1 B (1 Ong/ml) 
to significantly increase GAG loss in other species as measured by either increased 
content in medium or decreased GAG content in the cartilage itself (Venkatesan et 
al., 2004; Miller et al., 2007). 
One horse was excluded from the results (horse G) as no response, in terms of GAG 
release, was observed with the addition of IL-1 B. This could have been due to 
experimental error, but more likely the physiological status of the cartilage, notably 
age. Decreased responsiveness to cytokine stimulation has been noted in cartilage 
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from older horses (MacDonald et al., 1992; Fuller et al., 2001). The age of horse G 
was unknown and it is reasonable to suggest that age could have accounted for the 
lack of response to IL-1 ~ ~ treatment. The exclusion of horses that do not respond to 
catabolic stimuli has been reported previously (Petrov et al., 2005). Therefore, it was 
decided that data from this animal should be excluded from the analysis as it was a 
non-responder and would skew the data when combined with the other horses. This 
set the precedent for future studies that if cartilage explants from a horse did not 
respond to IL-1 ~ ~ addition with a significant increase in GAG loss, the data from that 
animal should be excluded from the overall analysis. 
2.5. Study 3. Testing the Human IL-Ip-Stimulated Model Using Curcumin and 
IGF-I 
The aim of the next study was to use the phytochemical curcumin to test the model 
as it has known anti-inflammatory properties, which may reduce cartilage 
degradation. Curcumin (diferuloylmethane) is a polyphenol found in turmeric 
derived from the rhizomes of Curcuma longa. Curcumin has both anti-inflammatory 
and anti-oxidant properties (Brouet and Ohshima, 1995; Sreejayan and Rao, 1997) 
and has been studied in clinical trials of patients with rheumatoid arthritis (RA) 
(Deodhar et al., 1980). At concentrations between 50-1 O O ~ M M it has been shown to 
have anti-inflammatory properties via its suppressive effects on I kappa B kinase 
(lKB) activity and consequently the NF-KB signalling pathway in various cell types, 
including chondrocytes (Jobin et al., 1999; Shakibaei et al., 2007). 
Curcumin is poorly soluble in aqueous solutions, but easily solubilised in organic 
solvents, such as dimethyl sulfoxide (DMSO) (Tonnesen and Karlsen, 1985). To 
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reduce any potential effects of DMSO on cartilage, a concentrated stock solution of 
curcumin (} OOmM) was prepared in DMSO to allow dilution in DMEM to a working 
concentration of no more than O.O} % DMSO in the highest curcumin concentration. 
Curcumin was tested against two IL-} ~ ~ concentrations used in the previous study, 
} Ong/ml and 2Sng/ml, to assess its effects on reducing GAG release on different 
parts of the dose response curve. 
When testing the model with plant extracts it was important to include a positive 
control on each plate, to ensure that a reduction in GAG release was achievable. 
Recombinant human IGF-l (lOng/ml) was selected as a positive control, due to its 
known antagonistic action on cytokine-induced proteoglycan release (Tyler, 1989). 
2.5.1. Materials and Methods 
Curcumin Preparation 
Highly concentrated stock solutions (} OOmM) of curcumin extracted from Curcuma 
longa (Sigma-Aldrich, C1386) were prepared in DMSO (Sigma-Aldrich) and diluted 
down to a 1 mM stock solution in DMEM, from which they were further diluted in 
the culture medium to their final working concentrations. In the highest 
concentration of curcumin tested in the model (100JlM), the volume of DMSO did 
not exceed 0.01% of the Iml total volume in each well. Multiple 100mM stocks of 
curcumin were aliquotted and frozen at -20°C. 
Study Design 
MCP and MTP joint cartilage from six horses was used for this study. A vial of 
100mM curcumin stock (made as described above) was defrosted and diluted to a 
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1 mM stock in DMEM. The following test concentrations were then further diluted 
in DMEM; O . l ~ M , , 0 . 5 ~ M , , l ~ M , , l O ~ M M and 1 0 0 ~ M . . Each treatment used three 
wells on each of two 24-well plates per horse. The first plate for each horse 
contained the cartilage in culture medium with the extracts to assess the effect of 
curcumin on 'normal' cartilage. The second plate contained the cartilage in culture 
medium co-treated with curcumin and either 10ng/ml (n=3) or 25ng/ml (n=3) human 
recombinant IL-l ~ ~ to induce cartilage inflammation and matrix degradation. These 
two concentrations were used so that the effect of curcumin could be assessed at 
different stages of the IL-I ~ ~ dose response curve. Both plates contained culture 
medium, which acted as the control and the base medium for other treatments. 
Recombinant human IGF-I (Roche Diagnostics; lOng/ml) was included on the IL-
I ~ - s t i m u l a t e d d plates as a positive control, and on the non-IL-I ~ - t r e a t e d d plates to 
ensure it had no detrimental effects in the absence of I L - l ~ . . Plates were incubated at 
37°C and 5% C02 for five days. Supernatants and explants were placed into 
individual microcentrifuge tubes and stored in a freezer at -20°C for until undergoing 
a GAG assay as previously described (page 53). 
Curcumin GAG Assay 
Samples underwent a GAG assay as previously described (page 53), but first a 
preliminary test was undertaken to ensure that there was no native GAG present 
within the curcumin and/ or that the presence of curcumin did not change the colour 
of the dye thereby affecting the colorimetric reading of the assay. In order to do this, 
curcumin stocks (0.1 ~ M , , 0.5 ~ M , , I ~ M , , 5 ~ M , , I O ~ M , , 1 0 0 ~ M M and I mM) were 
prepared in water added to the wells of a 96-well plate in duplicate. The stocks were 
added to the wells undiluted ( 4 0 ~ 1 1 per well) unlike when testing samples where they 
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are further diluted in water. This was to test the most concentrated curcumin samples 
for any effect. The DMMB solution was added and the plate was read as previously 
described (page 53). Photographs of the plate were taken as a visual addition to the 
results. 
Statistical Analysis 
Percentage GAG release data for each horse were statistically analysed individually. 
This highlighted that one horse in the IL-l ~ ~ (I Ong/ml) treated group was 
unresponsive to I L - I ~ , , so it was removed from the combined analyses. Thus, all 
data from the non-IL-l ~ - t r e a t e d d samples in triplicate from five horses (not six) were 
combined and statistically analyzed using a one-way ANOVA with Tukey's multiple 
comparison post hoc test. Similarly data from the IL-I ~ ~ treated plates were 
combined into either the 10ng/ml IL-I ~ ~ treatment group (n=2) or the 25ng/ml IL-I ~ ~
treatment group (n=3), with each group undergoing a one-way AN OVA with post 
hoc Tukey's test. For all analyses, statistical significance was set at p<0.05. Values 
are reported as means of combined animals + SEM. 
2.5.2. Results 
Curcumin contains no native GAG 
To ascertain whether any native GAGs were present in the curcumin preparations 
that could affect the colorimetric reading of the assay, neat stocks of curcumin were 
tested from 0.1 JlM to 1 mM in the 96 well plates (figure 13). The standards show the 
colour range of the DMMB assay ranging from pink (high levels of GAGs) to blue 
(low levels of GAGs). On the same plate, the curcumin stocks were assessed and it 
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could be seen from the blue colour that no GAGs were present. The GAG values 
obtained from this plate, showed that all concentrations of curcumin gave a value of 
OJlg sulphated GAG/ml from the assay, with the exception of 1 mM which altered the 
colour of well and gave a value of 24.75 Jlg/ml. However, the well was not pink in 
colour, which would have indicated the presence of GAG. Instead, the well was 
yellow, suggesting that the curcumin was affecting the reading, and not the presence 
of native GAG. It should be mentioned here that no explants were ever tested at this 
curcumin concentration (1 mM). In addition, all the curcumin stocks were tested 
neat, whereas all treatment samples were heavily diluted in water before running on 
the plate. Therefore, it was concluded that at the concentrations tested, curcumin has 
no native GAG content which could affect the assay. 
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Standards Curcumin 
70 ~ g / m l l - 3 0 ~ g / m l l 0 . 1 ~ M M -
60 ~ g / m l l - 2 0 ~ g / m l l
50 ~ g / m l l - 1 0 ~ g / m l l - 1mM 
40 ~ g / m l l - O ~ g / m l l - Blank 
Figure 13. Annotated photographs of a glycosaminoglycan (GAG) assay plate 
Plate contains the chondroitin sulphate standards (J.l.glml) from which the standard 
curve is derived and the wells containing curcumin stocks. All wells contain the 
dimethylmethylene blue (DMMB) dye which turns pink when it reacts with sulphated 
GAGs. 
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Curcumin and IGF-I Do Not Significantly Change GAG Release From 
Unstimulated Cartilage Explants Compared to Controls 
Control explants released a mean percentage GAG (mean GAG % ± SEM) of 11.02 
± 1.16% (figure 14). Neither IGF-1 nor any of the curcumin concentrations tested 
had any significant effects compared to controls in the non-IL-l p-treated samples. 
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Figure 14. Percentage of glycosaminoglycans (GAGs) released from nOI1-
interleukin-I beta (I L-I p)-treated cartilage explants from five horses after 5 
days, in response to insulin-like growth factor-I (lGF -I; JOng/ml) and curcumin 
(O.I-IOOJlM) 
Graphs give mean values collated from replicate wells (3 replicates per treatment) 
from 5 horses from 2 separate experiments. No sign[flcant differences compared to 
control were found. Bars represent standard error of the means (SEM). 
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Curcumin (lOOJlM) and IGF-I (IOng/ml and 2Sng/ml) Significantly Reduce IL-
IP Stimulated GAG Release From Cartilage Explants 
Mean control levels of GAG release differed between the IL-l ~ ~ (lOng/ml) group 
(figure IS) and the IL-l ~ ~ (2Sng/ml) group (figure 16) with explants releasing 6.S6 ± 
0.68% and 13 .21 ± 1.24% respectively. However, both IL-l ~ ~ concentrations 
significantly increased GAG release at lOng/ml (32.28 ± S.34%, p<O.OOI) and 
2Sng/ml (37.39 ± 3.32%,p<0.001). 
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Figure 15. Percentage release of glycosaminoglycans (GAGs) into culture 
medium from cartilage explants treated with recombinant human interleukin-
Ibeta (IL-l(J; IOng/ml) and insulin-like growth factor-l (IGF-I; IOng/ml) or 
curcumin (O.I-100J'M) 
Significance compared to IL-lfJ is indicated by * (p<O.05) and *** (p<O.OOl). 
Graphs give mean values collated from replicate wells (3 replicates per treatment) 
from 2 horses and bars represent standard error of the means (SEM). Control 
indicates cartilage discs incubated in the culture medium alone. 
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Figure t6. Percentage release of glycosaminoglycans (GAGs) into culture 
medium from cartilage explants treated with recombinant human interleukin-
tbeta (IL-tp; 2Sng/ml) and insulin-like growth factor-l (IGF-l; lOng/ml) or 
curcumin (O.t-tOOJiM) 
Significance compared to IL-lP is indicated by *** (p<O.OOl). Graphs give mean 
values collated from replicate wells (3 replicates per treatment) from 3 horses and 
bars represent standard error of the means (SEM). Control indicates cartilage discs 
incubated in the culture medium alone. 
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IGF-l (10ng/ml) significantly reduced IL-l ~ - s t i m u l a t e d d GAG release at both 
10ng/ml I L - l ~ ~ (16.92 ± 2.34%, p<0.05) and 25ng/ml I L - I ~ ~ (18.27 ± 3.03%, 
p<O.OO 1). Curcumin, at concentrations between 0.1 and 101lM, had no significant 
effect on reducing GAG release from explants co-treated with IL-l ~ ~ at either 
concentration. However, curcumin at IOOIlM significantly reduced the percentage of 
IL-I ~ - s t i m u l a t e d d GAG release down to unstimulated control levels when exposed to 
I L - I ~ ~ at either lOnglml (6.39 ± 0.84%, p<O.OOI) or 25ng/ml (10.16 ± 0.69%, 
p<O.OO 1). This meant a reduction in GAG release from the explants by an average of 
26% at 10nglml (p<0.00 1) and 27% at 25ng/ml (p<0.00 1). 
2.5.3. Discussion 
The aim of the present study was to use an in vitro explant model stimulated with an 
inflammatory mediator to induce cartilage changes typical of early OA and to test the 
model using curcumin, due to its anti-inflammatory effects and associated 
downstream benefits. Curcumin has been reported to protect human chondrocytes 
from IL-l ~ - i n d u c e d d activation and nuclear translocation of NF -KB thereby also 
protecting against inhibition of collagen type II and ~ ~ l-integrin expression, and up-
regulation of COX-2, MMP-9 and MMP-3 (Schulze-Tanzil et al., 2004; Shakibaei et 
al., 2007). Studies by other investigators have shown that curcumin inhibits MMP-l, 
MMP-3, MMP-13, ADAMTS-4 and TIMP-3 gene expression in chondrocytes 
stimulated with I L - I ~ , , TNF-a and OSM, a member of the IL-6 superfamily of pro-
inflammatory cytokines (Li et al., 2001; Liacini et al., 2002; Liacini et al., 2003; 
Sylvester et al., 2004). The results from the present study showed that curcumin at 
concentrations between O.IIlM and IOOIlM had no effect on unstimulated cartilage, 
suggesting that it has no gross effect on altering normal cartilage. However, 
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curcumin at 1 O O ~ M M effectively reduced IL-I ~ ~ stimulated GAG loss down to control 
levels in the presence of both 10ng/ml and 2Sng/ml I L - I ~ . . The reduced GAG loss 
observed in the present study may be attributed to the inhibitory effect of curcumin 
on the NF-KB inflammatory pathway and the mediators of cartilage degradation such 
as MMPs and ADAMTSs. This effect could initially occur between the doses of 
10flM and 100flM used in this study and further studies are warranted to determine 
whether the beneficial effect in reducing GAG release is seen within this 
concentration range. It is important to emphasize that the observation of reduced 
GAG release from the explants in the presence of higher concentrations of curcumin 
may not be a specific biological effect of curcumin. High concentrations of 
curcumin may, in fact, be toxic to chondrocytes (Toegel et al., 2008). Therefore, any 
curcumin-induced cytotoxicity would interfere with proteoglycan metabolism in the 
explant model and this may be reflected in the results of the GAG assays. 
Consequently, the observed reduction in GAG loss from the explants in the presence 
of high concentrations of curcumin may be due to curcumin induced cell death, 
which would influence the expression of matrix degrading enzymes. Thus, 
chondrocyte viability testing will be an essential pre-requisite in future studies in 
order to determine the precise mode of action of curcumin in the explant model. 
IGF-I is a growth factor involved in cartilage anabolism and can counteract the 
degenerative effects of pro-inflammatory agents (Tyler, 1989). In this study, human 
IGF-I (lOng/ml) effectively reduced IL-I ~ - s t i m u l a t e d d GAG release without affecting 
cartilage GAG release in the absence of I L - I ~ . . This is in agreement with previous 
studies which have found IGF-I to counteract IL-I a or IL-l p-stimulated 
proteoglycan release from porcine (Fosang et al., 1991 b) and equine (Frisbie and 
Nixon, 1997) cartilage explants. Thus, IGF -I was a suitable positive control for the 
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model. Although no effect on GAG release was observed with IGF-I alone in 
comparison to controls, it does not mean it has no effect on unstimulated cartilage. It 
is more likely that the effects were not detected by the assay used in this study. 
Although control levels of GAG release in individual animals varied, as would be 
expected with cartilage samples from individuals of unknown age, breed and 
background, the presence of IL-I p caused a significant increase in GAG release in all 
but one animal. The IL-I p-stimulated GAG release was always reduced to the 
control level for each individual animal by the addition of IOOIlM curcumin. Despite 
biological variation between animals, the reproducibility of the results suggests that 
this model is an effective in vitro system for testing the anti-catabolic potential of 
novel nutraceuticals and botanical extracts. These results suggest that in using 
curcumin, the GAG assay was able to pick up differences in GAG release consistent 
with the catabolic effects of IL-I p. It can be seen that curcumin antagonizes GAG 
release in vitro. However, further work is clearly needed to investigate the biological 
effects of curcumin at higher concentrations in order to determine its true efficacy 
and potential safety. 
Despite the significant effects observed in this study suggesting that human IL-I p is 
a suitable catabolic agent in the model, several studies have raised concerns about the 
applicability of human IL-I p to experiments using cells from different species such 
as bovine and equine (Lederer and Czuprynski, 1989; May et al., 1992). Using 
human recombinant IL-I p for high-throughput screening of anti-inflammatory 
botanicals, such as curcumin, that might support joint health in OA has distinct 
advantages over species specific IL-l p, in terms of lower cost and increased 
commercial availability. However, species-specific cytokines are more biologically 
relevant and hence, may be more appropriate for models studying the pathogenesis of 
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OA in a particular species. Therefore, it was decided that equine IL-I ~ ~ should be 
investigated in the model. 
2.6. Study 4. Using Equine IL-IP and Testing the Model Using Curcumin and 
IGF-l 
In the interests of biological relevance, a second study was conducted usmg 
recombinant equine IL-I ~ ~ in the model. Instead of repeating the previous 
experiments with multiple cytokines, equine IL-I ~ ~ was selected as the cytokine of 
choice and was tested at 10ng/mi in conjunction with the previous studies and other 
published literature. Following on from previous work, the aim of the present study 
was to investigate the effects of equine IL-I ~ ~ on cartilage degradation and 
inflammation, and to determine whether curcumin at concentrations between 10)lM 
and 100J.lM could reduce these effects. 
Due to the inflammatory nature of OA (Hedbom and Hauselmann, 2002) and the 
anti-inflammatory properties of many phytochemicals including curcumin (Jackson 
et al., 2006), the level of the inflammatory mediating prostanoid, PGE2, was 
measured in the media, in addition to the release of sulphated GAGs. 
2.6.1. Materials and Methods 
Study Design 
Mep joints from three horses were used for this study to reduce variation. Explants 
were treated as either controls using culture medium alone or with recombinant 
equine IL-I ~ ~ (R&D Systems; 10nglml) in culture medium, to a final volume of I ml 
per well. A frozen vial of curcumin 100mM (made as previously described on page 
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65) was defrosted and diluted to 1 mM in DMEM. This 1 mM stock was diluted 
further in DMEM to form the test concentrations of 2SflM, SOflM, 7SflM and 
100flM, which were added to wells to a total volume of 1 ml containing IL-1 ~ ~
(10ng/ml) per well. Treatments were repeated in triplicate wells per horse. The 
study was conducted over two experiments due to supply issues with the abattoir. 
Two horses were assessed in one study, then repeated with another horse two months 
later. 
The volume of DMSO did not exceed 0.01% of the 1 ml per well in the highest 
concentration of curcumin tested. Explants were incubated for 5 days (37°C/ 5% 
C02), after which time both explants and corresponding supernatants were removed 
and frozen at -20°C until ready to assay for GAG content as previously described 
(page 53), or for PGE2 content. 
PGE2 Assay (Normal Sensitivity) 
A competitive immunoassay kit (R&D Systems) was used to measure PGE2 
according to the manufacturer's instructions. Standards (39 - 20S0pg/ml) and 
supernatant samples (1 OOfll) were added to a 96-well plate coated in goat anti-mouse 
polyclonal antibody, followed by SOfll primary mouse monoclonal antibody solution 
and SOfll of PGE2 conjugate. The plate was covered and incubated for 2 hours at 
room temperature (21°C) on an orbital shaker at 500 revolutions per minute (rpm). 
The plate was thoroughly washed before adding 200fll substrate solution to each well 
and developing in the dark at room temperature for 30 minutes. Stop solution (50111) 
was added and the plate was read immediately on a plate reader at 4S0nm with 
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wavelength correction set at 540nm using Ascent Software (version 2.6). The 
standard curve was calculated using a four parameter logistic curve-fit. 
Statistical Analysis 
Percentage GAG release data from the three horses were combined and statistically 
analyzed using a one-way ANOV A with Tukey's multiple comparison post hoc test. 
Similarly, PGE2 data from the same samples were combined and analysed using a 
one-way ANOVA with post hoc Tukey's test. For all analyses, statistical 
significance was set at p<0.05. Values are reported as means of combined animals ± 
SEM. 
2.6.2. Results 
Curcumin Significantly Reduced IL-lp-Stimulated GAG Release ( ~ 5 0 J 1 M ) ) and 
PGE2 Release ( ~ 2 5 J 1 M ) )
Control explants from the three horses used for this study released a mean GAG 
percentage of 14.03 ± 1.36% after five days in culture (figure 17). The addition of 
IL-l ~ ~ (IOng/ml) resulted in significantly higher GAG release from the ex plants 
(40.83 ± 3.21%,p<0.001). IGF-l had no significant effect on reducing GAG release 
compared to IL-l ~ ~ alone (36.00 ± 5.58%, n.s). Curcumin (25jlM) did not 
significantly reduce IL-l ~ - s t i m u l a t e d d GAG release (32.45 ± 7.85%, n.s). However, 
IL-l ~ - i n d u c e d d GAG release was significantly reduced by curcumin at 50jlM (21.41 ± 
2.89%; p<0.05), 75jlM (15.93 ± 3.41%; p<O.OI) and 100jlM (9.78 ± 0.96%; 
p<O.OOI). 
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Explants in DMEM alone released 64.48 ± 8.93pg/ml (mean PGE2 pg/ml ± SEM) 
PGE2 over 5 days (figure 18). PGE2 release was significantly increased by the 
presence of lOng/ml IL-IP (226.40 ± 24.82pg/ml; p<O.OI). IGF-l did not 
significantly affect PGE2 release compared to IL-l palone (326.00 ± 66.97pg/ml; 
n.s). However, curcumin effectively attenuated the release of PGE2 caused by IL-l P 
treatment at all concentrations tested; 25/lM (54.65 ± 6.03pg/ml, p<0.05), 50/lM 
(56.01 ± 9.18pg/ml,p<0.01), 75/lM (75.40 ± 9.28pg/ml,p<0.01) and 100/lM (64.98 
± 4.83pg/ml, p<O.O 1). 
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Figure 17. Percentage release of cartilage glycosaminoglycans (GAGs) into 
culture medium from recombinant equine interleukin-lbeta (IL-IP; lOng/ml)-
treated cartilage explants in response to insulin-like growth factor-l (IGF-t; 
lOng/ml) or curcumin (25-100JiM) 
Significance compared to IL-lP is indicated by * (p<O.05), ** (p<O.Ol) and *** 
(p<O.OOl). Graphs give mean values collated from replicate wells (3 replicates per 
treatment) from 3 horses and bars represent standard error of the means (SEM). 
Control indicates cartilage discs incubated in the culture medium alone. 
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Figure 18. Prostaglandin E2 (PGE2) release from recombinant equine 
interleukin-l beta (IL-lfJ; lOng/ml)-treated cartilage explants into culture 
medium in response to insulin-like growth factor-l (IGF-l; lOng/ml) or 
curcumin (25-l00fJM) 
Significance compared to IL-IP is indicated by * (p<O.05) and ** (p<O.Ol). 
Controls indicate cartilage discs incubated in culture medium alone. Graphs show 
the mean of 3 replicates from 3 horses per treatment and bars represent standard 
error of the means (SEM). 
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2.6.3. Discussion 
This study set out to ascertain whether equine IL-I ~ ~ at 10ng/ml could increase GAG 
and PGE2 release from cartilage explants in the culture media, and to determine 
whether curcumin could effectively reduce these species-specific cytokine effects. 
Equine IL-I ~ ~ (10ng/ml) significantly increased GAG release from the cartilage 
explants compared to controls. The mean GAG release from the equine I L - I ~ ~
treated explants was higher (40.83%), compared with the previous studies in the 
chapter using human IL-I ~ ~ at the same concentration (32.30% study I, 28.39% study 
2 and 32.28% study 3). In terms of percentage increase from controls, the studies 
using human IL-l ~ ~ (10ng/ml) caused an average 21 % increase in GAG release from 
control levels, whereas equine IL-I ~ ~ caused a 27% increase. Thus, equine IL-I ~ ~
induces greater GAG loss from equine explants compared to human IL-I ~ ~ at an 
equivalent concentration (10ng/ml) in the model and is therefore a suitable stimulus 
for inducing GAG loss. 
Curcumin at 50llM and above significantly reduced IL-I ~ - s t i m u l a t e d d GAG loss. 
Previously, we observed that curcumin (100IlM) significantly reduced human I L - I ~ ~
stimulated GAG release from equine cartilage explants, but this effect was not seen 
at 101lM. This effect may be initiated at 50llM but it must be remembered that the 
previous study used human IL-l ~ ~ on equine explants, which induced lower levels of 
GAG release compared to the equine I L - I ~ ~ used in the current study. 
Inflammatory mediators playa critical role in the development and progression of 
OA. PGE2 levels are significantly increased in osteoarthritic joints compared to 
normal joints (Kirker-Head et al., 2000) and for this reason it was chosen as a marker 
of inflammation in this study. I L - I ~ ~ significantly increased the release ofPGE2 from 
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normal equIne articular cartilage explants compared to non-stimulated controls, 
consistent with previous equine explant studies (Takafuji et al., 2002; Petrov et al., 
2005). 
The anti-inflammatory effects of curcumin (Jagetia and Aggarwal, 2007) have 
generated increasing interest in its potential for the treatment of inflammatory 
diseases. Curcumin significantly reduced IL-J ~ - s t i m u l a t e d d PGE2 release at all 
concentrations tested, from 2 5 ~ M M and above. Curcumin is thought to exert its anti-
inflammatory effects through reducing COX-J (Handler et al., 2007), COX-2 (Hong 
et al., 2004) and mPGES expression (Moon et al., 2005), thus preventing PGE2 
release. This is most likely due to its inhibitory effect on the upstream NF-KB-
signalling pathway which promotes PGE2 production via up-regulating the COX and 
PGES genes (Catley et al., 2003). Other studies have found significant anti-
inflammatory effects of curcumin on other cells types at lower concentrations. No 
curcumin concentrations tested in this study failed to reduce IL-J ~ - s t i m u l a t e d d PGE2 
release, thus it is likely that concentrations lower than 2 5 ~ M M are likely to exert anti-
inflammatory effects on cartilage explants in this model. 
With regard to the PGE2 assay, the method used was the normal sensitivity option, 
which detected PGE2 levels in the culture media of between 39 - 2050pg/ml. 
However, all the samples contained less than 1200pg/ml, meaning that measurements 
were read from the lower part of the curve. Therefore, future studies should use the 
high sensitivity method, which has a range of 19 .6-1250pg/ml. 
Interestingly, IGF-l was not effective in the model, in that it did not significantly 
reduce IL-l ~ - s t i m u l a t e d d GAG release, as had been observed previously. This 
indicated that the positive control had failed in the model. However, it could be seen 
that the data were consistent in that the explants responded to IL-l ~ ~ and that 
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curcumin reduced both GAG and PGE2 release from the IL-I ~ - s t i m u l a t e d d explants. 
This suggested that the model was still working and so it was IGF -I that had failed. 
Suggested reasons for the inability ofIGF-I to reduce I L - I ~ - s t i m u l a t e d d GAG release 
from the explants included reduced performance due to long term freezer storage and 
the change from human to equine IL-I ~ ~ which may have reduced the efficacy of the 
human IGF-I. In addition, there is thought to be an age related decline in the 
responsiveness of chondrocytes to IGF -I which is mediated in part by an increase in 
I G F binding proteins (Martin et al., 1997). Therefore, as the ages of the animals 
used in the study were unknown, it is possible that age may account for the lack of 
effect oflGF-I. However, despite this, IGF-I was not a suitable positive control for 
the new parameter of PGE2. Thus, a new positive control capable of reducing both 
PGE2 and GAG release was needed for the model. 
2.7. Study 5. Vehicle Controls 
Curcumin in DMSO effectively reduced I L - I ~ - s t i m u l a t e d d GAG and PGE2 release 
from the cartilage explants. However, DMSO has been found to have a detrimental 
effect on cartilage explant integrity, causing reduced proteoglycan synthesis after 3 
days in both bovine cartilage at 10% (Matthews et al., 1998), and in equine cartilage 
at 5% and above (Smith et al., 2000). Thus, it was important to carry out DMSO 
controls in order to determine whether the anti-catabolic and anti-inflammatory 
effects of curcumin were accurate or due to the DMSO vehicle. Vehicle controls 
containing the maximum volume of DMSO present in the weBs of the highest 
concentration of curcumin (lOOJlM) were used to elucidate whether observed effects 
with curcumin treatment were due to the solvent. 
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2.7.1. Materials and Methods 
Study Design 
Cartilage explants were collected from the MCP joints from a six-year-old horse as 
and acclimated in the incubator overnight. Culture medium was prepared as before 
and used as a control and to dilute all I L - I ~ , , DMSO and curcumin stocks. Two 
batches of curcumin (l O O ~ M ) ) were prepared from a 1 mM stock (diluted down in 
culture medium from a frozen 100mM stock); one batch was made up in the culture 
medium alone, and the other in culture medium containing recombinant equine IL-I ~ ~
(lOng/ml). Similarly, equivalent volumes of DMSO (to those in the curcumin 
I O O ~ M M treatments) were prepared in both plain and IL-I ~ - t r e a t e d d culture media, 
where the total volume of DMSO was 0.01% of the total 1 ml volume in the well. A 
plain control and IL-I ~ ~ alone treatment was also included to verify that the batch of 
IL-I ~ ~ used was effectively inducing GAG release in the model. A GAG assay was 
performed as previously described (page 53). 
Statistical Analysis 
Percentage GAG release data from each treatment in triplicate were combined and a 
one-way between-groups ANOV A was conducted to test for a statistically significant 
difference at the p<0.05 level. Post hoc comparisons using the Tukey test were 
conducted to determine where the differences among the groups occurred. Values 
are reported as means of three replicates per treatment from one horse ± SEM. 
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2.7.2. Results 
Control explants released a mean GAG percentage of 15.67 ± 0.39% into the culture 
media over five days (figure 19). 
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Figure 19. Percentage release of glycosaminoglycans (GAGs) in response to 
curcumin (100JiM) or an equivalent concentration of dimethyl sulfoxide 
(DMSO) either with recombinant equine interleukin-lbeta (lL-IIJ; 10nglml; 
grey columns) or without (clear columns) 
Significance compared to IL-lfi is indicated by *** (p<O.OOl). Graphs give mean 
values collatedfrom replicate wells (3 replicates per treatment) from one horses and 
bars represent standard error of the means (SEM). Control indicates cartilage discs 
incubated in the culture medium alone. 
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Neither curcumin (I OOIlM) nor the equivalent volume of DMSO (100IlM) alone 
significantly affected this basal level of GAG release (13.S0 ± 1.3S% and IS.97 ± 
3.38% respectively). IL-l ~ ~ (10ng/ml) significantly increased GAG release to SO.27 
± 7.S6% (p<0.00 I). This IL-l ~ - s t i m u l a t e d d GAG release was significantly reduced 
by curcumin (100IlM) to 13.33 ± 1.24% (p<0.001), whereas the equivalent 
concentration ofDMSO (100IlM) had no significant effect (44.00 ± 2.70, n.s). 
2.7.3. Discussion 
DMSO is a polar solvent that is commonly used to solubilise hydrophobic drugs and 
phytochemicals, including curcumin (Elattar and Virji, 2000; Balakin et at., 2006). 
DMSO can aid the permeability of membranes and the transport of substances 
through membrane barriers without damaging them and so is used as a vehicle for 
both topical and oral medications (Jacob et at., 1964; Jacob and Herschler, 1986). 
However, DMSO itself has a number of pharmacologically relevant properties 
including anti-inflammatory and anti-oxidant activity (Santos et at., 2003), and 
reduced proteoglycan synthesis in cartilage explants (Matthews et at., 1998). Thus it 
was necessary to determine the effects of DMSO in the model, to ensure that it was 
not responsible for the effects observed with curcumin. 
This study showed that at the highest concentration of curcumin tested (I OOIlM), the 
equivalent volume of DMSO (amounting to 0.01% DMSO) did not produce a 
significant decrease in IL-I ~ - s t i m u l a t e d d GAG release. This suggested that DMSO 
was not interfering with the effects seen with curcumin treatment. 
Although a previous study found DMSO (S%) reduced proteoglycan synthesis in 
cartilage explants, the same study also found that culturing explants with 1% DMSO 
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for up to 72 hours did not significantly alter proteoglycan synthesis compared to 
controls (Smith et al., 2000). Therefore, although proteoglycan synthesis was not 
measured in this study, the low levels of DMSO used (0.01 %) suggest that it was 
unlikely to be affecting proteoglycan synthesis. Thus, it was concluded that the 
reduction of IL-I ~ - s t i m u l a t e d d GAG release observed in the curcumin-treated 
explants in the model was not due to the presence of DMSO. Subsequent studies did 
not include DMSO controls due to space restrictions on the culture plates. However, 
they used same batches ofDMSO and curcumin, as used in this study, for continuity. 
2.B. Study 6. Final Test of the Equine IL-IP Model Using Curcumin and 
Carprofen 
The failure of IGF-I to reduce I L - I ~ - s t i m u l a t e d d GAG release in study 4 lead to the 
investigation of an alternative positive control. Due to space restrictions on the plate, 
it was necessary to find a single positive control that could reduce both I L - I ~ ~
stimulated GAG and PGE2 release. In addition, the positive control needed to be a 
conventional pharmacological treatment that is a realistic and widely used treatment 
for patients, rather than IGF-I, which is not a practical treatment option. After 
consulting with a veterinarian and studying the literature, the NSAID, carprofen was 
selected as a positive control, due to its anti-inflammatory activity and beneficial 
effects on cartilage metabolism (Benton et al., 1997; Armstrong and Lees, 1999). 
Control wells were distributed around the plate to monitor within plate variability. 
The aim of the study was to investigate further the anti-inflammatory and anti-
degradative effects of curcumin at concentrations between 3 ~ M M and 5 0 ~ M M using 
carprofen as the positive control. The proteolytic enzyme, MMP-3, is a catabolic 
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mediator of cartilage degradation and is present in its active form at higher levels in 
the synovial fluid from osteoarthritic joints compared to normal joints (Brama et al., 
2000c). Curcumin has been previously shown to reduce IL-l ~ - s t i m u l a t e d d MMP-3 
levels in human chondrocytes cultured in mono layers (Schulze-Tanzil et al., 2004). 
Therefore, the levels of MMP-3 released into the culture media of the cartilage 
explants were investigated alongside GAG and PGE2 release. 
2.8.1. Materials and Methods 
Study Design 
Three horses (two pony types and one cob type) were used for the study. Both the 
MCP and MTP joints were used due to the joints being small and limiting the 
cartilage harvested from them. Explants were incubated in DMEM containing 
recombinant equine IL-I ~ ~ (lOng/ml) and various concentrations of curcumin (3 ~ M , ,
6 ~ M , , 1 2 ~ M , , 2 5 ~ M M and 5 0 ~ M ) ) prepared in I L - I ~ - t r e a t e d d media as previously 
described (page 65). The NSAID carprofen, Rimadyl® (Pfizer), (1 O O ~ g / m l ) ) was 
prepared in IL-I ~ - t r e a t e d d media and included as a positive control. 
All plates contained 1 ml culture media, which formed the base for other treatments 
and acted as a control for each plate. Plates were incubated at 37°C and 5% C02 for 
5 days. After 5 days, explants and the corresponding media were frozen at -20°C. 
Samples underwent a GAG assay, carried out as previously described (page 53), as 
well as a PGE2 assay and analysis ofMMP-3 by western blotting. 
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PGE2 Assay (High Sensitivity) 
A competitive immunoassay kit, as used previously, was used to measure PGE2 
according to the manufacturer's instructions. Samples from previous studies were 
found to contain under 1200pg/ml PGE2, therefore the high sensitivity procedure was 
undertaken to improve accuracy. In brief, standards (19.6 - 1250pg/ml) and 
supernatant samples (1501l1) were added to a 96-well plate coated in goat anti-mouse 
polyc1onal antibody, followed by primary antibody solution (50Ill) and PGE2 
conjugate (50IlI), then incubated for 19 hours at 6°C. The plate was thoroughly 
washed before adding 200111 substrate solution to each well and developing in the 
dark at room temperature for 20 minutes. A stop solution (501l1) was added and the 
plate was read immediately on a plate reader at 450nm with wavelength correction 
set at 540nm using Ascent Software (version 2.6). 
Protein Quantification of Samples 
The protein content of explant supernatants from the GAG and PGE2 studies was 
quantified using a detergent compatible (DC) protein assay (Bio-Rad Laboratories), 
similar to the Lowry assay (Lowry et al., 1951). It is based on the reaction between 
protein and copper in an alkaline solution and the subsequent reduction of Folin 
reagent by the copper-treated protein. 
Briefly, protein standards (0.2, 0.5, 0.75, I, 1.5mg/ml) were prepared in DMEM. 
Standards and samples (51ll) were added to the appropriate wells of a microtiter plate. 
An alkaline copper tartrate solution (251l1) was then added to each well, followed by 
Folin Reagent (2001l1). The plate was shaken for 5 seconds then left for 15 minutes. 
Absorbance was read at nOnm. 
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The protein content of each sample was calculated and divided into 50Jlg aliquots. 
The aliquots were freeze-dried (Heraeus-Christ) overnight before preparing for 
western blotting the following day. 
Western Blotting of MMP-3 
The resultant pellets were resuspended in 37JlI sample buffer (NuPAGE lithium 
dodecyl sulphate (LDS) sample buffer (IX» and electrophoresed on precast 4-12% 
Bis-Tris 10-well gels (Invitrogen) under denaturing and reducing conditions. 
Proteins were transferred to a 0.45Jlm Polyvinylidene fluoride (PVDF) membrane 
and blocked with 5% (w/v) non-fat milk with Tris-buffered saline (TBS) containing 
0.1 % (v/v) Tween20 for one hour. The membranes were incubated with a goat 
polyclonal antibody raised against the full length human MMP-3 protein (Abcam) 
diluted 1: 1 ,000 in 5% (w/v) non-fat milk at 4°C overnight. Membranes were then 
washed and incubated for 2 hours at room temperature with a secondary anti-goat 
antibody (1: 1 0,000; Dako). Membranes underwent a final 30 minute wash before 
chemiluminescence was detected using ECL+ (GE Healthcare) on a Typhoon Trio+ 
Variable Mode Imager (GE Healthcare). Densitometric quantification of the MMP-3 
bands was performed using ImageJ software (National Institutes of Health). The 
relative intensity of the bands in comparison to controls was measured for samples 
from each animal. 
Statistical Analysis 
Data from all horses in the experiment were combined (either percentage GAG 
release, PGE2 values in pg/ml, or relative intensity of western blotting bands 
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compared to control) and a one-way between-groups ANOV A was conducted to test 
for a statistically significant difference at the p<0.05 level. Post hoc comparisons 
using the Tukey test were conducted to determine where the differences among the 
groups occurred. 
2.8.2. Results 
Curcumin (3-50JlM) Significantly Decreases IL-lp-Stimulated GAG Release 
Control explants released 11.38 ± 1.26% of the total GAG content of the cartilage 
into the media over five days (range: 86-3231lg GAG/ml of culture supernatant) 
(figure 20). 
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Figure 20. Percentage glycosaminoglycan (GAG) release from recombinant 
equine interleukin-l beta (IL-lp)-stimulated cartilage explants treated with a 
nonsteroidal anti-inflammatory drug (NSAID; 1001lg/ml) or curcumin (3-50IlM) 
Control column indicates cartilage discs incubated in the culture medium alone. 
Values are reported as the mean of 3 replicates of 3 horses per treatment and bars 
represent standard error of the means (SEM). Significance compared to IL-lfi 
(lOng/ml) is indicated by ... (p<O.05), ** (p<O.Ol) and *** (p<O.OOl). 
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I L - l ~ ~ (lOng/ml) significantly increased GAG release to 44.31 ± 3.75% of total GAG 
content compared to control (p<0.00 1). The NSAID at 1 00 Ilg/m I significantly 
reduced IL-l ~ - s t i m u l a t e d d GAG release to 25.96 ± 3.59% of total GAG content 
(p<0.0 1). Curcumin significantly decreased equine IL-l ~ - s t i m u l a t e d d GAG release in 
the explants to 28.98 ± 2.45% at 31lM (p<0.05), 26.84 ± 2.49% at 61lM (p<0.01), 
24.51 ± 5.42% at 121lM (p<0.01), 18.91 ± 4.36% at 251lM (p<0.001) and 16.05 ± 
1.82% at 50llM (p<0.001). 
Curcumin (3-50JlM) Significantly Reduces IL-tp-Stimulated PGE2 Release 
PGE2 release into the media of unstimulated explants was 20.35 ± 3.67pg/ml (figure 
21 ). 
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Figure 21. Prostaglandin E2 (PGE2) released from recombinant equine 
interleukin- t beta (IL-t p)-stimulated cartilage explants treated with a 
nonsteroidal anti-inflammatory drug (NSAID; lOO,..g/ml) or curcumin (3-S0J.1M) 
Control column indicates cartilage discs incubated in the culture medium alone. 
Values are reported as the mean of 3 replicates of 3 horses per treatment and bars 
represent standard error of the means (SEM). Significance compared to IL-I{J 
(JOng/ml) is indicated by *** (p<O.OOI). 
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These levels were significantly increased (p<0.00 I) to 303.9 ± 73.38pg/ml by the 
addition of recombinant equine IL-l ~ ~ (1 Ong/ml). The NSAID significantly 
attenuated this effect, reducing levels to 19.72 ± 3.74pg/ml (p<0.001). Curcumin 
also significantly reduced IL-l ~ - s t i m u l a t e d d PGE2 release to 75.48 ± 10.68pglml at 
3 ~ M M (p<0.001), 54.72 ± 12.41pg/ml at 6 ~ M M (p<O.OOI), 45.65 ± 13.31pglml at 1 2 ~ M M
(p<O.OOl), 18.36 ± 2.38pglml at 2 5 ~ M M (p<O.OOI) and 26.73 ± 3.52pg/ml at 5 0 ~ M M
(p<O.OOI). 
Curcumin (12-50JiM) Reduces IL-lp-Stimulated MMP-3 Release 
Control explants released low levels of MMP-3, which were significantly increased 
by the addition o f I L - l ~ ~ (p<O.OOl) (figure 22). 
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Figure 22. Western blot quantification of matrix metalloproteinase (MMP)-3 
release from cartilage explants cultured with recombinant equine interleukin-
lbeta (IL-lP; lOng/ml) and a nonsteroidal anti-inflammatory drug (NSAID; 
lOO .... g/ml) or curcumin (3-50 .... M) 
Marker lane shows the molecular weights (MW) in kilodaltons (kDa). Graph shows 
the relative intensity of bands from 3 horses (A, B, C. Values are reported as the 
mean of 3 horses p er treatment and bars represent standard error of the means 
(SEM). Significance compared to interleukin (IL) -1/3 is indicated by ** (p<O.01) and 
*** (p<O.001). Lane 1 is the control. The remaining lanes contain IL-1/3 (JOnglml) 
either alone (lane 2), or with a NSAID (J OOfJ.glml; lane 3) , or with curcumin at 3fJ.M 
(lane 4), 6fJ.M (lane 5), 12fJ.M (lane 6), 25fJ.M (lane 7) and 50fJ.M (lane 8). 
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The addition of the NSAID significantly reduced IL-l ~ - s t i m u l a t e d d MMP-3 levels 
(p<0.0 1) in all animals to near that of controls. Curcumin showed a dose-dependent 
significant effect on reducing the IL-I ~ - s t i m u l a t e d d release at 1 2 ~ M M (p<0.0 1), 25 ~ M M
(p<0.0 1) and 5 0 ~ M M (p<0.00 1). However, the concentration at which this reduction 
became apparent differed between animals. For example, horse C, showed a 
reduction in pro-MMP-3 secretion at curcumin concentrations of 1 2 ~ M M and above, 
whereas in horses A and B, the equivalent reduction was not seen until curcumin 
concentrations of 5 0 ~ M M were used. The most apparent reduction in pro-MMP-3 
secretion was always seen at 5 0 ~ M M with levels near to that of the controls in all 
animals. 
2.8.3. Discussion 
This study set out to extend the knowledge of the biological actions of curcumin by 
determining whether it could inhibit IL-I ~ ~ stimulated cartilage degradation and 
inflammatory mediator production. 
I L - I ~ ~ (IOng/ml) significantly increased GAG, PGE2 and MMP-3 release in all horses 
as expected. Gene expression of MMP-3 is significantly down-regulated in late-
stage OA cartilage samples compared to early stage-OA samples (Bau et al., 2002). 
Therefore, the increased level of MMP-3 protein in the IL-I ~ - t r e a t e d d samples from 
this study supports the genomic data and the idea that the model represents early ~ A . .
The NSAID significantly reduced GAG, PGE2 and MMP-3 release in all horses 
suggesting that it is a suitable positive control for these quantitative methods. This is 
in agreement with a study reporting the anti-inflammatory and anti-catabolic effects 
of carprofen in equine cartilage explants stimulated with human IL-I ~ ~ (Armstrong 
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and Lees, 1999). Although there has been conflicting evidence with regard to the 
anti-catabolic effects of carprofen with one study finding that it did not reduce GAG 
release from canine cartilage explants, the cartilage was taken from dogs undergoing 
hip-replacement surgery, not from clinically normal animals as used in the present 
study (Benton et al., 1997). This reflects the value of carprofen in early OA, which 
is supported by evidence that carprofen reduced the progression of early structural 
changes (in terms of osteophyte size, and lesion size and severity) in a canine model 
of OA (Pelletier et al., 2000). In light of the present results, it was decided that 
carprofen (Rimadyl®) was an appropriate positive control for all the tested 
parameters in the model. 
Curcumin at 3 ~ M M and above significantly reduced I L - I ~ ~ stimulated GAG loss from 
cartilage explants. Previous studies in this chapter showed that curcumin ( 5 0 ~ M ) )
significantly reduced human I L - I ~ - s t i m u l a t e d d GAG release from equine cartilage 
explants, but this effect was not evident at 2 5 ~ M . . The concentration differences 
between these two studies may be linked to individual variation as curcumin ( 2 5 ~ M ) )
reduced I L - I ~ - s t i m u l a t e d d GAG loss to a mean of 18.91% in the present study, 
compared to 32.45% in the previous study. The high mean GAG release for the three 
horses in the previous study was due to explants from one horse releasing 57.02% 
mean GAG, whereas the other two horses had lower mean GAG levels (20.96% and 
16.98%), similar to the mean value of the combined horses in the present study. 
This high value was included in the analysis, as the horse responded to IL-l ~ ~ with a 
significant increase in GAG release, and showed a dose-dependent reduction in IL-
I ~ - s t i m u a t e d d GAG loss with increasing curcumin concentrations (although levels 
were still higher than those of the other two horses). This suggests that individual 
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variation in response to curcumm may be responsible for the concentration 
differences between studies. 
The involvement of pro-inflammatory cytokines and MMPs in OA is well 
documented (Shinmei et al., 1991; Chubinskaya et al., 1996). MMP-3 is a 
stromelysin produced by chondrocytes in OA cartilage tissue (Okada et al., 1992). 
MMP-3 gene expression is up-regulated in response to IL-I ~ ~ stimulation in 
chondrocytes (Tung et al., 2002). Similarly, MMP-3 protein expression is increased 
by the addition of I L - 1 ~ ~ to cartilage explants (Julovi et al., 2004). MMP-3 was 
chosen as a marker of cartilage explant degradation in this study as there is 
convincing evidence for a role for MMP-3 in cartilage destruction in OA. Curcumin 
reduced MMP-3 secretion at concentrations as low as 12j.tM in some animals, and as 
high as 50j.tM in others, suggesting some animal-to-animal variability. However, 
when treated with 50j.tM curcumin, IL-1 ~ - s t i m u l a t e d d explants from all animals 
secreted MMP-3 levels lower than, or equivalent to, unstimulated control explants. 
This is in agreement with a previous study showing that curcumin (50j.tM) 
effectively reduced MMP-3 levels in IL-I ~ - s t i m u l a t e d - h u m a n n chondrocyte Iysates 
(Schulze-Tanzi I et aI., 2004). However, lower curcumin concentrations have been 
reported as effective in cartilage from human OA patients post mortem, where 
curcumin reduced MMP-3 activity in the media of IL- I ~ - s t i m u l a t e d d chondrocytes at 
15j.tM and in cartilage explants at 5j.tM (Mathy-Hartert et al., 2009). Many variables 
may account for the difference in effective curcumin concentrations, including 
individual variation, pre-existing joint pathology, the explant model used, and the 
fact the latter study looked at MMP-3 activity rather than the presence of the protein 
by western blotting. It should be noted that many MMPs, including collagenases, 
matrilysin (MMP-7), and other stromelysins (e.g. MMP-IO), are involved in 
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osteoarthritic cartilage degradation (Mitchell et al., 1996; Ohta et al., 1998; Barksby 
et al., 2006). Thus, the reduction in MMP-3 secretion would contribute to, but not 
totally account for, the reduction in GAG release from IL-l p-stimulated cartilage 
explants. However, further work to determine the levels of activated MMP-3 in the 
samples is needed to confirm this. 
The reported anti-inflammatory effects of curcumin (Jagetia and Aggarwal, 2007) 
have stimulated increasing interest in its potential for the treatment of inflammatory 
disorders. In this study, curcumin at concentrations of 3J.1M and over significantly 
reduced PGE2 release in response to equine IL-I p (lOng/ml). This anti-inflammatory 
effect is consistent with previous work in other cell culture models, such as rat 
peritoneal macrophages where curcumin (I OJ.1M) inhibited PGE2 release by 45% (Joe 
and Lokesh, 1997), and in BV2 microglial cells where curcumin (IOJ.1M and 20J.1M) 
significantly reduced PGE2 release in response to LPS (0.5J.1g/ml) (Jin et al., 2007). 
The reduction in PGE2 levels in response to IL-I p in this chapter is postulated to be 
due to the inhibitory effects of curcumin on the NF-KB pathway. Curcumin (50J.1M) 
has been shown to inhibit various steps of the NF-KB pathway, such as IL-lP-
dependent phosphorylation of p65; nuclear-translocation of p65; and IKBa 
phosphorylation in IL-l p-stimulated human chondrocytes (Shakibaei et al., 2007). 
Thus, by inhibiting NF-KB signalling, curcumin prevents the downstream 
inflammatory effects of COX-2 expression and synthesis. This partly explains the 
anti-inflammatory effect of curcumin in response to LPS which activates the NF-KB 
pathway by activating toll-like receptors (TLRs) (Faure et al., 2000; Kawai and 
Akira, 2007). In support of this, curcumin (4J.1M-16J.1M) has been shown to 
significantly reduce LPS-induced COX-2 expression in BV2 microglial cells by 
inhibiting DNA binding of NF-KB and AP-l (Kang et al., 2004). However, 
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curcumin also reduces LPS-induced inflammation by preventing the dimerization of 
TLR4 required for activating downstream signalling pathways (Youn ef al., 2006). 
Thus, the inhibitory effects of curcumin on different pathways at mUltiple levels, 
highlights its potential for supporting joint health in response to a variety of 
inflammatory stimuli. 
In conclusion, this study added supporting evidence as to the suitability of using 
equine IL-I p (1 Ong/ml) in the model due to its significant effects on increasing 
GAG, PGE2 and MMP-3 release from explants. The results of the NSAID, 
carprofen, indicate that it is a suitable positive control, although further studies are 
needed with more horses to confirm its consistency in repeatedly reducing IL-l p-
stimulated GAG release. 
2.9. Chapter Discussion 
2.9.1. The Explant Model 
The cartilage explant system is a well-established in vitro model, which facilitates 
the study of chondrocytes in their native matrix. It is a very versatile model, 
enabling comparisons between cartilage from normal and OA patients (Lafeber et al., 
1993), as well as using various stimuli to create OA-like structural changes in 
healthy cartilage (Patwari ef al., 2003). It is applicable to multiple species (e.g. 
canine, porcine, bovine, equine, human) either to study in their own right or to be 
used as a model for other species, where material from the species of interest is 
lacking or difficult to obtain. The model can also utilise different cartilage types 
from different anatomical locations (e.g. nasal cartilage, or articular cartilage from 
various articulating joints) although these two types of hyaline cartilage differ in 
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matrix composition and response to IL-I a (Billinghurst et al., 2000; Jansen et al., 
2010). For the purpose of this thesis, equine cartilage was chosen for two reasons, 
firstly because the focus of the thesis was equine. Secondly, the horse is a suitable 
model of human OA, owing to the fact that horses are athletic animals that can suffer 
from naturally occurring injuries similar to those of human athletes (Koch and Betts, 
2007). There are also significant similarities in joint cartilage composition between 
the two species (Frisbie et al., 2006). However, the disadvantage of using equine 
cartilage is the natural variation that is inherent with a non-production animal. 
Horses are utilised for a diverse range of sport and leisure purposes with varied 
exercise intensities. Equine euthanasia may be selected due to injury (resulting in 
loss of performance or permanent discomfort) or for financial reasons. Thus, horses 
entering British abattoirs vary widely in age, breed, history of use and reason for 
euthanasia. In contrast, meat-production animals are often of similar breed, 
experience similar animal husbandry practices and are slaughtered before they reach 
a certain age. Although the variability in equine material could have been reduced 
by breeding horses specifically for the study, this was not an option due to ethical 
and financial constraints. Utilising abattoir material and horses brought to the 
veterinary school for non-research related euthanasia, meant that no horses were 
sacrificed for the work in this thesis. This was an important ethical requirement of 
the commercial sponsor. Therefore, a large variety of horses were used in the studies 
in this thesis and the variability of the cartilage obtained from them resulted in the 
setting of inclusion criteria for the model as it developed. 
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2.9.2. Subject Age 
Age has a marked effect on cartilage metabolism, with cartilage from older horses 
being less responsive, in terms of GAG synthesis and release, to IL-I a stimulation 
(MacDonald et al., 1992; Morris and Treadwell, 1994). These studies do differ in 
their classification of 'aged' animals and in anatomical locations of cartilage 
collection, i.e. the carpal joints of one 14-year-old stallion (Morris and Treadwell, 
1994) and the MTP joints of two 20-year-old geldings (MacDonald et al., 1992). 
Although these studies used IL-l a instead of IL-l p and used different joints, this 
age-associated decreased responsiveness to cytokines highlights the importance of 
considering age when using the explant model. Many of the studies described in this 
chapter did not account for age. After the completion of this chapter, a different 
source of equine material was discovered, where at the time of euthanasia, the age of 
the horse was determined from examining the teeth. Thus, inclusion criteria for the 
model was set on Thoroughbred-type animals under the age of 12-years-old as they 
were the most common breed-type in the abattoir and were of a similar weight range. 
2.9.3. Animal Numbers 
In the model, each animal was analysed individually and then animals were 
combined to assess whether the overall results reflected the trends seen in individual 
animals. Although some of the earlier studies used more than three horses, the time-
consuming nature of processing and collecting samples meant that, in the interests of 
consistency, three horses were used per study. This meant that nine values were 
obtained for each treatment group (three replicates from three horses). This number 
of animals is more than some used in other studies looking at the effects of a 
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treatment on the GAG content of cartilage, for example using only one horse with 
four replicates per treatment (Takafuji et al., 2002) or two horses with 4 replicates 
(Dechant et al., 2005). Some studies have used 10 horses, with three replicates per 
treatment (Petrov et al., 2005). However, initial studies with larger numbers of 
horses found that three horses were enough to indicate a trend and achieve 
significance. Therefore, in the interests of consistency and accuracy, three horses 
were used per study. 
2.9.4. Joint Selection 
Previous studies have highlighted the variation between joints, for example, cartilage 
catabolism, in terms of GAG release, in the MCP joints is relatively lower than in the 
proximal interphalangeal and distal interphalangeal joints (Fuller et al., 200 I). Thus, 
studying a similar anatomical region is of importance in the model. Consequently, 
the MCP and MTP joints were selected for the model, due to their weight bearing 
properties and the fact that they have a wide range of motion and are a common site 
for equine OA. To reduce variation further, it was decided that future studies would 
only use the MCP joints in the explant model, unless the cartilage yield was 
exceptionally low. 
Another criteria for inclusion included macroscopically normal joints as determined 
by observation of a smooth intact cartilage surface, clear viscous synovial fluid and a 
non-inflamed synovium. This was supported with use of histology. Twenty-eight 
histological samples were collected from the MCP, MTP, carpal and tarsal articular 
surfaces of the joints from ten horses whose joints appeared suitable (at the 
macroscopic level) for use in the model (appendix 4). Samples were declared 
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microscopically suitable for the model if they were free of lesions in the articular 
surface. This established that the correct samples were being identified, so 
subsequent samples were not routinely processed for histology, but were collected 
and stored for future reference. 
2.9.5. Cartilage Pooling and Explant Selection 
Cartilage from an individual animal was pooled for that animal. However, cartilage 
from different horses was kept separate, to enable the individual responses of each 
animal to be assessed. Pooling animals would have affected the results by increasing 
variation and masking the individual effects. 
Explants were excised from cartilage slices with a 3mm biopsy punch and explants 
were distributed around the culture wells at random (three explants per well) to 
ensure that there was a variety of explants from different cartilage slices in each well. 
Explant studies in the literature have used differing sizes of explants ranging from 
1 mm cubes (Fuller et al., 2001) to 8mm discs (Parkkinen et al., 1992). However, the 
size of the donor species and the target joint often restrict the size of the explants that 
can be obtained. Several different sized explants were collected during the thesis and 
it was found that 3mm discs allowed the desired number of explants per well to be 
obtained without wasting cartilage or compromising uniformity in thickness as found 
in larger explants. Explant diameters of 3mm have been used previously for 
evaluating GAG release (Patwari et al., 2003). Thus 3mm discs were selected for the 
model. 
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2.9.6. Culture Period 
For the model, harvested cartilage explants were placed in culture medium without 
FBS overnight to acclimate and increase the stability of cultures. Damage to the 
cartilage matrix, either in OA or by the process of cutting, decreases the tension of 
the collagen network, consequently allowing the tissue to swell and allowing 
peripheral GAGs to leach out (Maroudas, 1976; Urban and Maroudas, 1981). Thus, 
overnight acclimation media were removed from the wells to reduce any residual 
effects from the explant harvesting procedure. Following this acclimation period, the 
media were replaced with media containing the treatments for five days. A five day 
culture period was selected because it allowed enough time to see beneficial effects 
in the model without having to change the media and alter the steady state 
environment of the cultures. Although the lack of time course data could be 
criticised in the studies, this has been addressed previously (Bird et al., 1997; 
Williams et al., 2003), and the objective of this study was not to monitor the kinetics 
of GAG release, but to compare GAG release at five days in comparison to control 
cartilage. 
2.9.7. Serum-Free Culture 
With regard to culturing conditions, there is conflicting evidence over the use of 
foetal bovine serum (FBS) in explant models. The presence of serum in culture 
medium can cause chondrocytes to change their phenotype (Malpeli et al., 2004) and 
cartilage explants to lose their biochemical and mechanical properties (Bian et al., 
2008). Thus it appears culturing without serum would be preferable, however some 
studies report that proteoglycan synthesis is reduced without serum and there is a 
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gradual loss of proteoglycans from the tissue (Hascall et ai., 1983; MacDonald et ai., 
1992; Kawcak et ai., 1996). This is in contrast to other studies showing that cartilage 
explants did not decrease their GAG content after a six week period in serum-free 
culture (Bian et ai., 2008). Culturing cartilage explants in serum-free medium has 
distinct advantages over culturing with FBS as it removes the confounding factors of 
adding endogenous cytokines and proteases present in FBS and the natural batch 
variability of its constituents. Thus, in the interests of consistency, it was decided 
that serum-free culture conditions should be used in this model. Despite the steady 
proteoglycan loss that has been reported with serum-free cultured explants, 
expressing GAG release as a percentage of the total GAG available allows this loss 
to be monitored in control explants cultured in medium alone, before comparing to 
treated explants. Taken as a whole, all the explants used as controls in all the studies 
in this chapter (66 values) released an average of 11.46 ± 0.51 % (GAG ± SEM) over 
five days (appendix 5). More often than not, this was under 10% but a few higher 
values increased the mean. Previous work with equine MCP/ MTP cartilage explants 
cultured in serum-free media has shown that control explants (incubated in serum-
free media) release roughly 7% GAG over three days (Petrov et al., 2005), and four 
days (Fuller et ai., 2001). Considering that the studies in this chapter quantified 
GAG release over five days and used different size of explant to those in the 
published studies, as well as taking into account the biological variation between 
horses, it can be seen that total GAG release is not markedly different from the 
values in the literature. 
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2.9.8. Measuring GAG Release in the Model 
It should be noted when looking at the GAG loss data that these are only a 
measurement of net GAG loss. Cytokines such as IL-l ~ ~ and TNF -a are known to 
reduce the synthesis of matrix proteoglycans, thereby limiting the reparative ability 
of cartilage (Dingle, 1984; Saklatvala, 1986; Taskiran et al., 1994). No measurement 
of GAG synthesis was taken in these studies, which would show whether the 
material being tested could remove the inhibitory effect of IL-l ~ ~ on GAG synthesis. 
Measuring both GAG synthesis and release would result in four different scenarios, 
which would determine whether the overaJl effect on the cartilage was positive or 
negative. For example, a product that increases GAG release is detrimental when 
coupled with reduced GAG synthesis, but in the presence of increased synthesis, it 
may simply represent increased matrix turnover. Likewise, a product that decreases 
GAG release would be beneficial in the presence of increased synthesis. However, if 
both GAG synthesis and release were reduced then this may represent a negative 
overall effect on the cartilage resulting from reduced metabolism. GAG synthesis in 
cartilage explants can be evaluated by measuring the incorporation of sulphur 35 
e5S)-labelled sodium sulphate into proteoglycans (Yaron et al., 1989; Benton et al., 
1997; Bird et al., 1997). Measuring GAG synthesis would be a beneficial future step 
to this work to gain a better understanding of GAG turnover in response to different 
plant extracts. However, time and radiation restrictions meant that the measure of 
GAG loss alone was chosen as an indicator of a beneficial effect for this thesis as has 
been used previously (Petrov et al., 2005). 
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2.9.9. Units of GAG and PGE2 Measurement 
It can be argued that GAG results should be expressed as GAG (Jlg) per milligram of 
cartilage to account for variation in explant weight, as previously shown as either wet 
weight (Pratta et al., 2003) or dry weight (Bird et al., 1997). However, percentage 
GAG release has been used in previous studies (D'lima et al., 2001; Petrov et al., 
2005) and was selected as a more accurate measure. Expressing the results as a 
percentage meant that the proportion of GAG released in relation to the total content 
of GAG available per explant was quantified. Obviously, this is not the case when 
discussing the PGE2 results but although the data are expressed as a total value of 
PGE2 per ml, pilot studies showed that the explant weight variation was low, with a 
mean wet weight (± SEM) of 4.24 ± 0.1 Omg (appendix 6). Thus, the explants were 
of a similar weight and size. The assay used in these studies was able to detect a 
significant increase in PGE2 in response to IL-1 ~ ~ and consequent reduction in 
response to an anti-inflammatory phytochemical after five days, effects which have 
been reported in equine explants stimulated with human IL-J ~ ~ (J Onglml) in response 
to an anti-inflammatory agent after three days (Petrov et al., 2005). 
2.9.10. Effects of Curcumin in the Model 
With regard to using curcumin in the model, the level at which GAG release was 
reduced changed between studies. This is more than likely due to the changes that 
occurred in the model as it developed, such as the species-specificity of IL-l ~ ~ and 
improved assay technique. However, the final study showed that low micromolar 
concentrations effectively antagonize GAG release in vitro and exerted a potent anti-
inflammatory effect on cartilage explants treated with I L - l ~ . . This shows that as the 
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model developed using curcumin, the assays were able to detect differences in GAG, 
PGE2 and MMP-3 release consistent with the use o f l L - l ~ . . Many of the degradative 
and inflammatory effects of IL-l ~ ~ are thought to be mediated by the NF-KB, 
mitogen-activated protein kinase (MAPK) and AP-l signalling pathways, which 
increase the transcription of degradative MMPs and inflammatory COX enzymes 
resulting in PGE2 production, amongst others (Liacini ef al., 2002; Kida et al., 2005). 
Curcumin acts via inhibiting various stages of the NF-KB pathway including the 
inhibition of IKBa degradation and thus activation of the NF-KB complex and 
preventing the nuclear translocation of NF-kB and the up-regulation of degradative 
and inflammatory mediators (Schulze-Tanzi I et al., 2004; Shakibaei et al., 2007). 
Hence curcumin was an appropriate phytochemical to test on IL-l ~ - s t i m u l a t e d d
cartilage. However, it must be considered that other test substances may block 
pathways that are not activated in this model. So although a material may not reduce 
IL-l ~ - s t i m u l a t e d d PGE2 or GAG release, it does not necessarily mean it would be 
ineffective as a joint health supplement. However, for the purpose of this thesis, 
product efficacy was based on its anti-inflammatory and anti-degradative effects in 
the model. 
Although the aim of the study was to develop the model, the beneficial effects of 
curcumin on reducing GAG, MMP-3 and PGE2 release at low micromolar 
concentrations were interesting and were a useful test of the model. The data 
generated from the model add support to the existing evidence suggesting that 
curcumin may be a suitable adjunct to conventional medicine for the treatment of 
inflammatory and degenerative disorders such as OA. However, IOOIlM is a very 
high concentration considering that previous studies have shown that curcumin 
(50IlM) is toxic to a variety of cells such as astrocytes (Scapagnini ef al., 2002) and 
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synoviocytes (Jackson et al., 2006). Therefore, there were concerns that the drastic 
reduction in GAG release seen at 100J.lM curcumin may have been a consequence of 
reduced metabolism in dead or dying chondrocytes. Consequently, cytotoxicity 
studies were needed to support the work carried out with curcumin in this chapter. 
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CHAPTER 3. ASSESSING CYTOTOXICITY OF 
CURCUMIN IN CHONDROCYTES 
3.1. Introduction 
Curcumin at concentrations between 50-100j.lM has been shown to have anti-
inflammatory properties via its suppressive effects on IKB activity and consequently 
the NF-KB signalling pathway in various cell types, such as human intestinal 
epithelial cells and chondrocytes (Jobin et al., 1999; Shakibaei et al., 2007). Studies 
in the previous chapter confirmed the anti-inflammatory and anti-catabolic 
capabilities of lower concentrations of curcumin on IL-l ~ - s t i m u l a t e d d cartilage 
explants. However, the significant effects of curcumin (lOOj.lM) on reducing I L - I ~ ~
stimulated GAG and PGE2 levels to that of unstimulated controls could have been a 
consequence of cytotoxicity. 
Curcumin is known to exert pro-apoptotic effects in cancer cells and cancer cell lines 
(Jiang et al., 1996; Jee et al., 1998; Chen et al., 1999; Wang et al., 2006). 
Consequently, it has been proposed as an anti-cancer chemotherapeutic agent. With 
regard to cartilage, during the course of this thesis, a paper was published indicating 
that curcumin was cytotoxic to transformed chondrocyte cell lines at 50j.lM (Toegel 
et aI., 2008). However, past research has indicated that curcumin exerts different 
effects on normal cells and 'transformed' or immortalised cancer cells (Syng-Ai e( 
al.,2004). Primary cells in their initial passages can be more phenotypically relevant 
than transformed cells (Finger et al., 2003). Therefore, the cytotoxicity observed in 
chondrocyte cell lines may be a consequence of the transformation induced by the 
SV virus. Although virus-based transformation causes only a minor alteration at the 
genomic level, it has major consequences for the transcriptome and hence the 
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phenotype of the cells. However, it is clear that further research is required to 
determine the difference in curcumin cytotoxicity between healthy and diseased 
cells, as well as between primary cells and transformed cell lines. Thus, for this 
chapter, it was important to assess the viability of primary equine chondrocytes 
cultured with curcumin. Accordingly, concentrations at which a commercially 
available curcumin extract, previously shown to reduce cartilage loss and 
inflammatory mediator production in an in vitro model of early OA, were evaluated 
for toxicity towards primary equine chondrocytes. The studies in this chapter used a 
variety of methods to determine cytotoxicity using trypan blue staining, 
fluorescence-activated cell sorting (F ACS) and a two-colour fluorescence cell 
viability assay. The aim of this was to produce a rapid and reliable method for 
detecting cytotoxicity of potential substances, in order to determine non-cytotoxic 
dose ranges to test in the explant model. The hypothesis to be tested was that non-
toxic concentrations of curcumin could have beneficial anti-inflammatory effects in 
the explant model. 
3.2. Materials and Methods 
Subjects 
Macroscopically normal articular cartilage samples were obtained from II horses (2-
12 years old), of mixed breed and sex. Studies were carried out over five separate 
experiments due to horse tissue availability and the development of the method for 
detecting cytotoxicity. Thin cartilage shavings (less than O.2cm in depth) were used 
for chondrocyte isolation from the animals in the first four studies. The final study 
used full depth cartilage for explant culture. Chondrocytes and cartilage explants 
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from each animal were kept separate throughout this study to account for inter-
individual variability in response to curcumin. Cartilage shavings were aseptically 
harvested into low glucose DMEM containing 4% penicillin/streptomycin before 
washing in PBS containing 10% penicillin/streptomycin for 20 minutes. 
Chondrocyte Isolation and Culture 
Thin cartilage slices were digested overnight in 0.1 % collagenase type I (Sigma-
Aldrich) at 37°C and 5% C02. The resulting cell suspension was filtered and washed 
before undergoing first expansIon In low glucose DMEM with 2% 
penicillin/streptomycin and 10% FBS. Once con fluency was reached, cells were 
either passaged into 25cm2 flasks or into 6- or 12-well plates. Only first, second and 
third passage confluent cells were used in this study. 
Study Design - Monolayer Cultures for Morphology Pictures 
Third passage chondrocytes from the MTP joints of a cob-type horse were grown to 
95% confluence in 6-well plates. Culture medium containing serum was used as the 
control and as the base for the other treatments. Frozen stock solutions of curcumin 
(IOOmM; C1386, Sigma-Aldrich) that had been previously prepared in DMSO were 
defrosted and diluted in DMEM to 1 mM. From this 1 mM stock, test concentrations 
of curcumin (25JlM, 50JlM, 75JlM and 100JlM) were prepared in DMEM and added 
to the appropriate wells. Ice cold methanol (70%) was added as a positive control for 
cell death. The plates were incubated overnight at 37°C and 5% C02 for 24 hours 
before being examined under a microscope and photographed. 
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Study Design - Monolayer Cultures for Trypan Blue Staining 
First passage chondrocytes from the MCP and MTP joints of a pony were grown to 
near confluence in 12-well plates. 37°C and 5% C02. Frozen stock solutions of 
curcumin (I OOmM) that had been previously prepared in DMSO, were defrosted and 
diluted in DMEM to 1 mM. From this 1 mM stock, test concentrations of curcumin 
(6IlM, 121lM, 251lM, 50llM and 1001lM) were prepared in DMEM and added to the 
appropriate wells. DMSO concentrations equivalent to those found in the curcumin 
61lM treatment and IOOIlM treatment were added as vehicle controls. The plates 
were incubated with the treatments for 24 hours at 37°C and 5% C02 before adding 
0.4% trypan blue solution (I 001l1) to the I ml medium in each well. Non-viable cells 
absorb the trypan blue dye and stain blue, whereas viable cells with intact 
membranes exclude the dye. The plates were incubated for 5-10 minutes at room 
temperature, before removing the medium, placing on a haemocytometer and looking 
for stained cells under a microscope. PBS (Iml) was added to the adhered cells in 
the wells, before observing under a microscope. Five different views of cells were 
photographed per well. 
Study Design - Monolayer Cultures for F ACS analysis 
First passage primary equine chondrocytes from the MCP and MTP joints of the 
pony used in the trypan blue study were grown to near confluence in 25cm2 flasks. 
Culture medium was removed and replaced with either control medium (as 
previously described), 70% methanol to induce cell death, or curcumin at 31lM, 61lM, 
121lM, 251lM, 50IlM, or 1001lM. Cells were placed in an incubator for 24 hours. 
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The following day, an Annexin V- fluorescein isothiocyanate (FITC) apoptosis 
detection kit (Sigma-Aldrich) was used according to the manufacturer's instructions. 
The reagents were equilibrated to room temperature before use. The culture medium 
was removed from each wel1 into separate microcentrifuge tubes. The media were 
centrifuged at 9.6rcf for 10 seconds at room temperature and the resulting pellet 
resuspended in 500).11 DMEM + FBS. The adhered cells were washed in the wells 
with PBS before trypsinising for 5 minutes. The trypsinised cells were placed into 
separate microcentrifuge tubes, centrifuged at 9.6rcf for 10 seconds at room 
temperature, and the resultant pellet resuspended in 500).11 DMEM + FBS. 
Resuspended cel1s from the wells and the media were combined in corresponding 
microcentrifuge tubes, centrifuged at 9.6rcf for 10 seconds at room temperature, and 
the resulting pellets resuspended in 500).11 IX binding buffer. 500).11 of cell 
suspension was placed into separate FACS tubes before adding 5).11 annexin V-FITC 
conjugate to each cell suspension except unstained controls. 10).11 propidium iodide 
(PI) was then added to each cell suspension and the tubes were incubated at room 
temperature for 10 minutes in the dark. The F ACS machine (F ACSCanto II, BD 
Biosciences) cycle was started and the results analysed using FACSDiva Software 
(version 6.1.2, BD Biosciences). 
The F ACS results are produced as a graph, and the locations of the cell populations 
within the graph can be interpreted as shown in figure 23. The percentage of cells in 
each quadrant were tabulated and graphed. 
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Figure 23. Key to cell populations in the F ACS graphs 
Annexin V is conjugated to the fluorescent dye FITe to facilitate the detection of 
bound annexin V by flow cytometry. Annexin V has a high affinity for 
phosphatidylserine, which trans locates from the inner to the outside of the plasma 
membrane during apoptosis. Thus, apoptotic cells appear in quadrant (Q)J of the 
graph. Propidium iodide (PI) stains deoxyribonucleic acid (DNA) and is 
impermeable to live cells, so as necrotic cells swell and burst their nuclear material 
stains positively for PI in Q4. However, necrotic cells also release 
phosphatidylserine when they burst, so they stain positively for both annexin V and 
PI and appear in Q2. Live cells do not stain with either annexin V or PI as they have 
intact sUrface membranes, so they are shown in Q3. 
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Study design - Monolayer Cultures for Cytotoxicity Assays 
First and second passage primary equine chondrocytes from three horses and two 
ponies were grown to near confluence in 12-well plates. Culture medium was 
removed and replaced with treatment medium (lmllwell). Control wells contained 
medium alone (low glucose DMEM with 2% penicillin/streptomycin and 10% FBS) 
which formed the base for the other treatments. The NSAID carprofen (1 OOllg/ml) 
was included as a positive control, as it had been used in previous studies. The NO 
donor, sodium nitroprusside (SNP; Sigma-Aldrich) was dissolved in DMEM 
(50mM) and used to induce cell death. Frozen stock solutions of curcumin 
(100mM), previously prepared in DMSQ, were defrosted and diluted in DMEM to 
ImM. From this ImM stock, test concentrations of curcumin (311M, 61lM, I 211M, 
251lM, 50llM and lOOIlM) were prepared in DMEM and added to the appropriate 
wells. A DMSO control was prepared in DMEM and contained an equivalent 
volume of DMSO to that found in the highest curcumin concentration. The DMSO 
control was included on each plate to ensure that any observed effects were not due 
to the carrier solvent. The plates were incubated at 37°C and 5% C02. Toxicity was 
assessed after 24 hours, 48 hours and five days. Five day plates underwent a medium 
change mid-way through the experiment. The removed media were spun down and 
the resulting pellet of cells resuspended in fresh media containing curcumin before 
adding back to the appropriate wells. 
Chondrocyte viability was assessed using a commercially available live/dead assay 
(Invitrogen) that utilises calcein AM and ethidium homodimer-l to identify live and 
dead cells, respectively. The principle behind this method is that calcein AM is 
taken up by live cells and converted by intracellular esterases to fluorescent green 
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calcein. Ethidium homodimer-l is impermeable to live cells but enters through the 
disrupted membranes of dead cells and stains the nucleic acids in their nuclei red. 
Media were removed and centrifuged at 10,000rpm for 25 seconds at room 
temperature. The resulting pellet of detached cells (if any) was washed and 
resuspended in 20lll PBS. Adherent cells in the wells were washed in PBS before 
returning the whole detached cell suspension to the appropriate well and incubating 
in calcein AM (2IlM) and ethidium homodimer-l (4IlM) in PBS for 30 minutes at 
room temperature. Fluorescence was detected and captured using an inverted 
contrasting microscope (Leica DM IL, Leica Microsystems Ltd) with Leica 
Application Suite imaging software (Version 2.4.0 RI, Leica Microsystems Ltd.). 
Six different fields of view of live and dead cells were taken per well (magnification 
x 100). Live and dead cells were counted with Image J Software and the percentage 
of dead cells (expressed as a percentage of the total number of cells counted) was 
calculated at 24 hours, 48 hours and five days for each treatment. 
Cartilage Explant Culture 
Full depth cartilage shavings from the MCP joints of three Thoroughbred-type horses 
were cut into 3mm discs. Three discs per well from the same animal were placed in 
24-well plates containing Iml of culture medium (serum-free low glucose DMEM 
supplemented with 2% penicillin/streptomycin) and allowed to equilibrate overnight 
at 37°C under 5% CO2• The following day, the culture medium was replaced with 
fresh medium before the study began. 
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Study Design - Cartilage Explant Model 
All plates contained Iml culture medium which formed the base for other treatments 
and acted as a control for each plate. Curcumin (l2J.lM, 25J.lM and 100J.lM) was 
prepared in DMEM and added wells in quadruplicate. SNP (50mM) was used as a 
positive control for cell death. One well per treatment per animal was used for the 
explant cytotoxicity assay and the remaining three wells per treatment per animal 
were used to determine GAG release from unstimulated explants in response to 
curcumin. DMSO controls were performed previously and found to have no effect 
on GAG release from cartilage explants at volumes equivalent to that found in the 
highest curcumin concentration (data shown in chapter 2). 
Plates were incubated at 37°C and 5% CO2 for five days. After five days, explants 
were immediately assayed for cytotoxicity or frozen at -20°C with their 
corresponding supernatants for subsequent GAG assays as described on page 53. 
Cartilage Explant Cytotoxicity Assays 
After a five day incubation, chondrocyte viability was assessed using the live/dead 
assay. Explants were washed in PBS then incubated with calcein AM (2J.IM) and 
ethidium homodimer-l (8J.lM) in PBS for 30 minutes at room temperature. A 
microscope slide was adapted to enable an explant to be studied under the confocal 
microscope without drying out. This was done using ring reinforcers to create a well 
for the explant to sit in (figure 24). The explant was covered with sterile PBS to 
prevent dessication. A cover slip was then placed over the explant fixing it in place. 
A confocal microscope (Leica TC SP2) was used to detect and measure fluorescence 
in 15 J.lm z-sections through each explant (magnification x to). 
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B 
c 
Figure 24. Slide adaptation for confocal imaging of cartilage explants 
Photographs of the adapted slide with ring reinforcers from above (A) and from the 
side (B) . C shows a diagram of the slide from above with the carlilage explant 
(yellow circle) in PBS (blue) within the ring reinforcer well, held in place by a 
square coverslip. 
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Statistical Analysis 
Statistical analysis was performed on the percentage dead cell data from the 
cytotoxicity assays on combined animals for the monolayer cultures, using a one-
way ANOV A with Tukey's post hoc test. Cytotoxicity was defined as the 
percentage of dead cells being significantly more (p<O.05) than controls. 
3.3. Results 
Curcumin ( ~ S O J . l M ) ) Alters Chondrocyte Morphology After 24 Hours 
After 24 hour incubation with curcumin at concentrations of 50llM and over, primary 
equme chondrocyte morphology was markedly different from controls. 
Chondrocytes became more spherical in shape and detached from the surface of the 
culture plate. Methanol-treated chondrocytes stayed attached to the surface (figure 
25). 
At a higher magnification, control and most curcumin (25IlM)-treated chondrocytes 
stayed attached to the culture plate in their mono layers after 24 hours. Some 
chondrocytes cultured with 251lM curcumin showed signs of starting to become more 
spherical but did not detach. Twenty-four hour culture with curcumin (50IlM and 
above) caused chondrocytes to become more spherical in shape and detach from the 
surface of the culture plate. Methanol-treated chondrocytes stayed attached to the 
surface, but were less defined and appeared to have some holes on the surface of the 
cells (figure 26). 
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Figure 25. Phase contrast photomicrographs of third passage primary equine chondrocytes after 24 hour culture in serum 
supplemented medium (control), methanol (positive dead control) and curcumin (25-100,...M), magnification x50 
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Figure 26. Phase contrast photomicrographs of third passage primary equine chondrocytes after 24 hour culture in serum 
supplemented medium (control), methanol (positive dead control) and curcumin (25-100 .... M), magnification x400 
Increasing Curcumin Concentrations Increase Cell Death - Trypan Blue 
Staining 
The change in morphology with increasing curcumin concentrations was 
accompanied by increased cell death, as indicated by trypan blue staining in cells at 
curcumin concentrations of 251lM and over (figure 27). However, in this study, cells 
started to detach with 121lM curcumin; an effect not observed with 251lM curcumin 
in the previous study. It must be noted here that it was difficult to distinguish 
between stained and unstained cells under the microscope. 
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Figure 27. Trypan blue stained first passage primary equine chondrocytes after 24 hour culture in serum supplemented medium 
alone (control), with dimethyl sulfoxide (DMSO) or with curcumin (6-100J.1M), magnification xlOO 
DMSO concentrations were equivalent to that in curcumin 6J1.M (DMSO low) and lOOf.1M (DMSO high) treatments, Trypan blue positive cells 
are denoted by arrows or circles encapsulating groups of cells, 
Increasing Curcumin Concentrations Increase Cell Death - F ACS 
The unstained controls defined the cell population from which the remaining cells 
were determined and showed that there was low autofluorescence in the sample 
population (Table 2 and Figure 28). Stained controls were used to confirm the 
viability of the population with minimal staining for both PI and Annexin V. 
However, the stained control showed that only half of the population was viable with 
64.9% live chondrocytes, and a large proportion of necrotic cells. The methanol 
dead control had 14.9% live chondrocytes. Compared to controls, curcumin 31lM, 
61lM and 12JlM had good viability with 74.9%, 79.6 and 77.9% live cells 
respectively. However, as the concentration of curcumin increased the cell 
population moved towards the upper right hand quadrant (necrotic cell death) and 
cell viability decreased with the percentage of live cells falling to 6.2% (curcumin 
25JlM). This was more pronounced at higher concentrations with 3.1 % live cells 
(50IlM) and 0.1 % (lOOJlM). 
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Percentage of cells 
Quadrant Curcumin 
(Q) Control Control Control 
U S M 3J1M 6JlM 12JlM 25JlM 50JlM IOOJlM 
Ql-
(FITC) 0.0 4.9 2.8 3.5 2.1 7.6 8.8 2.9 0.0 
Apoptotic 
Q2-
(FITC+PI) 0.2 28.0 36.9 16.8 10.0 12.6 84.7 94.0 99.8 
Necrotic 
Q3-
(U nstained) 99.7 64.9 14.9 74.9 79.6 77.9 6.2 3.1 0.1 
Live 
Q4-
(PI) 0.0 2.2 45.4 4.8 8.3 1.9 0.3 0.1 0.0 
Necrotic 
Q2+ Q4-
Total 0.2 30.2 82.3 21.6 18.3 14.5 85.0 94.1 99.8 
Necrotic 
Table 2. Percentages of primary equine chondrocyte cells in their first passage 
cultured with curcumin (3-100pM) in each quadrant on the FACS graphs 
Percentage of cells stained with Annexin V-FITC conjugate and/ or Propidium 
Iodide. or neither. Stained (S) and unstained (U) controls represent media from 
ex plants cultured in culture medium alone. Methanol (M) control represents the 
dead control. 
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Figure 28. Graph to show the percentage of live, apoptotic and necrotic cells 
from the F ACS results of primary equine chondrocytes in their first passage 
cultured with curcumin (3-100JiM) 
Percentage of cells stained with Annexin V-FITe conjugate (QI - Apoptotic) and! or 
Propidium Iodide (Q2 +Q4 - Total Necrotic), or neither (Q3 - Live). Stained and 
unstained controls represent media from explants cultured in culture medium alone. 
Methanol control represents the dead control. 
Despite this indication of curcumin toxicity towards chondrocytes, the large quantity 
of dead cells in the stained control, means that no definitive conclusions can be 
drawn from the F ACS data. 
Curcumin ( ~ 5 0 J 1 M ) ) Increases Cell Detachment and Cell Death After 24 Hours -
Cytotoxicity Assay 
Curcumin at 50llM and lOOIlM noticeably altered the morphology of adherent equine 
articular chondrocytes at the light microscopic level (figure 29) compared to control. 
Chondrocytes became more spherical in the presence of curcumin ( ~ 5 0 I l M ) ) and 
detached from the surface of the plate but this change was not present with the same 
concentration of DMSO alone (the agent used to solubilize curcumin). This altered 
morphology was visible in a few cells at 25JlM curcumin but at 50llM the majority of 
cells were affected. 
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Figure 29. Phase contrast photomicrographs of second passage primary equine 
chondrocytes after 24 hour culture in serum supplemented medium (control), 
sodium nitroprusside (SNPj 50mM) and curcumin (3-100JlM), magnification 
x400 
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The morphological changes induced by curcumin 50flM were associated with an 
increase in cell death as indicated by less green (live )-stained cells and more red 
(dead)-stained cells (figure 30). Neither control nor curcumin at concentrations of 
25flM and below had any apparent effect on chondrocyte viability. 
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Figure 30. Fluorescent inverted contrast microscope images of live (green) and 
dead (red) second passage primary equine chondrocytes after 24 hour culture in 
serum supplemented medium (control), sodium nitroprusside (SNP; 50mM), 
and curcumin (2S"M, 50"M), magnification xl00 
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The numbers of dead cells were counted in each random field of view under the 
microscope for each horse. Significance levels were the same for all horses. Figure 
3 I shows the results from the young Thoroughbred type horse chondrocytes 
(morphology and live/dead staining shown in figures 29 and 30). Statistical analysis 
revealed that control chondrocytes had mean cell death of 0.72 ± 0.16% at 24 hours. 
OM SO has no significant effect on cell death at concentrations equivalent to 311M 
and 100j.lM curcumin. SNP significantly increased cell death (p<0.001) with mean 
cell death of 100 ± 0.0% at 24 hours. Curcumin had no significant effect on mean 
cell death at concentrations of 3j.lM (0.66 ± 0.30%), 6j.lM (0.61 ± 0.19%), 12!J.M 
(1.56 ± 0.35%), 25j.lM (2.56 ± 0.60%) after 24 hours. However, curcumin 
significantly increased cell death at 50llM (81.13 ± 5.15, p<O.OOI) and 100llM 
(99.42 ± 0.37,p<0.001). 
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Figure 31. Percentage dead chondrocyte cells f."om the total number counted 
after 24 hour culture with cur"cumin ( 3 - 1 0 0 ~ M ) )
Second passage primmy equine chondrocytes were cultured in media alone 
(contro!), in dimethyl sulfoxide (DMSO) at concentrations equivalent to those found 
in the curcumin 3flM (DMSO Low) and curcumin lOOpM (DMSO High) wells. 
Results are expressed as the mean percentage of dead cells per fi eld of view per 
treatment and bars represent standard error of the means (SEM). Significance 
compared to control is indicated by *** (p <O.OOJ). 
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Curcumin ( ~ 2 5 J 1 M ) ) Increases Cell Death After 48 Hours - Cytotoxicity Assay 
Over five days, toxicity was seen at concentrations of 251lM and above after 48 hours 
(figure 32). 
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Figure 32. Fluorescent images of live (green) and dead (red) first passage 
primary equine chondrocytes after 24 hour, 48 hour and 5 day culture in serum 
supplemented medium (control), sodium nitroprusside (SNP; 50mM) and 
curcumin (3-100"M), magnification xlOO, scale bars = 200"m 
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Quantification of dead cells expressed as a percentage of the total number of cells 
counted from all horses showed that untreated controls had a mean cell death 
percentage of less than 1 % at 24 hours, 48 hours and five days (figure 33). DMSO 
controls and the NSAID did not significantly increase cell death compared to 
controls at all time points. SNP effectively induced cell death (p<0.001 at all time 
points) with a mean cell death of 92.95 ± 2.29% at 24 hours, 99.6 ± 0.17% at 48 
hours and 100 ± 0.00% at five days. Curcumin significantly increased cell death 
compared to controls after 24 hours at concentrations of 5 0 ~ M M (71.75 ± 7.25%, 
p<O.OOI) and 1 0 0 ~ M M (99.55 ± 0.12%, p<O.OOI). After 48 hours a significant 
increase in toxicity compared to controls was seen at concentrations of 25JlM (30.67 
± 8.94%, p<O.OOI), 50JlM (95.9 ± 0.96%, p<O.OOI) and 100JlM (99.59 ± 0.18%, 
p<O.OOI). After five days in culture, curcumin at 25JlM caused a significant increase 
in cell death compared to controls (95.71 ± 0.72%, p<O.OOI), 50JlM (99.4 ± 0.39%, 
p<O.OO I) and 1 0 0 ~ M M (100 ± 0.00%, p<O.OO I). 
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Curcumin 
c. 5 days 
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Figure 33. Percentage chondrocyte cell death from the total counted after 24 
hours (A), 48 hours (8) and 5 days (C) with curcumin (3-100pM) 
Cells cultured in media alone (control), or with dimethyl sulfoxide (DMSO) 
equivalent to that in the curcumin 100JiM treatment (vehicle control), sodium 
nitroprusside (SNP; 50mM) or curcumin. Results are expressed as the mean 
percentage of dead cells per field of view per treatment and bars represent standard 
error of the means (SEM). Significance compared to control is indicated by *** 
(p<0.001). 
143 
Curcumin (2S,...M) is Not Cytotoxic to Equine Cartilage Explant Chondrocytes 
After 5 Days 
After five day culture without serum supplementation, explants retained fully viable 
chondrocytes as indicated by the intensive green staining and lack of red staining in 
the controls (figure 34). SNP induced cell death in the explants as shown by the 
increased red staining and fewer, less vibrant green stained cells in comparison to the 
controls. Curcumin ( 1 2 ~ M M and 2 5 ~ M ) - t r e a t e d d explants contained large numbers of 
green stained cells, suggesting that neither concentration was detrimental to the 
viability of chondrocytes after five days in explant culture. However, the large 
amount of red nuclei staining to the chondrocytes in the I O O ~ M M curcumin-treated 
explants indicates that curcumin was highly cytotoxic at this concentration. 
144 
Figure 34. Overlaid images of 15flm z-sections through cartilage explants after 5 
days in culture with curcumin (12-100"M) 
Control consists of culture media with 2% penicillin/streptomycin. Treatments 
consist of sodium nitroprusside (SNP; 50mM), or curcumin (J 2jJ.M, 25jJ.M and 
J OOjJ.M) in culture media. Green staining indicates live metabolizing cells and red 
staining highlights the nuclei of dead cells, magnification xlO. 
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Curcumin (12-100J.1M) has No Effect on GAG Release From Unstimulated 
Equine Cartilage Explants 
Control explants released 13.91 ± 1.13% of the total GAG content of the cartilage 
into the medium over five days (range: 159-4141lg GAG/ml of culture supernatant) 
(figure 35). SNP (50mM) significantly increased matrix GAG release to 82.01 ± 
2.43% (p<0.00 1) after the same period. Curcumin did not significantly alter GAG 
release from the explants after five days at 12IlM, 251lM and lOOIlM. 
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Figure 35. Effect of curcumin (12-100pM) on percentage glycosaminoglycan 
(GAG) release from unstimulated cartilage explants 
Control column indicates cartilage discs incubated in the culture medium alone and 
sodium nitroprusside (SNP; 50mM) was used as a positive control for cell death. 
Values are reported as the mean of 3 horses per treatment and bars represent 
standard error of the means (SEM). Significance compared to control is indicated 
by *** (p<O.OOJ). 
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3.4. Discussion 
The previous chapter in this thesis showed that curcumin has anti-catabolic and anti-
inflammatory effects on IL-1 p-stimulated cartilage at concentrations from 3-100/-lM. 
However, recent research suggests that curcumin (50/-lM) is cytotoxic to a 
chondrocyte cell line in vitro (Toegel et al., 2008). This study addressed the issue of 
curcumin cytotoxicity in equine cartilage explants and monolayer chondrocyte 
cultures. Phase contrast microscopy showed that after 24 hour culture with curcumin 
(50/-lM and above) monolayer chondrocytes began to round and detach from the 
wells. Thereby suggesting that the cells were losing their membrane anchor proteins, 
such as integrins, which are involved in cell attachment and survival (Bates et al., 
1995). A variety of methods were employed to detect whether curcumin was 
inducing cytotoxicity, including trypan blue, flow cytometry and live/ dead viability 
assay using two-colour fluorescence. Although the trypan blue method is a wel1-
established method of determining cel1 viability, it has been reported to overestimate 
cel1 viability (Altman et al., 1993). In agreement with this, it was difficult to 
distinguish between stained and unstained cel1s under the microscope and resulted in 
inaccurate estimations of viability. In addition, the trypan blue method was time-
consuming, inconsistent, and was limited by only confirming cel1 death not viability. 
The results from the F ACS method indicated that increasing concentrations of 
curcumin increased necrotic cell death of the chondrocytes. This is in contrast to the 
published literature showing that curcumin induces cel1 death through apoptosis in 
both cancer cells (Jiang et al., 1996) and non-tumour cells such as neutrophils 
(Jackson et al., 2006). However, other studies have suggested that curcumin caused 
apoptosis up to 50/-lM, but necrosis at 100/-lM in two breast tumour cell lines and a 
hepatocellular carcinoma cell line (Syng-Ai et al., 2004). Again, in contrast to this, a 
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recent study usmg F ACS analysis on pituitary tumour cells reported a time 
dependent increase in the proportion of necrotic cells up until 12 hours of culture 
with curcumin (30I-lM), but this was always accompanied by a larger increase in 
apoptotic cells, the proportion of which continued to increase after 24 hours (Schaaf 
et aI., 2010). Admittedly, this may be different with primary cells, as work has 
suggested that curcumin concentrations up to IOOI-lM are cytotoxic to tumour cell 
lines but show no detriment to viability of rat hepatocytes after 24 hours (Syng-Ai et 
ai.,2004). However, the data in this chapter show that curcumin (50I-lM and 1001-lM) 
significantly increased cell death in primary equine chondrocytes after 24 hours. 
Whether this was by an apoptotic or necrotic mechanism is still to be discovered as 
the increased necrotic cell death seen in the present study may be due to the purity of 
curcumin used. For example, Schaaf et ai. (2010) used a 95% pure curcumin from 
Sigma-Aldrich, whereas the studies in this chapter used a 70% pure preparation. 
Consequently, the toxicity may have been due to impurities in the remaining 30% of 
the product. However, there was always a very high level of cell death in the control 
populations, suggesting that the process of preparing the cells for the F ACS analysis 
was causing them to die by necrosis, e.g. trypsinisation. Therefore, the data were not 
considered reliable. Although the F ACS method, if working correctly, would have 
distinguished between apoptosis and necrosis as the mode of cell death, this 
information was not essential for a screening method to detect general toxicity. In 
addition, the machine was expensive and unreliable to use, so the F ACS method was 
not pursued further. However, the information on the mode of cell death would be a 
useful addition to future studies looking at a specific ingredient. 
Consequently, the live/dead assay was selected as the method of detecting 
chondrocyte death as it can relatively quickly provide qualitative and quantitative 
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data on both monolayer and explant chondrocyte cultures (Aizawa et al., 2001; 
Grogan et al., 2002). Although this method has been reported to overestimate cell 
viability in osteochondral allografts, (Lightfoot et al., 2007), the use of two 
fluorescent dyes clearly separated live cells from dead cells and thus reduced the risk 
of the false positive results found with the trypan blue method. It should be noted 
here that cell death in monolayer cells can be underestimated, as dead cells can 
detach and be removed with the medium (Puttonen et al., 2008). However, this risk 
was minimized by centrifuging the discarded media so that the resulting pellet of 
detached cells could be resuspended and returned to the well before the live/dead 
stain reagents were added. 
At the same time as the live/dead stain method was developed, the positive control 
for cell death was changed from methanol to SNP. Methanol was recommended by 
the manufacturer of the live/dead assay as a suitable method for killing cells. 
However, methanol appeared to fix the cells, supported by the fact that methanol has 
been used to fix chondrocyte cultures previously (Cheung et al., 2001). In addition, 
methanol did not cause 100% death in the F ACS assay. Thus, SNP was selected as 
an alternative inducer of cell death, due to its known cytotoxicity towards 
chondrocytes (Notoya et al., 2000). SNP (50mM) was an effective positive control 
for cell death, causing 100% death of chondrocytes after 24 hours. 
In contrast to the monolayer cell cultures, curcumin (25IJM) did not show 
cytotoxicity towards chondrocytes cultured in cartilage explants after 5 days, 
although toxicity was observed at 100IJM. Within cartilage, chondrocytes are 
embedded in a complex ECM across which diverse diffusion gradients and fluid flow 
occurs (Garcia et al., 1996). This could account for the differing toxicity threshold 
between monolayers and explants. Chondrocytes are more vulnerable to cell death 
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when they are no longer encased within a matrix, as cell adhesion and integrin 
attachments are important factors in promoting cell survival (Cao et al., 1999). Thus, 
without a protective ECM, monolayer chondrocytes may be more exposed and 
susceptible to external agents in the culture medium than those within explants, as 
has been shown with bupivacaine (Chu et al., 2006). 
The results of this investigation suggest that curcumin, at concentrations of 251lM, 
induces chondrocyte death in monolayer primary equine chondrocytes after 48 hours, 
but not in cartilage explants after five days. The cytotoxic effects of curcumin 
(501lM) have been observed in other non-equine cell types, notably tumour cell lines 
(Moon et al., 2005). Concentrations as low as 811M caused a maximal decline in cell 
viability of 77% in a Ewing sarcoma cell line (Singh et al., 2009). In fact, the 
induction of apoptosis through cytochrome c release and subsequent caspase 
activation is thought to be a key chemopreventive effect of curcumin in cancer 
studies (Anto et al., 2002; Woo et al., 2003). Curcumin (501lM) has also been shown 
to reduce the viability of an immortalised human chondrocyte cell line after 24 hours 
(Toegel et al., 2008). The results from this chapter suggest that this is also the case 
with primary equine chondrocytes. However, a recent study on primary human 
chondrocytes found that curcumin (501lM) did not reduce cell viability and 
successfully inhibited IL-I p-induced cytotoxicity as demonstrated by a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT) assay (Csaki et al., 
2009). This could be due to species-specific differences in chondrocyte 
susceptibility to curcumin, differences between assays used to measure viability, or 
more likely, the different sources of curcumin used. This highlights the importance 
of assessing toxicity alongside efficacy, with the same form of curcumin in each 
individual study. In addition, it suggests that testing multiple batches of curcumin on 
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the cells would be beneficial to monitor batch variability. For comparative purposes, 
it would be useful to conduct further studies with other cell types, such as the 
transformed chondrocyte cell line as tested by Toegel et al. (2008) to evaluate the 
results in this chapter with those from other laboratories. 
Once the uppermost observed safe level of curcumin was determined in monolayer 
primary chondrocytes, the effect of curcumin and SNP on cartilage explants was 
determined. No significant effect of curcumin alone on matrix GAG release from 
normal cartilage explants at both safe and toxic concentrations was observed. This 
suggests that curcumin does not alter the basal level of GAG released from 
unstimulated cartilage explants in culture, even at cytotoxic concentrations. 
Interestingly, in these unstimulated explants, the two treatments that caused cell 
death had different effects on GAG release: SNP (50mM) caused extensive GAG 
loss into the medium whereas curcumin (lOOJ.lM) did not alter GAG release 
compared to controls. GAG loss does not directly lead to cell death in cartilage 
explants (Otsuki et al., 2008), thus it can be considered that the GAG loss and cell 
death caused by SNP are likely to involve different mechanisms. SNP generates NO, 
ceramide and cyanide which, aside from causing apoptosis, reduce proteoglycan and 
collagen synthesis by chondrocytes and increase inflammatory mediator production 
and MMP activity (Blanco and Lotz, 1995; Murrell et al., 1995; Khatib et al., 2002) 
resulting in cartilage matrix loss. Conversely, although curcumin (lOO/!M) induces 
cell death, it is likely to use a mechanism that does not involve the release of many 
proteases. Curcumin is known to reduce the release of inflammatory mediators, 
MMPs and NO (Brouet and Ohshima, 1995; Shakibaei et al., 2007). The previous 
chapter showed that cytotoxic levels of curcumin reduced IL-l ~ - s t i m u l a t e d d PGE2 
and MMP-3 release. This reduced production of inflammatory mediators and 
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catabolic enzymes, suggests that curcumin is unlikely to induce extensive GAG loss 
as demonstrated in both IL-l ~ - t r e a t e d d and untreated cartilage explants in this study. 
In conclusion, curcumin at 251lM and below is not cytotoxic to cartilage explants 
after 5 days in culture, and curcumin at 121lM and below is not cytotoxic to 
monolayer primary equine chondrocytes after 5 days. The previous chapter showed 
that using the same batch of curcumin, concentrations as low as 31lM effectively 
reduced GAG and PGE2 release from IL-I ~ - s t i m u l a t e d d cartilage explants. Thus non-
cytotoxic concentrations of curcumin effectively attenuate the catabolic and 
inflammatory effects of IL-I ~ ~ in the model. 
The results from this chapter only provide an indication of toxicity to a specific cell 
type, from a specific species in this particular culture system using a certain batch of 
curcumin. Conclusions cannot be drawn regarding the toxicity of curcumin to other 
cell types in vitro or even in vivo. However, though the results do not signify safety 
outside of this culture system, they do indicate that the positive effects of curcumin 
seen at lower concentrations in vitro are not a consequence of cell death. This 
highlights the importance of toxicity testing any potential substances for testing in 
the model. This chapter also established that the live/dead stain was a rapid and 
consistent method for detecting toxicity. A valuable finding from this research was 
that monolayer chondrocytes were more sensitive to curcumin in media and showed 
signs of cytotoxicity at lower concentrations than those embedded within cartilage 
explants. Thus, it was decided that future studies would use monolayer chondrocytes 
to assess toxicity of potential joint health products to determine concentrations 
suitable for testing in the explant model. 
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CHAPTER 4. IN VITRO ASSESSMENT OF A PLANT 
EXTRACT COCKTAIL 
4.1. Introduction 
The previous chapters set the scene for developing and testing the in vitro models 
and establishing the methods to determine cytotoxicity and efficacy, in terms of 
reducing GAG and PGE2 release from IL-Ip-stimulated cartilage explants. Once 
these were established, a cocktail of plant extracts (referred to as PT) was tested in 
the model. The rationale for this was that combinations of ingredients in a 
formulation are likely to be more potent as they may act synergistically to produce a 
greater overall effect (Williamson, 2001). For example, a product containing an anti-
inflammatory ingredient and anti-catabolic ingredient may improve the overall 
efficacy of the product. Using a combination product also tested the ability of the 
model and the assays to detect effects of different ingredients in combination. In 
addition, the PT was intended for a field trial, so it was of interest to test it in the 
models first to assess its effects in vitro. 
The PT ingredients included Boswellia serrata extract, grape skins, bromelain 
extract, rosemary leaf powder and ginger. They were selected based on their 
postulated safety and effects on various anti-inflammatory pathways in other species 
(Tsai et al., 1999; Secor et al., 2005; Aktan et al., 2006; Altinier et al., 2007; 
Gayathri et aI., 2007). Curcumin was also an ingredient due to its safety and anti-
inflammatory activity as reported in chapters 2 and 3 in this thesis and as found in 
the literature (Chainani-Wu, 2003). 
This study used a formulated cocktail of plant extracts in an in vitro chondrocyte 
model and in an explant model of ~ A . . The objective of this study was to assess 
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cytotoxicity of the cocktail to the target cells (the chondrocytes) and determine 
whether non-cytotoxic concentrations could effectively reduce IL-l ~ - s t i m u l a t e d d
GAG and PGEz release from cartilage explants in vitro. The hypothesis of the study 
was that the cocktail of plant extracts would reduce IL-l ~ - s t i m u l a t e d d GAG and PGE2 
release at non-cytotoxic concentrations. 
Two other supplements that were intended for use in the PT field trial were also 
tested in the model. These were a commercially available joint health product (CP) 
and a placebo (PL). The CP contained forms of chondroitin sulphate and 
glucosamine, components which are reported to have anti-inflammatory (Chan et al., 
2005b) and anti-catabolic effects (Dechant et al., 2005) on cartilage in vitro, as well 
as anabolic activity through stimulating proteoglycan production in chondrocytes 
(Bassleer et aI., 1998a; Bassleer et al., 1998b). The PL contained alfalfa meal, a 
typical constituent of the domestic equine diet, and was not expected to have any 
significant effects on GAG release in the model. Given that the PL was a recognised 
feed ingredient being fed at very low levels, it was not tested for cytotoxicity. PT 
underwent all cytotoxicity, GAG and PGE2 assays. However, the manufacturer of 
the PGE2 assay then changed the kit and it no longer worked with the samples. 
Financial reasons prevented optimisation of the new assay. Consequently CP and PL 
were not tested for PGE2. 
4.2. Materials and Methods 
Materials 
Materials included a formulated cocktail of plant extracts (PT). The cocktail was 
composed of 30% Boswellia serrata extract, 18% dehydrated grape skin residue, 
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10% curcumin from Curcuma longa, 10% bromelain extract from Ananas comosus 
L, 10% rosemary leaf powder from Rosemarinus officinalis, 10% dried olive leaf, 5% 
ginger from Zingiber officinale, 3% vermiculite and 2% Hemp oil. All ingredients 
were purchased from Park Tonks Ltd and combined at MARS Horsecare UK Ltd. 
A market leading, commercial joint health product (ep), known as eortaflex (Equine 
America), was also evaluated. According to the product literature, the ep contained 
dehydrated alfalfa meal, ground rice hulls, isolated soy protein, dextrose, glycine, 
glutamine, chondroitin sulphate, glucuronic acid, proline, glutamic acid, sodium 
hyaluronate, aspartic acid, arginine, histidine, alanine, serine, valine, isoleucine, 
manganese sulphate, pyridoxine Hel (vitamin B6), ascorbic acid (vitamin e), 
sulphur, copper sulphate 5 mglkg (added), vegetable oil, and is preserved with 
ammonium propionate. 
Thirdly, a placebo (PL) of alfalfa meal was evaluated in the model. It was selected 
for being similar in appearance to that of the treatments and for being a staple horse 
feed constituent. 
Assessing Solubility of Materials to Test in the Models 
All materials were provided as they would be fed to horses, in a coarsely powdered 
supplement. For in vitro evaluation they needed to be solubilised and filter sterilised. 
However, due to the varied and sometimes fibrous nature of the supplements, 
complete solubilisation was not possible. Therefore, only the soluble component of 
the products (when dissolved in two different solvents; an aqueous solvent, DMEM, 
and an organic solvent, DMSO) were evaluated in this study. 
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Materials were added to DMEM at a concentration of 10mg/ml, and to DMSO at a 
concentration of 100mg/ml (to allow for dilution in DMEM down to the working 
concentrations, to reduce the amount of DMSO present in the wells). All solutions 
were put on a roller for I hour to mix them. All solutions were then sonicated on ice, 
using a stepped microtip with an amplitude of 40%. DMEM solutions were 
sonicated for 30 minutes with a 15 second pulse and 15 second interval. DMSO 
solutions were sonicated for less time to prevent overheating, 10 minutes with a 15 
second pulse and 15 second interval. 
All solutions were centrifuged at 3,000rpm at 4°C for 20 minutes. The supernatant 
was removed and filtered through a 0 . 2 ~ m m Whatman filter into 1.5ml sterile 
microcentrifuge tubes, before freezing at -20°C. To enable accurate estimates for the 
soluble components, it was necessary to assess the weight lost in the undissolved 
pellet from the total. Therefore, the remaining undissolved pellet was dried for 30 
minutes in the oven at 160°C. The dried pellet was then weighed and the amount of 
substance in dissolution was calculated. Concentrations for the in vitro work were 
based on degree of dissolution in the selected solvents. 
Chondrocyte Collection for the Cytotoxcity Studies 
Cartilage was obtained from the MCP joints of two horses (a three-year-old cob 
gelding and a three-month-old welsh mountain pony filly), as previously described in 
chapter 3. Cartilage was washed, digested with collagenase and filtered before first 
expansion in culture medium (DMEM, 2% penicillin/streptomycin and 10% FBS). 
Confluent cells were passaged and seeded at 50,000 cells per well in 12-well plates. 
Only first and second passage cells were used for these studies. 
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Pilot Study Design- PT Cytotoxicity Assay 
A pilot study on chondrocytes growing in six 12-well plates was conducted to 
determine approximate working concentrations for the PT. Frozen stock solutions of 
PT were dissolved and diluted in DMEM to the final working concentrations. 
However, the pilot studies were conducted before estimates of the soluble 
components of the stock solutions were calculated. Therefore, the pilot study used 
PT concentrations of 10ng/ml, I ~ g / m l , , 1 O O ~ g / m l l and 1 mg/ml from the assumption 
that 100% of the PT was dissolved in the stock solutions. This meant that, when 
calculated accurately, the concentrations used differed between solvent and 
treatment. Thus PT was tested in DMEM at concentrations of 2.84ng/ml, 284ng/ml, 
2 8 . 4 ~ g / m l l and 2 8 4 ~ g / m l , , and in DMSO at 6.69ng/ml, 669ng/ml, 6 6 . 9 ~ g / m l l and 
6 6 9 ~ g / m l . . Plates were incubated at 37°C and 5% C02 for 24 hours before 
undergoing the live/dead cytotoxicity assay as described in chapter 3. 
Study Design - Determining Cytotoxicity of PT in DMEM, in DMSO, and in 
DMEM with added DMSO 
The pilot PT study showed that toxicity differed between solvents. This may have 
been due to something dissolving in DMSO that did not dissolve in DMEM. 
Alternatively, the substance could have been present in DMEM and DMSO, but the 
presence of DMSO permeabiJised the ceIJ membranes to the dissolved substance. 
Therefore, a study was designed to test the hypothesis that DMSO permeabilised the 
cell to the substance that was solubilised in both DMEM and DMSO. The study 
tested the three concentrations of PT in DMSO, PT in DMEM. and PT in DMEM 
with exogenous DMSO added at the same concentrations that would be present in the 
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PT in DMSO treated wells. Three accurately calculated PT concentrations in both 
DMEM and DMSO were used; 101lg/ml (not toxic in either solvent), 651lg/ml 
(toxicity seen in DMSO but not DMEM) and 150Ilg/ml (strong cytotoxicity seen in 
DMSO but not in DMEM). Plates were incubated for 24 hours at 37°C and 5% C02 
before and undergoing the cytotoxicity assay as described in chapter 3. 
Final Study Design - PT and CP 5 Day Cytotoxicity Test 
The final cytotoxicty test using accurate concentrations used first passage 
chondrocytes in 12-well plates. Control wells contained culture medium alone which 
formed the base for the treatments. DMSO in culture medium was included as a 
solvent control. The NO generator, sodium nitroprusside (SNP), was dissolved in 
DMEM (50mM) and used as a positive control for cell death. Stock solutions 
(1 mg/ml) of PT and CP were prepared in DMEM and DMSO and diluted in DMEM 
to their final working concentrations. PT test concentrations in DMSO (O.51lg/ml, 
lOllg/ml, 20llg/ml, 451lg/ml, 651lg/ml) and in DMEM (lOllg/ml, 651lg/ml, 150Ilg/ml, 
300llg/ml, 600llg/ml) were prepared and added to the appropriate wells. The upper 
limits tested for each solvent varied based on the values at which toxicity occurred 
after 24 hours in the pilot study (66.91lg/ml in DMSO in the pilot study), or above the 
level at which toxicity did not occur (2841lg/ml in DMEM in the pilot study). PT 
concentrations were added to the appropriate wells. CP in DMEM (450ng/ml, 
451lg/ml, 450llg/ml) and DMSO (400ng/ml, 40llg/ml, 400llg/ml) were also prepared 
and added to the appropriate wells. Plates were incubated at 37°C and 5% C02 for 
five days, with a medium change mid-way through the experiment. The removed 
media were spun down and the resulting pellet of cells resuspended in fresh medium 
containing the treatments before adding back to the appropriate well. Four plates 
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were assessed for toxicity at 5 days with the live/dead cytotoxicity assay as described 
in chapter 3. 
Cartilage Collection for the Explant Studies 
Macroscopically normal articular cartilage samples (selected as previously 
described) were obtained from the MCP joints of fifteen Thoroughbred-type horses 
aged between three and 12 years old. Cartilage explants were collected as described 
previously and equilibrated overnight (37°C/ 5% C02) before media were replaced 
with fresh media containing the treatments. All treatments were repeated in triplicate 
per horse and three horses were used per study. 
Study Design - Effect of PT on GAG and PGE2 Release 
DMEM with 2% penicillin/streptomycin formed controls and the base medium for all 
treatments. DMSO controls were previously shown not to affect GAG release (see 
chapter 2), and were not included on the plate due to space restrictions. 
Recombinant equine IL-l P (1 Onglml) was added to all treatment wells. 
To determine the appropriate solvent in which the PT effectively reduced GAG 
release, the PT treatments were evaluated in two studies, with the first study dictating 
the solvent and concentrations to be used in the second study. The first study tested 
PT in DMEM or PT in DMSO at O.4/-lg/ml, 40/-lg/ml and 400/-lglml in 1 ml medium 
per well containing IL-lP (IOng/ml). The volume of DMSO did not exceed 1% of 
the I ml per well in the highest concentration tested. Explants were incubated for 5 
days (37°C/ 5% C02), after which time both explants and supernatants were removed 
and frozen at -20°C until ready to assay. A GAG assay and a high sensitivity PGE2 
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assay respectively were performed as previously described in chapter 2 (pages 53 
and 93 respectively). 
The second study used fresh cartilage explants to examine a narrower dose range, 
from physiologically relevant concentrations to those at which initial signs of adverse 
effects on cell viability were observed. The lowest concentration selected was lower 
than the published blood plasma levels after oral administration of one of the PT 
ingredients, curcumin, to mice ( 0 . 2 2 ~ g / m l l maximum plasma concentration) (Pan et 
al., 1999). Consequently, PT in DMSO was diluted to 25ng/ml, 0 . 5 ~ g / m l , , I O ~ g / m l , ,
2 0 ~ g / m l l and 451lg/ml and added to the treatment wells to a final volume of I ml. In 
this study, the maximum concentration of DMSO in the PT treated wells did not 
exceed 0.0005% of the 1 ml per well. Positive controls were included in the second 
study and contained the NSAID, carprofen (Rimadyl®, Pfizer; I O O ~ g / m l ) , , to reduce 
IL-I ~ - s t i m u l a t e d d GAG release. As before, explants were incubated for five days 
(37°C/5% C02), before both explants and supernatants were removed and frozen at-
20°C until ready for GAG assay assessment. 
Study Design - Effect of the Commercial Product on GAG Release 
Similarly, the CP was evaluated in two studies, but only efficacy in terms of GAG 
release was measured due to financial reasons. The CP was first tested in DMEM 
and DMSO at O . 4 ~ g / m l , , 4 0 ~ g / m l l and 4 0 0 ~ g / m l l in 1 ml medium per well containing 
IL-I ~ ~ (I Ong/ml) to determine the appropriate solvent in which the treatment 
effectively reduced GAG release over five days. These results led to the second 
study examining CP in DMEM at 25ng/ml, 0 . 5 ~ g / m l , , l O ~ g / m l , , 2 0 ~ g / m l l and 
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45Jlg/ml on fresh cartilage explants. Positive controls were included in the second 
study as before. 
Study Design - Effect of the Placebo on GAG Release 
PL treatment was tested in DMEM and DMSO at O.4Jlg/ml, 40Jlg/ml and 400Jlg/ml 
in 1 ml medium per well containing IL-l p (lOng/ml) to determine whether the 
treatment in either solvent effectively reduced GAG release. After five day 
incubation (37°CI 5% C02), the samples underwent a GAG assay as previously 
described (page 53). 
All test substances (PT, CP and PL) were tested alone in the GAG assay for their 
native GAG content, which may have interfered with the assay. However, at the 
concentrations used for the studies in the GAG assay, the levels of GAG were low 
and read either near to or off the bottom of the curve (i.e. 10Jlg/ml), suggesting that 
native GAG in the samples wasn't affecting the GAG assay (appendix 9). The PT at 
the highest concentration tested (400Jlg/ml) contained 11 Jlg GAG according to the 
assay but this was due to the colour of the extract affecting the result, not the 
presence of sulphated GAGs. Consequently, plates for the GAG assay containing PT 
in DMEM 400Jlg/ml contained a blank to account for this effect. 
Statistical Analysis 
For the cytotoxcity studies, six different fields of view of live and dead cells were 
taken per well (magnification xlOO), the live and dead cells were quantified with 
Image J Software and the percentage of dead cells calculated. Statistical analysis 
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was performed using a one-way ANOVA with Tukey's post hoc test. An adverse 
effect on cell viability was defined as percentage of dead cells being significantly 
more (p<O.OS) than controls. 
For the explant studies, percentage GAG and total PGE2 release into the media were 
calculated and results were statistically analyzed using a one-way ANOV A with 
Tukey's multiple comparison post hoc test. Statistical significance was set at 
p<O.OS. Values are reported as means of combined animals ± SEM. 
4.3. Results 
PT (2!66.9f1g/ml) is Cytotoxic in DMSO After 24 Hours 
The pilot study showed that the PT was cytotoxic at 66.91lg/ml when dissolved in 
DMSO, whereas no toxicity was seen with the PT dissolved in DMEM at 
concentrations up to and including 2841lg/ml after 24 hours (figure 36). 
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Figure 36. Pilot study chondrocyte cytotoxicity results of 24 hour culture with 
the plant extract cocktail (PT) solubilised in Dulbecco's modified Eagle's 
medium (DMEM) or dimethyl sulfoxide (DMSO) at various concentrations 
Control represents basal culture medium alone, DMSO control contains a volume of 
DMSO equivalent to that found in the 669f.lglml treatment. Results are expressed as 
the mean percentage of dead cells per field of view out of the total number of cells 
counted + SEM Significance compared to control is shown by * .... (p<O.OOJ). 
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Mean cell death in the controls after 24 hours was 0.10 ± 0.03%. The PT in DMSO 
significantly increased mean cell death to 26.96 ± 5.22% (66.9Jlg/ml) and 99.83 ± 
0.05% (669Jlglml). 
PT Cytotoxicity in DMSO is Caused by a Substance Not Dissolved in DMEM 
The PT in DMSO at 65Jlg/ml caused cells to begin to round and detach, which was 
more pronounced at 150Jlg/ml (figure 37). This was not seen in the PT in DMEM 
alone, or with exogenous DMSO-treated cells. The cytotoxicity assay confirmed that 
this change in morphology seen in the PT in DMSO-treated cells at 65Jlg/ml and 
above was consistent with increased cell death (as shown in figure 38 and quantified 
in figure 39). 
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Figure 37. Morphology of primary equine chondrocytes after 24 hours with the 
plant extract cocktail (PT) solubilised in Dulbecco's modified Eagle's medium 
(OM EM), dimethyl sulfoxide (oMSO), or in DMEM with an equivalent 
concentration of DMSO (magnification x400) 
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Figure 38. Viability of primary equine chondrocytes after 24 hours with the 
plant extract cocktail (PT) solubilised in Dulbecco's modified Eagle's medium 
(DMEM), dimethyl sulfoxide (DMSO), or in DMEM with an equivalent DMSO 
concentration (magnification x400) 
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Figure 39. Percentage of dead primary equine chondrocytes after 24 hour 
culture with the plant extract cocktail (PT) solubilised in dimethyl sulfoxide 
(DMSO), Dulbecco's modified Eagle's medium (DMEM), or in DMEM with 
DMSOadded 
Control represents basal culture medium alone, sodium nitroprusside (SNP; 50mM) 
was used a positive control for cell death, DMSO control contains a volume of 
DMSO equivalent to that found in the J50f.1.g/ml treatment. Results are expressed as 
the mean percentage of dead cells per field of view out of the total number of cells 
counted and bars represent standard error of the means (SEM). Significance 
compared to control is indicated by * .. (p<O.OOJ). 
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Control cells had a mean cell death level of 0.09 ± 0.02%, which was significantly 
increased by the cell-death inducing agent SNP to 99.97 ± 0.03% after 5 days. At 
IOl-lg/ml, the PT did not increase cell death compared to controls and DMSO controls 
when dissolved in DMSO (0.14 ± 0.03%), in DMEM (0.13 ± 0.03%) and in DMEM 
with exogenous DMSO (0.13 ± 0.04%). At 65I-lg/ml, the PT in DMSO significantly 
increased cell death to 23.76 ± 3.50% (p<0.001) whereas the PT in DMEM did not, 
either alone (0.23 ± 0.07%, n.s.) or in conjunction with the addition of exogenous 
DMSO (0.16 ± 0.09% n.s.). These results were supported by the PT at 150I-lg/ml 
which also significantly increased mean cell death in DMSO to 88.16 ± 3.07% 
(p<0.001), but did not in OM EM (0.12 ± 0.03%, n.s.) nor in DMEM with exogenous 
DMSO (0.19 ± 0.03%, n.s.). 
PT ( ~ 4 5 f l g / m l ) ) is Cytotoxic in DMSO After 5 Days 
Cytotoxicity of PT at five days was visualised and quantified with a cytotoxicity 
assay (figure 40). Control wells provided the basal level of cell death after five days 
(mean cell death (%) ± SEM; 0.25 ± 0.05%. SNP (50mM) significantly increased 
cell death to 100 ± 0.00% (p<0.00 1). DMSO did not significantly increase cell death 
after five days (0.59 ± 0.10%) compared to control. 
PT (651-lg/m1) in DMSO significantly increased cell death compared to controls 
(95.65 ± l.l8%,p<0.001) (figure 40.A). PT (451-lg/m1) caused a small but significant 
increase 2.59 ± 1.18% mean cell death (p<0.0 1). However, PT in DMEM did not 
increase cell death at concentrations up to and including 600l-lg/ml (figure 40.B) (PT 
in DMEM 600l-lg/ml, mean cell death 0.06 ± 0.02%). 
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Figure 40. Mean percentage of dead primary equine chondrocytes per field of 
view for dose ranges of the plant extract cocktail (PT) in dimethyl sulfoxide 
(DMSO) (A) or Dulbecco's modified Eagle's medium (DMEM) (8) after 5 days 
Control represents basal culture medium alone, DMSO control contains a volume of 
DMSO equivalent to that found in the PT in DMSO 65pglml treatment. Results are 
expressed as the mean percentage of dead cells per field of view and bars represent 
standard error of the means (SEM). Significance compared to control is shown by 
** (p<O.OJ) and *** (p<O.OOJ). 
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PT ( ~ 4 0 J 1 g / m l ) ) Reduces GAG Release in DMSO but Increases GAG Release in 
DMEM After 5 Days 
Cartilage explants were stimulated with IL-l ~ ~ to initiate the early stages of cartilage 
degradation as determined by GAG release (figure 41). Control explants released a 
mean GAG level of 14.07 ± 1.04% after five days in culture, which was significantly 
increased to 47.44 ± 5.75% with the addition o f I L - l ~ ~ (lOng/ml,p<O.OOI). The plant 
cocktail at O.4llg/ml had no significant effect on GAG release when dissolved in 
OMEM at (49.38 ± 3.82%) or DMSO (40.75 ± 5.31%). In OM SO, the plant cocktail 
significantly decreased IL-l ~ - s t i m u l a t e d d GAG release at 40llg/ml (20.91 ± 2.23%; 
p<O.OO 1) and 400Ilg/ml (12.51 ± 2.26%; p<O.OO 1). However, in DMEM, the plant 
cocktail increased IL-l ~ - s t i m u l a t e d d GAG release at 40llg/ml (82.63 ± 2.42%; 
p<O.OOI) and 400Ilg/ml (90.97 ± 0.60%;p<0.001). 
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Figure 41. Percentage of glycosaminoglycan (GAG) release from interleukin-
tbeta (IL-tp)-stimulated equine cartilage explants after S day culture with the 
plant extract cocktail (PT) dissolved in DMEM (vertical stripes) or DMSO 
(horizontal stripes) 
Results are expressed as percentage GA G released and represent mean values from 
3 replicates per treatment from 3 separate experiments (individual horses), i.e. n=3 
per graph. Bars represent standard error of the means (SEM). Significance 
compared to IL-lfJ (lOng/ml; chequered column) is indicated by *** (p<O.OOJ). 
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PT in DMSO ( ~ 4 0 " , g / m l ) ) Reduces PGE2 Release After 5 Days 
The mean PGE2 release from control explants over 5 days was 14.10 ± 1.08pg/ml. 
Explants released 434.20 ± 109.30pglml PGE2 in response to IL-I p stimulation 
(figure 42). The plant cocktail in OM EM did not significantly affect IL-1P-
stimulated PGE2 release at O . 4 ~ g / m l l or 40",g/ml, however it significantly reduced 
PGE2 release at 4 0 0 ~ g l m l l (78.19 ± 27.80pglml; p<O.O 1). In DMSO, the plant 
cocktail significantly reduced PGE2 release from IL-l p-treated explants at 40ug/ml 
(70.83 ± 7.85pg/ml;p<0.OI) and 4 0 0 ~ g / m l l (86.21 ± 6.65pg/ml;p<0.01). 
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Figure 42. Prostaglandin E2 (PGE2) release from interleukin-lbeta (IL-IP)-
stimulated explants after 5 days with the cocktail of plant extracts (PT) in 
Dulbecco's modified Eagle's medium (DMEM) (vertical stripes) or dimethyl 
sulfoxide (DMSO) (horizontal stripes) 
Control indicates ex plants incubated in culture medium alone. Values are reported 
as the mean of 3 horses per treatment and bars represent standard error of the 
means (SEM). Significance compared to IL-l{i (JOng/ml; chequered column) is 
indicated by ** (p<O.Ol) and *** (p<O.OOl). 
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Non-Cytotoxic PT Concentrations (lO"g/ml and 20"g/ml) in DMSO Reduce 
GAG Release 
From these initial results, the PT underwent a further study in DMSO as this was the 
solvent which effectively reduced IL-l ~ - s t i m u l a t e d d GAG release. This was done, to 
determine the effect of PT at concentrations ranging from physiologically achievable 
to the lowest concentration at which cytotoxicity occurred in either solvent (i.e. 
25ng/ml to 4 5 ~ g l m l ) . .
IL-IP significantly increased GAG release compared to control (p<O.OOl) (figure 
43). This release was significantly reduced by the NSAID (p<O.OI). PT in DMSO 
significantly reduced GAG release from IL-I ~ ~ stimulated explants at l O ~ g l m l l
(p<O.05), 2 0 ~ g / m l l and 4 5 ~ g / m l l (bothp<O.OOI) 
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Figure 43. Percentage of glycosaminoglycan (GAG) release from cartilage 
explants in response to interleukin-lbeta (IL-IJJ; lOng/ml) and a nonsteroidal 
anti-inflammatory drug (NSAID; lOOJiglml) or the plant extract cocktail (PT) 
dissolved in DMSO 
Results are expressed as percentage GAG released and represent mean values from 
3 replicates per treatment from 3 separate experiments (individual horses). Bars 
represent standard error of the means (SEM). Significance compared to IL-l/l 
(chequered column) is indicated by * (p<O.05), ** (p<O.Ol) and *** (p<O.OOl). 
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CP (450"g/ml) is Cytotoxic in DMEM After 5 Days 
The CP was tested alongside PT on the same plates therefore the control, DMSO 
control and SNP mean cell death values in this section are the same as previously 
stated for the PT cytotoxicity results, i.e. 0.25 ± 0.05% (control); 0.59 ± 0.10% 
(DMSO control); and 100 ± 0.00% (SNP). 
CP in DMSO did not increase cell death at concentrations up to and including 
400llg/ml (CP in DMSO 400llg/ml, mean cell death 0.28 ± 0.08%) (figure 44.A). 
However, CP (450Ilg/ml) in DMEM caused a small but significant increase in cell 
death after five days to 4.6 ± 1.03% (p<0.001) compared to control (figure 44.B). 
177 
A 
*** 
CP In DMSO 
B 
*** 
CPln DMEM 
Figure 44. Graphs showing the mean percentage of dead cells per field of view 
for the commercial product (CP) in dimethyl sulfoxide (DMSO) (A) or 
Dulbecco's modified Eagle's medium (DMEM) (B) after 5 days 
Control represents basal culture medium alone, DMSO control contains a volume oj 
DMSO equivalent to that Jound in the CP in DMSO 400llg/ml treatment. Results are 
expressed as the mean percentage oj dead cells per field oj view and bars represent 
standard error oj the means (SEM). Significance compared to control is shown by 
*** (p<O.OOJ). 
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CP in DMEM ( ~ 4 0 J 1 g / m l ) ) Significantly Reduces GAG Release 
The CP in DMSO had no significant effect on GAG release, but CP dissolved in 
DMEM significantly reduced IL-I ~ - s t i m u l a t e d d GAG release at 4 0 ~ g / m l l (p<O.OOI) 
and 4 0 0 ~ g / m l l (p<O.OI) (figure 45). 
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Figure 45. Percentage of glycosaminoglycan (GAG) release from interleukin-
tbeta (IL-tp)-treated cartilage explants after 5 days with the commercial 
product (CP) in Dulbecco's modified Eagle's medium (DMEM) (vertical stripes) 
or dimethyl sulfoxide (DMSO) (horizontal stripes) 
Results are expressed as mean percentage GAG released from 3 replicates per 
treatment from 3 separate experiments (individual horses), i.e. n=3. Bars represent 
standard error of the means (SEM). Significance compared 10 IL-lfi (lOng/ml; 
chequered column) is indicated by ** (p<O.OJ) and *** (p<O.OOJ). 
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The CP then underwent a further study in DMEM, as this was the solvent which 
effectively reduced IL-l ~ - s t i m u l a t e d d GAG release. IL-l ~ ~ significantly increased 
GAG release compared to control (p<O.OOl) (figure 46). This release was 
significantly reduced by the NSAID (p<O.OI). CP in DMEM significantly reduced 
GAG release at concentrations of IOIlg/ml and above (p<O.OO 1). 
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Figure 46. Percentage of glycosaminoglycan (GAG) release from cartilage 
explants in response to interleukin-Ibeta (IL-IP; IOng/ml) and a nonsteroidal 
anti-inflammatory drug (NSAID; lOO"g/ml) or the commercial product (CP) 
dissolved in Dulbecco's modified Eagle's medium (DMEM) 
Results are expressed as mean percentage GA G released from 3 replicates per 
treatment from 3 separate experiments (individual horses). Bars represent standard 
error of the means (SEM). Significance compared to IL-IfJ (chequered column) is 
indicated by ** (p<O.OI) and *** (p<O.OOI). 
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PL Does Not Significantly Affect GAG Release After 5 Days 
Although there were trends for the placebo to reduce IL-I p-stimulated GAG release 
in DMEM and increase GAG release in DMSO, no results were significant. 
Therefore, PL did not significantly reduce IL-l p-stimulated GAG release in either 
DMEM or DMSO at concentrations up to 400f.lg/ml (figure 47). 
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Figure 47. Percentage of glycosaminoglycan (GAG) release from interleukin-
t beta (IL-t p)-stimulated cartilage explants after 5 days with the placebo (PL) 
dissolved in Dulbecco's modified Eagle's medium (DMEM) (vertical stripes) or 
dimethyl sulfoxide (DMSO) (horizontal stripes) 
Results are expressed as mean percentage GA G released from 3 replicates per 
treatment from 3 separate experiments (individual horses), i.e. n=3. Bars represent 
standard error of the means (SEM). Significance compared to lL-l/3 (lOng/ml; 
chequered column) is indicated by *** (p<O.OOI). 
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4.4. Discussion 
The objectives of the work described in this chapter were to test the PT for 
cytotoxicity and efficacy in tenns of reducing IL-l ~ - s t i m u l a t e d d GAG and PGE2 
release in an in vitro explant model of early OA. Initial 24 hour pilot studies with the 
PT found that it was cytotoxic to monolayer equine chondrocytes when dissolved in 
DMSO at 66.9)lg and above, whereas in DMEM, concentrations up to 284)lglml 
showed no adverse effects on chondrocyte viability. This may have been due to an 
ingredient solubilised in DMSO that was not soluble in DMEM. However, it is well 
known that DMSO permeabilises cell membranes through pore-fonnation (Notman 
et al., 2006; Gurtovenko and Anwar, 2007). Thus, although the material may have 
been solubilised in DMEM, the absence of DMSO may have prevented it entering 
the cell, thereby accounting for the differing toxicities between solvents. In order to 
test this, non-toxic and toxic concentrations of PT in DMSO and DMEM were tested 
along with PT in DMEM with an equivalent concentration of added OMSO to that 
found in the PT in DMSO treated wells. The results showed that concentrations of 
PT that were toxic in DMSO, were not toxic when dissolved in DMEM both with 
and without the presence of OMSO. Therefore, it was considered that the toxicity 
seen in the PT in DMSO-treated cells was more likely a solubility issue than due to 
the permeabilising activity of DMSO. 
Further tests with PT over five days showed that in DMSO initial signs of 
cytotoxicity were present at concentrations of 45)lglml, whereas in OM EM 
concentrations up to 600)lglml showed no signs of toxicity. In tenns of efficacy, the 
PT was able to reduce IL-l ~ - s t i m u l a t e d d GAG release, at concentrations non-
detrimental to chondrocyte viability. However, as with the cytotoxicity testing, this 
was affected by the choice of solvent used. The PT showed positive anti-catabolic 
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effects when in DMSO. DMSO controls confirmed that this was not due to the effect 
of the DMSO, which has known anti-inflammatory effects. However, some of the 
actives in the ingredients of the PT, such as resveratrol in grape skins and curcumin 
in turmeric, are known to be soluble in organic solvents such as DMSO and show 
little, if any, solubility in aqueous solutions (lwuchukwu and Nagar, 2008; Henrotin 
et al., 20 10). Thus, the beneficial effects of the DMSO soluble-actives would not be 
present in the DMEM preparation. 
Similarly, the effect of solvent on supplement effects was observed when increased 
GAG (82% of the total GAG present at concentrations of 40llg/ml PT) was released 
from explants treated with PT in DMEM but not DMSO. This could be attributed to 
the presence of bromelain, a mixture of water-soluble, stable, proteolytic enzymes 
extracted from the pineapple plant (Hale et al., 2005), which are likely to be active 
and able to break down the cartilage matrix, under culture conditions of 37°C. 
Consequently, when developing models to test supplements, their modes of action 
and solubility in different solvents must be considered when interpreting the results. 
Testing a cocktail of plant extracts with different actions in the model highlighted 
these issues sooner than testing individual ingredients would have done. 
Although this study was unable to show beneficial effects of PT in DMEM, in terms 
of reduced GAG release, it did significantly reduce IL-I ~ - s t i m u l a t e d d PGE2 release at 
400llg/ml. This agrees with other studies reporting the anti-inflammatory ability of 
bromelain in vivo (Secor et al., 2005). However, this anti-inflammatory effect is 
accompanied with significant GAG loss in the equine explant model, which is 
indicative of cartilage breakdown. This suggests either that the cocktail in DMEM is 
not supportive to joint health, or that the model and the GAG assay were unsuitable 
for evaluating certain components of the cocktail, such as bromelain. 
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The CP showed toxicity in DMEM at 450flg/ml but not in DMSO at concentrations 
up to 400flg/ml, suggesting that the water-soluble components in the CP were 
cytotoxic compared to the soluble components in the organic solvent. In DMEM, the 
CP significantly reduced IL-I ~ - s t i m u l a t e d d GAG release from cartilage explants at 
40flg/ml whereas equivalent concentrations of CP in DMSO had no effect. Further 
studies confirmed that this effect was seen at concentrations as low as 10flg/ml. The 
CP is marketed as a glucosamine and chondroitin sulphate-based product. 
Glucosamine hydrochloride has been investigated for its anti-catabolic effects in 
vitro, and has been shown to reduce recombinant equine IL-I ~ - s t i m u l a t e d d GAG 
release from equine cartilage explants at 2Smg/ml (Fenton et al., 2002). Similarly, 
glucosamine hydrochloride in combination with chondroitin sulphate at 2SOflg/mI 
each, significantly reduced GAG degradation in equine explants stimulated with 
recombinant human IL-l a (40ng/ml) (Dechant et al., 2005). The proportions of 
glucosamine and chondroitin sulphate in the CP are unknown, although the lack of 
native GAG at the highest CP concentration tested, suggests that levels of 
chondroitin sulphate are low in the preparations used. Despite this, the CP as a 
whole product showed a significant reduction in IL-l ~ - s t i m u l a t e d d GAG loss at 
40flg/ml, lower than the concentrations used in the aforementioned studies. Thus, 
suggesting that the CP has anti-catabolic properties, which may be due to the forms 
of glucosamine and chondroitin sUlphate that it contains. It should be noted here, 
that the reduction in GAG loss shown in this study may reflect reduced proteoglycan 
synthesis by the matrix, which may not be beneficial. Further studies on the effects 
of the CP and PT on GAG synthesis are required to answer this. 
The placebo did not show any beneficial effect in terms of GAG release, suggesting 
that it was suitable for use as a placebo. 
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In conclusion, the model was able to detect a beneficial effect of PT and CP in terms 
of reducing IL-l ~ - s t i m u l a t e d d cartilage GAG release. Although the degree of 
solubilisation and the solvent used affected this activity. Measuring GAG and PGE2 
alone provide a limited insight into what is happening in the model and does not 
address the complexities seen when working with the combination product. Thus, 
the ability to identify multiple cartilage protein products released from the explants 
in this system may increase the understanding of the processes occurring in this early 
OA model, and may enable a more comprehensive assessment of the effects of plant 
extracts tested in it. 
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CHAPTER 5. ADAPTING THE MODEL FOR 
PROTEOMIC ANALYSIS OF THE CARTILAGE 
SECRETOME 
5.1. Introduction 
The previous chapter highlighted that measuring more parameters in vitro may 
provide further information on the effects of plant extracts in different solvents in the 
model. One approach to achieve this is to characterise the proteins released from the 
cartilage (the secretome) in the early OA explant model. The value of proteomics is 
that proteins can be identified using database analysis and potentially quantified 
allowing an insight into what processes are involved, and to discover which 
processes may be modulated with plant extracts. 
OA involves the loss of structural constituents from the articular cartilage ECM via 
increased cartilage catabolism and consequent failure of the chondrocytes to 
maintain tissue integrity (Aigner et at., 2007). The degradation and release of 
proteins and glycoproteins may aid the diagnosis of OA. For example, increased 
levels of COMP and levels of COMP fragments in the synovial fluid can distinguish 
OA horses from normal horses (Arai et aI., 2005). Similarly, increased urinary 
COMP has identified horses with aseptic joint disease compared to animals free from 
joint disease (Misumi et at., 2006). The levels ofCOMP released from OA cartilage 
can also vary according to the severity of the disease process. For example, elevated 
serum COMP is correlated with OA severity in humans (Clark et at., 1999). 
Consequently, the ability to detect biomarkers of cartilage degradation and/ or 
inflammation in biological samples, such as serum, urine or synovial fluid, may 
enable clinicians to diagnose sub-clinical OA, determine disease stage and assess 
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response to therapy in human patients and companion animals. The complexity of 
OA means that combinations of biomarkers may be more effective in achieving these 
goals than single ones (Williams, 2009). Identifying these biomarkers will also aid 
drug discovery and drug safety/ efficacy monitoring in patients and in animal 
models. 
Proteomics is being increasingly applied in basic cartilage biology and OA research. 
Characterisation of cell lysates from isolated chondrocytes has yielded valuable 
information regarding the soluble protein fraction of the chondrocyte proteome, and 
paved the way for future studies on cartilage pathologies such as OA (Ruiz-Romero 
et al., 2005). Recently, proteomics has been used to identify differences in the 
intracellular proteome of chondrocytes in response to IL-\ p or TNF-a (Cillero-Pastor 
et al., 2010), and the effects of glucosamine and chondroitin sulphate on intracellular 
mechanisms in IL-\ p-stimulated chondrocytes (Calamia et al., 2010). Studies of 
soluble proteins in cartilage tissue from OA patients has increased the knowledge of 
the proteins contained within the ECM of diseased versus normal tissue (Wu et al., 
2007). Similarly, the synthesis and release of proteins from human OA cartilage 
explants have recently been examined (Polacek et al., 2010). However, only a few 
papers have reported on proteins secreted from the cartilage ECM in response to a 
controlled pathological insult, such as IL-\ a and all-trans-retinoic acid-treated mouse 
cartilage (Wilson et al., 2008), and IL-lP, TNF-a and mechanical compression 
treated bovine explants (Stevens et al., 2008). Identifying proteins released from 
cartilage in a serum-free model therefore has the potential to give an indication of 
proteins likely to be present in the synovial fluid or blood of patients in the early 
stages of OA, especially when the ECM has been structurally compromised or 
exposed to inflammatory mediators. 
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The present study used healthy equine cartilage explants cultured in serum-free 
media, either alone (representing healthy cartilage), in the presence of recombinant 
equine IL-l ~ ~ to replicate the early inflammatory stages of OA, or a combination of 
IL-l ~ ~ and carprofen, a NSAID, to simulate anti-inflammatory pharmacotherapy. The 
aim of this chapter was to use proteomic analysis of the explant culture media to 
identify the proteins secreted from I L - l ~ ~ treated and untreated equine explants in the 
model, with a view to improving its applicability for evaluating the effects of plant 
extracts for improving joint health. The primary hypothesis of the study was that this 
proteomic approach could be used to detect proteins specifically secreted in response 
to stimulation with pathophysiologically relevant stimuli, such as IL-! p. 
5.2. Material and Methods 
Cartilage Explant Culture 
Normal articular cartilage from the weight bearing regions of the MCP joints of three 
horses were used for this study. Cartilage shavings of equal thickness were 
aseptically harvested into low glucose (lgiL glucose) DMEM containing 4% 
penicillin/streptomycin before being washed twice in PBS for 20 minutes. Cartilage 
shavings from each animal were cut into 3mm discs using a sterile biopsy punch and 
five discs/ well were placed into 18 wells of a 24-well plate, containing I ml of 
OM EM supplemented with 2% penicillin/streptomycin. Plates were incubated 
overnight (37°C/ 5% C02). Cell culture media were then replaced with fresh media 
before the experiment began. 
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Study Design 
Explants from three individual animals were subjected to three treatments; control, 
IL-IP, NSAID + IL-IP (six sample replicates per treatment) totalling 18 samples per 
animal, equalling 54 samples in total. All wells contained 1 ml of culture medium. 
Control wells contained the culture medium alone. Recombinant equine IL-I ~ ~
(IOnglml) was added to the remaining weBs to induce cartilage inflammation. IL-I ~ ~
alone formed the negative control and the addition of carprofen (lOOllg/ml; 
Rimadyl®, Pfizer), to the remaining IL-I p-treated wells acted as a positive control to 
counteract the IL-Ip-stimulated inflammation. Explants were incubated at 37°C and 
5% CO2 for six days. After six days, the supernatants were removed and frozen at -
20°C. 
Trypsin Digestion of Soluble Proteins 
Dithiothreitol (DTT, Sigma-Aldrich) was added to 100111 of sample to a final 
concentration of IOmM and incubated at 37°C for 30 minutes. Iodoacetamide 
(Sigma-Aldrich) (55mM) was added to each sample and incubated for 45 minutes at 
3rC in the dark. Ice-cold acetone (Sigma-Aldrich) was added to each tube and 
mixed well. Samples were left on ice for 1 hour, vortexing for 10 seconds every 15 
minutes. The precipitate was then centrifuged at 15,000 x g for 5 minutes at 4°C and 
the supernatant discarded. The protein pellet was air dried and re-suspended in 
SOmM ammonium bicarbonate (Sigma-Aldrich) solution to a final concentration of 
10)lg protein/mL. Mass spectrometry grade trypsin (Promega) was added to each 
tube at a ratio of I :50 enzyme/target protein at 37°C overnight. The reaction was 
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stopped by adding 1111 formic acid (Sigma-Aldrich). Samples were stored at -80a C 
until analysis by electrospray ionisation (ESI) mass spectrometry (MS). 
Analysis by Liquid Chromatography and Tandem Mass Spectrometry 
Liquid chromatography (LC) was performed using an Easy-nLC (Bruker UK Ltd) 
under the control of Hystar (Bruker UK Ltd). Peptides generated by tryptic digestion 
were prepared for LC-MS/MS as follows; 2111 digest was added to 48111 solvent A 
(95% (v/v) H20, 5% (v/v) acetonitrile (Sigma-Aldrich), 0.1 % (v/v) formic acid). A 
volume (511\) of this dilution was then loaded onto a C18 Pepmap column (751lm ID, 
15cm, LC Packings, Dionex). Peptides were separated at a flow rate of 300nllmin 
and the introduction of solvent B (95%(v/v) acetonitrile, 5% (v/v) water, 0.1 % (v/v) 
formic acid) over a 30 minute linear gradient (solvent B went from 0% to 5% in 30 
seconds, then from 5% to 55% in 22 minutes, up to 95% in 4 minutes, was held at 
95% for 2 minutes 30 seconds to wash the column, then returned to 5% over 1 
minute followed by 10 minute equilibration in 5% before the next injection, total run 
time 40 minutes). The LC system was interfaced directly with a 3-D high capacity 
ion trap (HCT) mass spectrometer (amaZon, Bruker DaItonics) via the nanoESI 
spray source and a target of 200,000 was set for Smart ion charge control ( I c C ) n ~ . .
Up to 5 precursor ions above a threshold of 10,000 were selected per MS scan. Each 
precursor was fragmented twice and then the mass was excluded for 1 minute. 
Singly charged ions were excluded. Smart parameter setting (SPS) tuning was 
allowed for transmission of the precursor into the trap. SmartFrag ™ controlled the 
fragmentation of each precursor ion and this was achieved using helium gas and a 
30-200% collision energy range with amplitude I.3V. 
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Data Processing and Analysis 
Raw LC-MS/MS data were processed automatically and Mascot compatible files 
(* .xml) were created using DataAnalysis ™ 4.0 software (Bruker UK Ltd) with the 
following parameters: compounds (autoMS) threshold 10,000, unlimited number of 
compounds, one minute retention time windows for C18 (30 min gradient). 
A database search was performed using Mascot (Perkins ef al., 1999) software and 
the SwissProt database (version 5.16), with the following parameters: 2+ and 3+ 
ions, peptide tolerance 0.5 Da, J3C=I, fragment tolerance 0.5 Da, missed cleavages: 
I, instrument type: ESI-TRAP. Fixed modifications: carbamidomethyl cysteine and 
variable modifications: oxidation of methionine, deamidation of asparagine and 
glutamine residues. 
Data from the Mascot search are expressed as a Mowse score. This is a statistically 
calculated weighting score for each peptide match, generated from comparing 
experimental data with the calculated peptide mass or fragment ion mass value for 
each entry in a sequence database (Pappin et al., 1993). Higher Mowse scores result 
from increasing numbers of matched peaks and increase the chance that the 
identification is real and not random. Mowse scores lower than 40 were inspected 
manually and only included in the statistics if a series of at least 4 continuous 
fragment ions were observed. However, proteins with less than 4 continuous 
fragments ions were also recorded out of interest. 
A schematic overview of the study design is shown in figure 48. 
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Figure 48. Schematic overview of the proteomic study design 
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Western Blotting 
Replicate samples for each treatment were combined to give a total of three samples 
per horse. The protein content of each sample was quantified using a DC protein 
assay (as described on page 93) and concentrated to yield 50J.1g protein per sample by 
means of a freeze-dryer (Heraeus-Christ). Positive tissue controls were made by 
crushing equine cartilage shavings with liquid nitrogen into a fine powder. 
Housekeeping controls were not used as cellular housekeeping proteins such as beta-
actin were inappropriate for these studies of the ECM protein secretome. 
Supernatant and cartilage control samples were re-suspended in 37J.1l LDS sample 
buffer (Invitrogen) and loaded onto 4-12% NuPAGE® buffered gradient pre-cast Bis-
Tris gels (50J.1g proteinl lane. A full range molecular weight marker (GE Healthcare) 
was loaded (5J.1l) onto each gel. Samples were electrophoresed for 1 hour under 
denaturing and reducing conditions. Gels were either silver stained with a silver 
stain kit (Bio-Rad Laboratories) to observe the protein profiles of the samples, or 
electro-transferred onto PVDF membranes for western blotting. After blocking, 
primary antibodies were diluted as recommended by the manufacturer in 5% milk 
powder in TBS/Tween and added to the membrane for overnight incubation at 4°C. 
A variety of primary antibodies were selected for validating the secreted proteins 
discovered by the proteomic analysis. 
Cartilage intermediate layer protein-l (CILP-I) blots were performed using a sheep 
antibody (l :300 dilution, R&D Systems). Clusterin (1 :500 dilution, Santa Cruz) and 
MMP-3 (l: 1000 dilution, Abeam) were goat polyc1onal antibodies. A rabbit 
polyc1onal to MMP-I was used at 1 :5000 dilution (Abeam). Thrombospondin (TSP) 
(I: 1000 dilution, Abeam) and TSP-I (I :50 dilution, Santa Cruz) were mouse 
monoclonal antibodies. All antibodies were produced against human peptide 
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sequences with 99-100% identity to their counterparts in Equus cabal/us. The 
peptide sequences used by each manufacturer for antibody production were checked 
using the NCB I Basic Local Alignment Search Tool (Protein BLAST; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins). 
Appropriate secondary antibodies conjugated to HRP were used; polyclonal rabbit 
anti-sheep HRP (diluted 1: 10000, Abeam), polyclonal rabbit anti-goat 
ImmunoglobulinslHRP (diluted 1: 10000, Dako) and goat anti-mouse/anti-rabbit 
labelled polymer HRP (diluted 1 :400, Dako). 
After rinsing the membranes, chemiluminescence was detected using ECL+ on a 
Typhoon Trio+ Variable Mode Imager. Densitometric quantification of the Western 
blot bands was performed using ImageJ software. The relative intensity of protein 
bands in IL-l p and NSAID + IL-l P treated samples were compared to those in 
control samples from each horse 
5.3. Results 
Differing Media Protein Profiles from Control, IL-lfJ and NSAID-treated 
Samples 
An initial screen was used to visually assess whether the various treated samples had 
different protein profiles. Silver staining of one-dimensional (1-D) gels revealed 
differences in the secretome protein profiles between control, IL-l p-treated and IL-
l P plus NSAID-treated samples (figure 49). 
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Figure 49. Electrophoretic protein profiles of medium from cartilage explants 
incubated alone (control), or treated with equine interleukin-lbeta (IL-IP), and 
a nonsteroidal anti-inflammatory drug (NSAID + IL-IP) 
Silver staining of the one-dimensional (/ -D) gel identified stronger bands in the IL-
l fJ and NSAID-treated samples compared to controls at roughly ll O kilodaltons 
(kDa) (arrow A), 90kDa (arrow B) and 66kDa (arrow C). Arrow D highlights a 
band around 55kDa present in IL-lJ3-treated samples, but not in control or IL-lfJ 
plus NSAID-treated samples. 
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Identification of Proteins in the Sample Media 
The majority of secreted proteins identified using LC-MSIMS with high Mowse 
scores in mUltiple samples were cartilage ECM proteins or proteins with well-
established matrix functions (table 3). Abundant proteins that were identified in the 
majority of samples from all horses included aggrecan core protein, fibronectin, 
decorin and COMPo The database search identified some proteins more frequently in 
IL-l ~ - t r e a t e d d samples compared to untreated controls, namely MMP-3 and TSP-I. 
Cross-species matching compares the protein sequence entries in the database, which 
exhibit the closest homology to the 'unknown' protein of interest (Lester and 
Hubbard,2002). This method enabled identification of proteins for which the equine 
versions were absent or incomplete. Some peptides, such as decorin, matched 
proteins from multiple species hits (human, horse, cow, rat, dog and rabbit), and 
where the horse sequence was present in the database, it generally achieved the 
higher Mascott Mowse score compared to that of the closest homologous sequence in 
the other species. The only exception was fibronectin, which achieved a top Mascott 
Mowse score of 642 with the bovine sequence but only 221 with the equine 
sequence. This could be due to the entry in the equine database containing an error, 
which is possible when a protein sequence has been translated directly from DNA 
(Barrett et al., 2005). It could also be due to there being two variants of this protein 
in vertebrates (insoluble found in the ECM and soluble found in the plasma), the one 
currently present in the equine database may not have been detected, hence the 
greater homology with bovine. Where the horse sequence was absent from the 
database, multiple species matching increased confidence in the protein detected, for 
example, aggrecan core protein which had peptide matches with human, mouse, rat, 
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pig and dog. Some peptides only matched proteins from one species such as equine 
MMP-3, or two species such as equine and bovine MMP-l. 
The majority of proteins identified in this study were ECM components or ECM-
associated, however, a small number of additional proteins were also found. Eleven 
non-ECM proteins were present in mUltiple samples and are shown in table 4. Many 
of these had lower Mowse scores under 55, except serum albumin precursor with a 
score of 71. Peptides with lower Mowse scores mean they are more likely to be 
random matches than real matches, but the automatic threshold score above which 
matches were considered real was set at a score of 40. Peptides with fragment ion 
matches under this threshold were manually checked to determine their accuracy. 
Many proteins were only identified in a single sample from the 54 samples tested. 
Table 5 details peptides from these proteins that contained four or more continuous 
fragment ions in a series. The presence of four or more fragment ions in a row was 
defined as the criterion for which a single peptide match was considered to be a true 
positive, rather than five fragment ions as is standard. This was because some of the 
peptides were small and only consisted of five or six amino acids. Therefore, as 
detecting all ions is unlikely, the detection of four ions in a row was set as the limit 
confirming the peptide match. The presence of some of the proteins in table 5 may 
be due to contamination, for example keratin from hair, skin or nails during tissue 
collection, culture or sample processing (Chamrad et al., 2003). Table 6 shows the 
proteins found in only one sample which have peptides with fewer than 4 continuous 
fragment ions in a series. These proteins have low Mowse scores of 55 or less. 
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IV 
C) 
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Accession Mascot Sequence No. of Protein name Species matched 
number Entry name Mowse Coverage matched Function 
score (%) peptides 
Fibronectin Horse, Mouse, Cow, Rat P07589 FINC_BOVIN 642 9 16 ECM structure, interacts with cells + collagen 
Cartilage Oligomeric Matrix Mouse, Human, Cow, Rat 09ROG6 COMP_MOUSE 554 16 11 ECM structure, interacts with collagen, fibronectin, Protein integrins 
Matrix-Metalloproteinase-3 Horse 028397 MMP3_HORSE 366 19 11 ECM degradation: fibronectin, collagen, gelatins, proteoglycans 
Aggrecan Core Protein Human, Mouse, Rat, Pig, P16112 PGCA_HUMAN 353 3 8 Compression resistance in ECM Dog Interacts with COMP 
Clusterin Horse, Dog 029482 CLUS_HORSE 318 14 5 Secreted glycoprotein, extracellular molecular chaperone activity + apoptosis regulation 
Thrombospondin-1 Human, Mouse, Cow P07996 TSP1_HUMAN 227 5 6 Adhesive glycoprotein for cell-cell + cell-matrix interactions 
Matrix-Metalloproteinase-1 Horse, Cow 09XSZ5 MMP1_HORSE 227 10 5 ECM degradation: collagens 
Fibronectin Horse, Mouse, Cow, Rat 028377 FINC_HORSE 221 11 3 
Chondroadherln Human, Mouse, Cow, Rat 015335 CHAD_HUMAN 220 13 4 Chondrocyte attachment via integrins Interacts with collagen type II 
Biglycan Horse,Cow 046403 PGS1_HORSE 183 13 4 Collagen fibre assembly 
Decorln Horse, Human, Cow, Rat, 046542 PGS2_HORSE 156 10 3 Fibril formation in ECM, binds to collagen I, II, Dog, Rabbit fibronectin, TGF-J3 
Cartilage Intennediate Layer Human, Mouse, Pig 075339 CILP1_HUMAN 99 2 3 ECM organisation (scaffolding) Protein-1 Antagonises TGF131 and IGF-1 function 
Prolargin precursor Human, Mouse P51888 PRELP _HUMAN 96 3 1 Anchors basement membranes Binds collagens and proteoglycan 
TNF receptor 11 B precursor Mouse 008712 TR11B_MOUSE 87 3 1 TNF receptor superfamily member 11 B Promotes osteoclast apoptosis 
Fibromodulin Rat, Human, Mouse P50609 FMOD RAT 82 8 3 Fibril formation in ECM, binds to collagen I, II 
-- '---- -- ----.--
L ___ .-:'" ___ 
Table 3. Secreted extracellular matrix proteins and proteolytic enzymes present in multiple samples identified using the SwissProt 
51.6 database 
Protein identification using cross species matching often found matches with multiple species. Horse sequence-matched proteins normally 
achieved the top Mowse score out of all species matched for that protein, except for fibronectin (grey shaded rows), which had a higher Mowse 
score for the bovine sequence than the horse sequence. Proteins listed in order of Mowse score (highest score first), 
IV 
o 
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Accession Mascot Sequence No. of Protein name Species matched Number Entry name Mowse Coverage matched Function score (%) peptides 
Vimentin Cow, Green P48616 VIME_BOVIN 301 12 6 Intermediate filament protein part of cellular 
monkey cytoskeleton 
Trypsin Pig P00761 TRYP_PIG 134 16 3 Used to digest protein 
Serum amyloid A protein Horse, Cow, P19857 SM_HORSE 123 25 3 Apolipoprotein secreted into plasma in response to cytokines 
Alpha Enolase Cow, Human 09XSJ4 ENOA_BOVIN 94 7 4 Intracellular metabolic enzyme role in glycolysis 
and hypoxic tolerance 
Serum amyloid A-2 protein American mink P02739 SAA2_MUSVI 74 12 2 Apolipoprotein secreted into plasma in response to cytokines 
Transcription termination factor 1 Human 015361 TTF1_HUMAN 68 2 3 Nuclear protein terminating transcription 
Serum albumin Cow P02769 ALBU_BOVIN 71 1 1 Plasma protein 
Breast cancer type 2 protein Cat 0864S8 BRCA2_FELCA 51 0 3 Involved in double strand break repair susceptibility homolog 
Lysozyme C, kidney isozyme Sheep P80190 L YSCK_SHEEP 47 6 1 Bacteriolytic function 
Sodiumlhydrogen exchanger 2 Rabbit P50482 SL9A2_RABIT 45 1 1 Membrane protein involved in pH regulation to 
eliminate acids generated by metabolism 
Cytoplasmic dynein 1 heavy chain 1 Human 014204 DYHC1_HUMAN 44 0 1 Organelle and vesicle motility along microtubules 
Table 4. Non-extracellular matrix proteins identified in six or more samples identified using the SwissProt 51.6 database 
Protein identification using cross species matching often found matches with multiple species. Horse sequence-matched proteins normally 
achieved the top Mowse score out of all species matched for that protein. Table lists the non-extracellular matrix (EeM) proteins in order of 
Mowse score (highest score first). 
IV 
o 
w 
No. of 
Species Accession Mascot Sequence No. of continuous Protein name 
matched Number Entry name Mowse Coverage matched fragment Function score (%) peptides ions in a 
series 
Keratin, type II cytoskeletal 1 Human P04264 K2C1_HUMAN 87 3 2 9 Hairl skin contaminant 
Triosephosphate isomerase Dog P54714 TPIS_CANFA 52 4 1 9 Glycolytic enzyme 
Fc receptor-like A Mouse 0920A9 FCRLA_MOUSE 49 1 1 5 Cytoplasmic proteins resembling Fc receptors 
Glucose-6-phosphate 1- Mouse P97324 G6PD2_MOUSE 45 3 2 4 Cytosolic enzyme involved in NAPDHI dehydrogenase 2 glutathione protection against oxidative damage 
Centromere protein C1 Mouse P49452 CENPC_MOUSE 42 0 1 4 Nuclear protein apoptotic cells 
Lactadherin Pig P79385 MFGM_PIG 40 2 1 4 Secreted membrane protein involved in phagocytic removal of apoptotic cells 
Max-like protein X Human 09UH92 MLX_HUMAN 38 2 1 4 Nuclear and cytoplasmic isoforrns - regulate transcription 
Table 5. Non-extracellular matrix proteins identified in only one sample, with four or more continuous fragment ions 
Identifications of proteins using cross species matching often found matches with multiple species. The identifications of these proteins relied on 
peptides with four or more continuous fragment ion matches using the SwissProt 51.6 database. Proteins listed in order of Mowse score (highest 
score first). 
tv 
~ ~
Protein name Species Accession 
Mascot Sequence No. of 
matched number Entry name Mowse Coverage matched Function score (%) peptides 
DNA-dependent protein kinase catalytic Dog 08WN22 PRKDC_CANFA 
subunit 55 0 3 Nuclear protein, molecular sensor for DNA damage 
Serine-protein kinase AlM Mouse 062388 ATM_MOUSE 55 0 3 
Nuclear /cytoplasmic vesicle protein, molecular 
sensor for DNA damage 
Histone acetyltransferase Human 08WYB5 MYST4_HUMAN 53 1 2 
Nuclear protein, involved in transcriptional activation l 
and repression 
Bromodomain and PHD f i n g e r ~ o n t a i n i n g g Human 09ULD4 BRPF3_HUMAN Nuclear protein, component of complex with MYST4 protein 3 51 2 3 activity 
Ubiquitin carboxyl-tenninal hydrolase 24 Human 09UPU5 UBP24_HUMAN 50 0 2 
Involved in the ubiquitin-dependent proteolytic 
pathway 
Putative pre-mRNA-splicing factor AlP Human 043143 DHX15_HUMAN Nuclear protein, pre-mRNA processing factor dependent RNA helicase DXH15 48 2 2 involved in disassembly of spliceosomes 
Nuclear mitotic apparatus protein 1 Human 014980 NUMA1_HUMAN 48 0 2 Nuclear chromosome protein, structural component 
Bullous pemphigoid antigen 1 Human 003001 BPA1_HUMAN 47 0 2 Cytoplasmic protein, a cytoskeletal linker protein 
Sodium/calcium exchanger 1 Cow P48765 NAC1_BOVIN 47 1 2 
Cen membrane protein, transports Ca out during 
relaxation to prevent intracellular stores overloading 
Thyroid receptor-interacting protein-11 Human 015643 TRIPB_HUMAN 47 0 1 
Golgi, cytoplasmic and peripheral membrane protein, 
enhances thyroid receptor-modulated transcription 
Plectin-1 Rat P30427 PLEC1_RAT 46 0 3 
C y t o ~ a s ' ! l i c c protein, involved in cross-linking and 
stabilisation of cytoskeletal intermediate filament 
Bcl-21adenovirus E1 B 19kDa-interacting Mouse 099JU7 BNIPL_MOUSE Nuclear and cytoplasmic protein bridging BCL2 and protein 2-1ike protein 45 6 1 ARRHGAP1/CDC42 in promoting cell death 
--
Table 6. Non-extracellular matrix proteins identified in one sample with fewer than four continuous fragment ion matches 
Identifications of proteins using cross species matching often found matches with multiple species. The identifications of these proteins relied 
on peptides with less than four continuous fragment ion matches using the SwissProt 51.6 database. Proteins listed in order of Mowse score 
(highest score first). Continued on next page. 
IV 
C> 
VI 
Protein name Species Accession 
Mascot Sequence No. of 
matched number Entry name Mowse Coverage matched Function 
score (%) peptides 
i Epidermal growth factor receptor kinase Human 08TE67 ES8L3_HUMAN Cytoplasmic protein, interacts with ABI1 to regulate 
, substrate 8-1ike protein 3 44 2 2 cell growth and Erk pathway activation 
Glutaminyl-tRNA synthetase Human P47897 SYO_HUMAN 44 2 2 
Cytoplasmic protein, involved in catalysing reaction 
for glutamate metabolism, and ATP->ADP 
Integrin beta-5 Human P18084 ITB5_HUMAN 43 1 2 Membrane protein, receptor for fibronectin 
Glial fibrillary acidic protein Cow 028115 GFAP_BOVIN 43 5 2 
Cytoplasmic protein, a cell-specific marker 
distinguishes astrocytes from other glial cells 
Chinese P50310 PGK1_CRIGR Phosphoglycerate kinase 1 Hamster 43 2 1 Cytoplasmic glycolytic enzyme 
Synergin gamma (AP1 subunit gamma- Mouse 05SV85 SYNRG_MOUSE Cytoplasmic protein involved in endocytosis and binding protein 1) 42 1 2 membrane trafficking at the trans-Goigi network 
Beta, beta carotene 9',10'oOxygenase 
Crab eating 08HXG8 BCD02_MACFA 42 
macaque 3 2 Oxidatively cleaves beta-carotene and Iycopene 
Oeath-associated protein kinase 3 Rat 088764 DAPK3_RAT 41 2 1 
Nuclear + cytoplasmic protein, positively regulates 
apoptosis 
Isocitrate dehydrogenase [HAD] subunit Cow 077784 IDH3B_BOVIN Mitochondrial enzyme involved in the citric acid cycle beta, mitochondrial 41 1 1 by oxidative decarboxylation of isocitrate 
Cytosolic phospholipase A2 delta Mouse Q50L43 PA24D_MOUSE 40 2 2 
Cytoplasmic protein that hydrolyses 
glycerophospholipids 
Cytoplasmic + nuclear protein, catalyses 
Human Q9UM07 PADI4_HUMAN 39 1 2 citrullination/ deimination of arginine residues of 
Protein arginine deiminase type4 proteins 
--
Table 7. continued. Non-extracellular matrix proteins identified in one sample with fewer than four continuous fragment ion matches 
Identifications of proteins using cross species matching oftenfound matches with multiple species. The identifications of these proteins relied 
on peptides with less than four continuous fragment ion matches using the SwissProt 51.6 database. Proteins listed in order of Mowse score 
{highest score first}. 
Quantitative Western Blotting Confirms Identity of Several Proteins as 
Predicted by the Swiss Prot 51.6 Database 
To validate some of the putative identifications, quantitative western blotting was 
used to confirm the presence of selected matrix associated proteins and quantify the 
relative intensities of the protein bands in the IL-I ~ - t r e a t e d d and IL-I ~ ~ plus NSAID-
treated samples versus the untreated controls (figure 50). Western blotting 
confirmed the presence ofCILP-1 (60kDa), clusterin (39kDa) and its precursor form 
(70kDa) and MMP-3 (S4kDa) in the samples. Three proteins had a different 
observed molecular weight (MW) compared to their predicted weights: MMP-l 
(observed MW -102kDa, predicted MW = 54kDa), TSP-l (observed MW -125kDa, 
predicted MW = 165-198kDa) and TSP (observed MW -125kDa, predicted MW = 
170-180kDa). 
IL-l ~ - t r e a t e d d samples showed increased protein levels of MMP-l, MMP-3 and TSP-
1 in comparison to controls, which were decreased with the addition of the NSAID. 
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Figure 50. Western blot quantification of proteins in media from cartilage 
explants alone (control), and with equine interleukin-lbeta (IL-IP), and the 
nonsteroidal anti-inflammatory drug, carprofen (NSAID + IL-IP) combined 
Blotting for cartilage intermediate layer protein-i (ClLP-i), clusterin (CLUS), 
matrix metalloproteinase (MMP)-i , MMP-3 and thrombospondin (fSP)-l . Arrows 
labelled with the protein name indicate the predicted molecular weight (MW) in kilo 
Daltons (kDa), arrows with no protein name indicate the observed MW. 
207 
5.4. Discussion 
This study set out to refine a serum-free explant model of equine articular cartilage 
and test the feasibility of using it for studying the major proteins in the secretome, as 
well as changes in the secretome in response to a pro-inflammatory mediator and 
anti-inflammatory drug. The intention was to investigate the model's potential as a 
screening system for identifying potential biomarkers of structural change in early 
OA. High-throughput proteomics and cross species peptide matching were then used 
to identify the main proteins present in the secretome. This approach is rapid and 
invaluable for investigating protein expression in animal species that have few 
protein sequences in the databases (Liska and Shevchenko, 2003). 
Using comparative proteomic analysis, this study identified the presence of several 
expected proteins in the supernatants of equine cartilage explants stimulated with IL-
I p. A number of abundant secreted proteins involved in cartilage structure and thus 
constitutively expressed by cartilage were also identified, such as aggrecan, 
fibromodulin, decorin and biglycan. These proteins have been found in proteomic 
studies of cartilage from other species such as human (Wu et al., 2007) and mouse 
(Wilson et al., 2008), and thus aid the validation of this equine cartilage model. 
One of the most abundant proteins in the explant system was COMP, a non-
collagenous matrix protein that mediates chondrocyte attachment to the matrix (Oi 
Cesare et al., 1994) and organises matrix assembly (Rosenberg et al., 1998). COMP 
has been found in the synovial fluid, serum and urine from human and equine OA 
patients, and its correlation with disease severity and progression has led to it being 
suggested as a potential biomarker for OA (Lohmander et al., 1994; Peters son et al., 
1998; Clark et al., 1999; Arai et al., 2005; Misumi et al., 2006; Tseng et al., 2009). 
This suggests that COMP may be a useful marker of OA. The presence of COMP in 
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control and treated samples from this model concurs with that of other in vitro 
studies, which have found abundant COMP in the media of cartilage explants (Wu et 
al., 2007; Stevens et al., 2008; Wilson et al., 2008). Therefore, although further 
work is needed to determine levels of COMP in the model, these initial findings 
support the use of the model for testing clinically defined markers. 
IL-I ~ - t r e a t m e n t t always resulted in equine MMP-3 being detected in the secretome, 
in comparison to being detected in only one of the 18 untreated control samples. 
MMP-3 is a proteolytic enzyme that degrades ECM components such as fibronectin, 
collagens and cartilage proteoglycans. Its protein levels are increased in equine 
clinical OA cases and its gene expression up-regulated in IL-I ~ - s t i m u l a t e d d
chondrocytes in vitro (Brama et al., 2000c; Tung et al., 2002). Immunolocalisation 
studies have located MMP-3 in the synovium, cartilage and medium of cultured 
cartilage explants from OA patients (Okada et al., 1992). The proteomic data 
suggested that MMP-3 was significantly higher in IL-I ~ - t r e a t e d d samples compared 
to controls. However, this required confirmation using a quantitative method. 
Therefore, western blot analysis of the samples was used to confirm the presence of 
MMP-3 and demonstrate that levels of this protein were higher in IL-I ~ - t r e a t e d d
cartilage explants in comparison to controls. Moreover, the level of this proteolytic 
enzyme was lower in the NSAID-treated samples. The weak band(s) in the tissue 
homogenate controls showed that MMP-3 was present in cartilage, but in lower 
concentrations, than in the IL-I ~ - t r e a t e d d samples and thus may have been below the 
detection threshold used to analyse the samples. However, both the LC-MS/MS and 
western blot data confirm that equine articular cartilage explants also secrete MMP-3 
in response to equine I L - I ~ . . Interestingly, a recent study investigating the secretome 
of human articular explants and chondrocytes in culture using stable isotope labelling 
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with amino acids in cell culture (SILAC) found that MMP-3 was actively synthesised 
and released in both culture systems (Polacek et al., 2010). These authors used 
macroscopically healthy cartilage, suggesting that the results differ from those found 
in this thesis where MMP-3 was predominantly found in the media of IL-IP-
stimulated cartilage, rather than unstimulated controls. However, despite the fact the 
cartilage was macroscopically healthy, it was obtained from patients with moderate 
to advanced knee cartilage defects. Therefore, although the cartilage used by 
Polacek et al. (2010) looked healthy, the fact that it was obtained from diseased 
joints suggests that it was not, as it could have been exposed to various pathological 
stimuli such as IL-I p. In fact, a study has shown that macroscopically healthy 
cartilage taken from joints with OA lesions commonly have microscopic changes 
associated with OA, such as increased presence of IL-I P in the superficial and 
middle cartilage zones, and higher glycosaminoglycan loss compared to lesion-free 
joints (Weaver et aI., 2006). Consequently, the work of Polacek et al. (2010) appears 
to concur with the findings of this chapter, namely that proteomic techniques have 
confimed that MMP-3 is secreted in response to the degenerative stimulus, IL-I p. 
The results of this study therefore add further support to the work in chapter 2 that 
the explant model is a model of early OA. 
Positive cross species matching for TSP-I was identified with bovine, human and 
mouse. The equine sequence for TSP-I was not present in the SwissProt database at 
the time of this study. However, the fragments matched the protein motifs of TSP-I 
from multiple other species, thus increasing our confidence in the presence of this 
protein in the cartilage secretome. TSP-I is an adhesive glycoprotein that mediates 
cell-to-cell and cell-to-matrix interactions (Lawler and Hynes, 1986; Chen et al., 
2000). Human cartilage studies have shown that TSP-I is increased in early OA 
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cartilage lesions (Pfander et al., 2000) and the proteomic and western blot results 
from this study, suggest that this is reflected in the cartilage explant model of early 
equine OA. Although the cartilage positive control produced a band at about 
170kDa (within the range of the antibody manufacturers' predicted molecular 
weight) with two TSP-l specific antibodies from different companies, the observed 
bands in the secretome samples were roughly 40kDa lower with a molecular weight 
at approximately 125- I30kDa. TSP-l is reported in the literature as a 420-480kDa 
protein with 180kDa subunits, that are revealed on sodium dodecyl sulphate (SOS) 
polyacrylamide gel electrophoresis (PAGE) gels under reducing conditions (Oi 
Cesare et al., 1994). Calculation of the predicted protein mass for TSP-I_ HUMAN 
using the expasy tools program (http://www.expasy.org/tools/peptidemass.html) 
revealed that the full length sequence has a predicted protein mass of 1 29.4kDa and a 
predicted protein mass after signal peptide cleavage of 127 .5kDa. Post-translational 
cleavage by signal peptidases are responsible for the proteolytic processing of protein 
precursors as they leave the cell, thereby reducing the molecular weight of the 
protein (Dalbey et al., 1997). The observed molecular weight of TSP-l in the 
secretome samples corresponds well with the predicted protein mass after signal 
peptide cleavage from the amino acid sequence in the database. This suggests that 
TSP-l may have been post-translationally cleaved. However, the cartilage control 
still had a higher molecular weight than predicted. Work using epithelial cells has 
shown that despite an expected molecular weight of approximately 130kDa, TSP-l 
migrates with a molecular mass between 160 and 180kDa on traditional SOS-PAGE 
gels (O'Rourke et al., 1992), which corresponds to the weight seen in the cartilage 
tissue. Although the cartilage tissue was run on a Bis/Tris gel in an SOS-PAGE 
system, aberrant migration may be responsible for the discrepancy in predicted and 
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observed molecular weight. However, the SwissProt database entry for TSP-l infers 
that it is associated with the external side of the plasma membrane. Thus, it may 
require cleavage off the membrane to be present in the secretome. The unmodified 
C-terminal domain for TSP- I is 27.9kDa, which when subtracted from the observed 
secretome mass (l70kDa), results in a band of 142.1kDa, nearing the observed 
molecular weight of TSP-l in the secretome samples. Thus aberrant migration or 
cleavage of TSP- I from the membrane seem the most likely explanations for the 
differences. 
Western blotting for MMP-l produced an observed band of roughly 102kDa in both 
the cartilage control and all the secretome samples (present as a double band in IL-
l ~ - t r e a t e d d samples), which was nearly double the predicted molecular weight 
(S4kDa). The MMP-I sequence has the potential to form a double bond by virtue of 
possessing more than one cysteine residue in its amino acid sequence, and although 
the samples were run under reducing conditions, it may be that the observed band is 
a dimer that is resistant to the reducing agent. However, there are few published 
reports of a dimer form of MMP- I (Iyer et al., 2006). Post-translational 
modifications such as phosphorylation and glycosylation can lead to a mass 
increment relative to the calculated molecular weight of proteins, but these are not 
generally detectable on I-D gels (Jensen, 2004). However, there are no reports of 
these modifications in the published literature or in the uniprot database for 
MMPI_HORSE. Therefore, it may be that the MMP-l band is due to the dimer 
being present or non-specific binding. Further studies using human cartilage as a 
positive control are neded to ensure that the antibody is working correctly. After 
this, several sample preparations incubating with reducing agent for different lengths 
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of time and at different temperatures can be conducted to try and prevent 
dimerisation. 
The abundance of cartilage ECM-associated proteins in the top scoring entries 
highlights the specificity of this model for studying the secretome. However, despite 
using a targeted approach and an explant culture system, a small number of non-
matrix associated proteins were also identified in the media of several samples, for 
example, vimentin, dynein heavy chain, alpha enolase and sodium hydrogen 
exchanger 2 (see table 4). There are a number of possible explanations and 
interpretations for the presence of these proteins. The obvious explanation for the 
presence of these non-ECM proteins is cell death; the detection of these proteins may 
be attributable to dead or dying chondrocytes. However, it is known that there are 
frequently observed proteins in many proteomics experiments regardless of species 
or tissue being studied, such as alpha enolase and vimentin (Petrak et al., 2008; 
Wang et al., 2009). Thus, whilst these proteins may reflect a commonly observed 
cellular stress response between tissues, it must be considered that they may simply 
represent a limitation of the method. 
In addition to the cartilage ECM and chondrocyte-associated proteins, the database 
search also detected some seemingly unlikely candidates for biomarkers of arthritis. 
For example, breast cancer type 2 protein susceptibility homolog, which is the 
protein encoded the tumour suppressor gene, BRCA2. However, this protein is 
involved in DNA repair, namely double-strand break repair and homologous 
recombination (O'Donovan and Livingston, 2010). DNA damage is found in OA 
articular chondrocytes, and in non-OA chondrocytes where oxidative strand breaks 
are induced by NO produced from culturing with IL-l a (Davies et aI., 2008). Thus, 
oxidative damage is involved in OA and it may be that breast cancer type 2 protein 
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susceptibility homolog is involved in the chondrocyte repair response, and released 
into the media from dying cells. 
It is also highly likely that some of these less abundant proteins with lower Mowse 
scores could be proteins of interest in their own right or modifications of the 
abundant proteins, which are relevant to OA. Ideal biomarkers for OA are those that 
can indicate the very early stages of disease before too much destruction has 
occurred, therefore they are unlikely to be fragments or degraded forms of ECM 
proteins (Mobasheri and Henrotin, 2010). Thus, although the method used a Mowse 
score of 40 as the cut-off point, it could be that proteins just under the detection 
threshold have the most useful potential as biomarkers. For example, protein 
arginine deiminase type-4 (PADI4) which had a Mowse score of 39 in table 6, is 
known to catalyse citrullination of arginine residues of proteins. Citrullinated 
peptides can act as autoantigens, thereby increasing the risk of RA (Vossenaar et al., 
2004). As such, PADI4 gene expression has been detected in the synovial tissue 
from RA patients (Suzuki et al., 2003). In addition, autoantibodies against PADI4 
are associated with increased RA severity (Harris et al., 2008). Although RA is an 
autoimmune disease, unlike OA, the protein may have other functions and potential 
involvement in OA. The presence of PADI4 in the supernatant of the cartilage 
explants in this study may partly explain why this enzyme could be a target of 
autoantibodies to citrullinated proteins; in fact, this antigen may not be as specific for 
RA as previously suggested (Auger et al., 2010; Kolfenbach et al., 2010), the 
enzyme may also be released in OA. PADI4 is one of the many less abundant 
proteins identified in the model that may be potential biomarkers. More studies with 
larger sample numbers should provide more information in this area. However, 
greater potential lies in using methods that facilitate mining below the abundant 
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proteins in the secretome to allow robust and clear detection of the lower abundance 
components. The most obvious of these methods would be the depletion of the 
major/ high abundance proteins, which is commonly used when studying biological 
fluids such as plasma and cerebrospinal fluid (Tirumalai et al., 2003; Shores and 
Knapp, 2007). Another approach would be the use of metabolic labelling during 
culture to allow the newly synthesised proteins to be studied (Zwickl et al., 2005). 
Adopting these approaches will aid identification of these less abundant but 
potentially more interesting proteins. 
Proteomics has been used to study soluble extracts of cartilage (Wu et al., 2007; Guo 
et aI., 2008), chondrocyte whole cell lysates (Ruiz-Romero et al., 2008), synovial 
fluid (Gobezie et al., 2007) and synovial fibroblasts (80 et al., 2009), from both 
normal and OA patients. However, using cartilage and chondrocytes from OA 
patients raises a number of complications. Firstly, it can be difficult to obtain 
appropriate controls, using healthy joints from one group of patients as a control does 
not address individual variation. Similarly using control cartilage from a healthy 
corresponding joint of an OA patient, is invasive, and may not be an appropriate 
control due to altered use of the non-affected limb. Secondly, early OA clinical 
samples can be difficult to obtain, because the disease can be subclinical in the early 
stages and conventional radiography (the standard test for assessing joint space 
narrowing), has limited sensitivity (Chan et al., 1991). Consequently, many explant 
studies use cartilage taken whilst the patient is undergoing corrective surgery such as 
joint replacement (Uitterlinden et al., 2006; Attur et al., 2008). Thus, many clinical 
samples would be from the more advanced stages of OA. The cartilage explant 
model uses macroscopically and microscopically healthy cartilage from the same 
animal, allowing the same cartilage to be treated both as a control and with 
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inflammatory stimuli, such as cytokines, to induce degradation in the explants. 
Therefore, the model can reduce some of the confounding variables associated with 
clinical OA samples such as individual variation, differing disease aetiology and the 
stage of disease progression. In effect, using the cartilage explant system provides a 
more homogenous model with appropriate controls. In addition, explants can be 
cultured in serum-free medium, which removes the issue of contaminating serum 
proteins binding to the proteins and preventing the identification of the potentially 
more interesting lower abundance proteins. 
The absence of fibrillar and non-fibrillar collagens in the secretome supports the 
existing evidence that the model reflects early events in OA, before any major 
structural changes occur in the fibrillar matrix. Increased collagen type II 
denaturation and loss from the cartilage is seen in OA (Hollander et al., 1994). In 
juvenile bovine cartilage explants stimulated with IL-l a and OSM, collagen loss is 
not observed until after 22 days in culture, an effect less evident in older cartilage 
(Blain et al., 2010). Thus, suggesting that the proteins identified in the secretome 
preceed the degradation and release of collagens and their fragments, thereby 
supporting the use of the model as an early model of OA. 
The advantage of a proteomic approach over a genomic approach to studying 
potential disease indicators are that gene expression levels do not necessarily 
correlate with protein levels (Nie et al., 2007). Clusterin mRNA expression levels 
are increased in early OA cartilage compared to control (Connor et al., 2001), 
whereas IL-I a-stimulated cartilage explants show decreased levels of clusterin 
protein compared to control cartilage (Wilson et al., 2008). This could reflect the 
differences between clinical cases and in vitro models of OA, the stage of OA being 
studied and the various stimuli used to initiate cartilage degradation. However, 
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whilst further in vivo work needs to be performed, to determine levels of proteins in 
the synovial fluid and serum of clinical cases, in vitro studies looking at proteins 
rather than gene expression are invaluable prerequisites. 
This chapter has used the existing explant model of equine articular cartilage and 
adapted it for subsequent high-throughput proteomic work. One of the key 
advantages of this cartilage explant model is that it is serum-free. Therefore, the 
problem of contaminating proteins such as albumins and immunoglobulins, which 
make up a large percentage of serum, is eliminated from this approach. Another 
advantage of this culture system is that the resident cells are maintained in their 
native microenvironment overcoming the difficulties and challenges associated with 
chondrocyte de-differentiation in proteomic studies that use cultured and passaged 
cells in vitro. Using cross species peptide matching, a number of relevant proteins 
with well-established ECM functions in cartilage including: cell-matrix and matrix-
matrix interactions (fibronectin, TSP-I, CaMP, CHAD); matrix turnover (MMP-I, 
MMP-3) and extracellular molecular chaperone activity (clusterin) were identified. 
Other proteomic studies using cartilage from other species have identified similar 
panels of extracellular proteins (Wu et at., 2007; Stevens et at., 2008; Wilson et al., 
2008). The similarities between the list of proteins identified in this study and those 
published by other laboratories increase confidence in these data and justifies the 
application of high-throughput techniques in cartilage research. This chapter has 
highlighted the presence of increased MMP-3 and TSP-I in the supernatants of 
equine cartilage explants stimulated with equine IL-I p. These proteins may be 
involved in early responses to pro-inflammatory cytokines in cartilage and may be 
potentially useful biomarkers for the detection of early changes in OA. The explant 
culture system employed facilitated a rapid analysis of secreted proteins in a cartilage 
217 
model that may aid the discovery of OA biomarkers. It may be that a combination of 
several of these biomarkers can improve accuracy in the diagnosis and prognosis of 
OA (Williams, 2009). Future studies will exploit this serum-free model to 
investigate the effects of other pathophysiologically relevant stimuli such as 
mechanical injury (Quinn ef al., 1998) hypoxia and reoxygenation (Cemanec ef al., 
2002) and acidic pH (Schwartz ef al., 1976). 
In conclusion, the work described here has highlighted a novel adaptation of this 
model. Although further research is needed, the promising results of these 
preliminary studies suggest that this high-throughput technique may help identify 
proteins, alone or in combination, that may be modulated by plant extracts in the 
model as well as having the potential to aid novel biomarker discovery. The 
detection of suitable biomarkers that can be quantified, validated and qualified in 
vitro and in vivo, would enable faster screening and evaluations of potential non-
protein nutraceuticals for supporting joint health in both humans and companion 
animals. Thus, this chapter describes a new method that may aid nutritional targeting 
of inflammatory pathways and catabolic mediators involved in equine OA. 
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CHAPTER 6. PILOT FIELD TRIAL OF A PLANT 
EXTRACT COCKTAIL 
6.1. Introduction 
Whilst work for the previous chapter was being undertaken, the opportunity to run a 
field-based trial arose. This was a useful chance to gain experience in designing and 
managing field trials, as well as determining the in vivo effects of the materials tested 
in chapter 4. The trial was set up to replicate a scenario of feeding joint health 
products to horses with chronic stiffness issues, and to judge efficacy as an owner 
would, i.e. a visibly detectable clinical improvement in mobility. 
The work in chapter 4 determined that non-cytotoxic concentrations of PT 
significantly decreased IL-l ~ - s t i m u l a t e d d GAG and PGE2 release from cartilage 
explants in the in vitro model. In the joint supplement industry, in vitro data such as 
these, are often extrapolated and translated into in vivo efficacy with limited, if any, 
supporting in vivo data. It is well recognised that despite the abundance of 
nutraceuticals on the market for human consumption purporting to improve joint 
mobility, there is a paucity of good quality, unbiased in vivo trials to support their 
claims (McAlindon et al., 2000). Many equine in vivo studies are poorly designed, 
either in numbers, lack of appropriate controls, assessor blinding or treatment cross-
over (Pearson and Lindinger, 2009). Therefore, in vitro studies may aid the 
discovery of novel actives, alone or in combination, for joint supporting joint health, 
that can be foHowed up by clinical or field trials to determine their effects in vivo. In 
addition, in vitro studies may identify the potential modes of action that may operate 
in vivo to cause a beneficial effect. 
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Animal trials lack the verbal input from their subjects from which to evaluate 
efficacy. Human subjects can inform the assessors of a perceived improvement in 
pain, stiffness or general well-being, but their opinion may be influenced by other 
people or the placebo effect. Therefore, different methods of assessment are required 
for animal and human trials. Previous equine trials have used standardised lameness 
scoring systems for detecting an improvement in response to drugs (Sabate ef al., 
2009) and supplements (Hanson ef al., 1997). However, the horses selected for this 
trial were not lame; instead, they were bilaterally stiff. Stiffness is defined as I. not 
easily bent; rigid or halfway to rigidity, tetany, 2. not moving freely, 3. being unable 
to move easily without pain (Blood and Studdert, 1999; Soanes, 2000). For the 
purposes of this thesis, stiffness is defined as a restricted range of motion in the 
hindlimb joints. There is no standardised scoring system for stiffness, therefore, a 
scoring system was developed by the assessor to detect changes in the severity of 
stiffness over time. Stiffness was selected rather than lameness, because the aim of 
the trial was to replicate a scenario in the field where owners feed joint supplements 
to stiff horses to see if they have a beneficial effect, sometimes before seeking 
medical advice. In addition, the target horse population was that of stiff horses that 
did not require medication. It was not possible to find a large group of lame horses 
that were not on medication. 
This study used both a commercialIy available joint health product and a formulated 
cocktail of plant extracts previously tested in an in vitro model ofOA (chapter 4) in a 
field-based trial. The objective was to determine whether either supplement could 
improve mobility in a group of horses with chronic, low-grade hindlimb stiffness 
over a six-week period. The hypothesis was that the PT and CP would significantly 
reduce stiffness in the horses. 
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6.2. Material and Methods 
Supplements 
The supplements in the trial were the same materials as described in chapter 4. The 
plant extract cocktail (PT), the commercial joint health product Cortaflex (CP) and a 
placebo (PL) of alfalfa meal. Supplements were provided to the farms in identical 
white containers, labelled A, Band C, the contents of which were unknown to the 
assessor and staff. 
Subjects 
Thirty-three horses and ponies in permanent care of Redwings horse sanctuary in 
Norfolk were non-randomly selected for the trial as they needed to meet the 
following inclusion criteria: I. chronic stiffness, defined as bilateral low-grade 
stiffness and clinically presented as reduced or restricted flexion and movement in 
hindlimbs, for over three months; 2. healthy horse or pony of any gender, breed, age 
and weight; 3. not receiving medication for musculoskeletal conditions. Exclusion 
criteria were as follows: 1. serious co-existing condition; 2. has been on long-term, or 
is currently receiving, NSAID or corticosteroid therapy. 
The number of horses for statistical power (n=ll per group) was based on a previous 
study that had used a similar stiffness assessment and shown significance at p<0.05 
with n=9 per group in a two-way cross-over trial (Dyson et al., 2001). 
Ages ranged from 4-25 years (mean 16.1 years) and height ranged from 9hh to l7hh 
(median 13hh). The ratio of horses under 400kg to over 400kg was 21: 12. The ratio 
of mares to geldings was 16: 17 (table 7). 
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Location Horse 10 Age Height Sex Colour Breed Weight 
(yrs) (hh) 
Haj)ton 1 15 12 Gelding Bay Native X <400kg 
2 18 12 Gelding Bay Native X <400kg 
3 18 14 Gelding Bay New Forest X >400kg 
4 13 15 Mare Chestnut Thoroughbred X >400kg 
5 10 14 Mare Chestnut Arab >400kg 
6 20 15 Gelding Bay X breed >400kg 
7 16 13 Gelding Bay Welsh Section D <400kg 
8 20 14.2 Gelding Mixed Welsh X <400kg 
9 16 12 Mare Grey Welsh X < 4 0 0 ~ ~
10 16 14 Gelding Chestnut Welsh Section D >400kg 
11 20 14 Gelding Bay X breed >400kg 
Piggots 12 11 13 Mare Grey Connemara <400kg 
13 23 16 Gelding Bay Hunter >400kg 
14 20 15 Gelding Chestnut Thoroughbred >400ka 
15 4 11 Mare Palomino Native X <400kg 
16 16 10 Gelding Bay Shetland <400kg 
17 17 11 Mare Bay Native X <400kg 
18 16 11 Gelding Bay Native X <400kg 
19 12 10 Mare Bay Native X <400kg 
20 21 14 Mare Mixed Native X >400kg 
21 7 15 Mare Bay Thoroughbred X >400kg 
22 6 13 Gelding Skewbald Welsh Cob X <400kg 
Halnford 23 17 15 Gelding Chestnut Thoroughbred X >400kg 
24 25 13 Gelding Chestnut Welsh X <400kg 
25 20 12.3 Mare Bay Roan Welsh Mountain <400kg 
26 18 17 Mare Black Shire >400kg 
27 17 12 Mare Chestnut Native X <400kg 
28 9 12 Gelding Grey Welsh Section B <400kg 
29 16 9 Gelding Grey/Roan Shetland <400kg 
30 13 12 Mare Bay Native X <400kg 
31 25 11 Mare Bay Welsh Section A <400kg 
32 17 12 Mare Bay Welsh Mountain <400kg 
33 19 13 Mare Grey Native X <400kg 
Table 8. Demographic details of the horses selected for the field trial 
Horse weights are categorised into under or over 400kg to determine supplement 
dosage as directed by the CP manufacturer. With regard to breed, X refers to a 
cross-breed, i. e. native X = a native pony breed crossed with an undefined breed. 
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Field Trial Design 
The study was designed as a blinded, three-way crossover, placebo-controlled trial 
lasting from January to June 2009. Assessment date temperatures ranged from _4°C 
to 22°C. Horses were located on three farms that were within a IS-mile radius and 
run under the same management regimen, with all horses permanently at pasture. 
The three-way design allowed each horse on each farm to receive each of the three 
substances. However, close to the planned start of the study, the managers of the 
farms changed the design for a number of reasons which resulted in the horses being 
split into three groups (n=11) as determined by the farm on which they resided, with 
one substance per farm. Therefore, the trial became a two-way cross over, with the 
horses grouped by farm. The trial was then run as follows: all three groups 
underwent two non-supplemented weeks of pre-trial assessments to ascertain their 
basal level of stiffness before the trial began. After this period one group (PL) was 
fed the placebo for the l6-week trial duration, to assess change in stiffness as 
temperatures increased from winter into spring. The remaining two groups were 
either fed CP or PT for six weeks then, after a four-week washout period, crossed 
over onto the other supplement for the remaining six weeks of the trial (figure 51). 
This cross-over was done to ensure that the horses in two different groups received 
both treatments, and to examine whether they produced similar results despite 
differences in location and the order in which they received the treatments. 
223 
Pre trial 1 
Pre trial 2 
3 
1W ... 1r1 
WASHOUT 
Week 10 
!WItek 13 
IWIIMltIr 11 
Figure 51. Field trial study design 
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Three groups of 11 horses were grouped by farm name (Rapton, Piggots, Rainford). 
One group (Piggots) were fed a placebo supplement (P L) throughout the trial. The 
remaining two groups were either fed the plant extract cocktail (PT) followed by the 
commercial product (ep) after a 4-week washout (Hapton), or vice versa (Hainford). 
All supplements were fed an equal loading dose for 2 weeks, followed by a 4-week 
maintenance dose. 
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Supplements were fed in a concentrated bolus of molasses once a day. Dosage of all 
treatments was determined by the recommended CP dose, which was a fixed dose. 
MARS Horsecare UK Ltd arranged that the PT (at the same weight as the CP loading 
dose) contained concentrations of potential active ingredients based on levels 
recommended for average daily intake, safety and! or anti-inflammatory activity 
reported in other species (Tsai et al., 1999; Chainani-Wu, 2003; JECFA, 2004; Secor 
et al., 2005; Aktan et al., 2006; Altinier et al., 2007). The PL could be fed at any 
dose. Therefore based upon the CP dosage guidelines, all supplements were given as 
follows: horses weighing over 400kg were given a loading dose of 14g1day for two 
weeks, followed by a maintenance dose of 7g/day for four weeks. Horses under 
400kg were fed a loading dose of7g/day and a maintenance dose of3.5g1day. 
Each horse was assessed a total of seven times: at two time points before the trial 
began, midway (three weeks) through trial periods I and 2, at the end of the trial 
periods (six weeks) and at the end of the four-week washout period. Groups were 
assessed on three consecutive days to ensure that assessments occurred at a similar 
time of day. Each group began the study on the day their assessments occurred, so 
that they had equal time on the treatment. Farrier visits were timed to ensure that 
horses were not trimmed in the week prior to the assessments. 
Assessments were judged by a veterinarian blinded to the trial with previous 
experience of scoring hindlimb stiffuess. All assessments were carried out on hard, 
level surfaces on each farm. Horses were assessed in walk and trot in a straight line 
from the front, behind and on either side; and on a tight circle (figure 52). 
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Horse 6 
Height: 15hh 
Age: 20 years 
Sex: Gelding 
Date: 01 .06.09 
Score: 1 
Horse 9 
Height: 12hh 
Age: 16 years 
Sex: Mare 
Date: 01.06.09 
Score: 3 
Horse 3 
Height: 14hh 
Age: 18 years 
Sex: Gelding 
Date: 01.06.09 
Score: 5 
Figure 52. Still video images of three horses ranging from 1 (not stiff) to 5 (very 
stiff) in score during assessment at Hapton 
Horses were assessed in walk and trot from in front, from behind, on both sides and 
in a tight circle on both reins. 
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Scoring criteria for the assessments were developed with the veterinary assessor 
(table 8). 
Score Description 
0 Free moving at walk, trot, during sharp turns and on transition from walk to 
trot. 
I Slightly reduced hock flexion at walk, mainly or only apparent upon tight 
turns. Moves easily from walk into trot. Trots freely throughout. 
2 Mildly reduced hock flexion at walk. Mild stiffness on sharp turns at walk. 
Some reduced flexion seen on transition from walk to trot. Once in trot, 
moves freely and shows good flexion. 
3 Moderately reduced flexion at walk. Moderate stiffness on sharp turns at 
walk but demonstrates correct crossover of hindlimbs. Reduced flexion on 
transition from walk to trot. Once in trot, shows considerable improvement 
in degree of flexion. 
4 Very limited flexion at walk. Profound stiffness on sharp turns at walk, 
preferring to keep hocks straight with limited crossover of limbs. Slight 
reluctance to move from walk to trot at transition. Once in trot, slight 
improvement in degree of flexion. Apparent reduced stride length. 
S No hock flexion at walk. Obvious difficulty on tight turns at walk. No 
crossover of limbs, preferring to 'pivot' behind. Reluctant to move from 
walk to trot. Noticeably reduced stride length with short, choppy action. In 
forward flight, horse lands 'flat footed' or shows 'toe drag' due to lack of 
hock flexion. 
Table 9. Scoring criteria for assessing equine hindlimb stiffness 
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Statistical Analysis 
Intention-to-treat analysis was conducted on the data, meaning that data from all 
horses that recieved at least one dose of supplement were analysed, including those 
from horses that did not complete the trial. Only two horses were withdrawn from 
the trial for medical conditions (unrelated to the trial) requiring NSAID therapy. One 
horse (Horse 4) was withdrawn before treatment began, and thus was excluded from 
the whole trial. The other (Horse 8) was withdrawn from the trial after period 1 so 
only these data were included. 
The average of the two-week pre-trial scores and the end of the four-week washout 
scores were taken as baseline measurements for the succeeding treatment scores in 
periods 1 and 2 respectively. This was done in case the products were effective and 
the washout period was too short which may have caused a significant difference 
between the starting scores and the washout scores. This would have meant that 
horses were not starting the second phase of the trial on the same stiffness score with 
which they began the first phase thus meaning that the scores from the treatment 
periods could not be compared directly. By averaging the two pre-trial scores and 
using the post washout score, a baseline with which to compare the treatments in 
both periods could be used. 
Change from baseline at weeks three and six were then analysed using a General 
Linear Model analysis, with horse (nested in treatment), treatment (PL, CP or PT), 
week (3 or 6) and the interaction between treatment and week as factors investigated 
in the model. Analyses were performed by a WALTHAM associate, Alison Colyer, 
using Statistica v8 statistical software and inferences were made using the 5% 
significance level. The statistical analysis of the in vivo data as described relies on 
the commonly made assumption that there is a consistent meaningful difference 
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across the measurement scale (e.g. a difference going from 1-2 is the same as going 
from 4-5). For completeness, a non-parametric Wilcoxon matched pair test (that 
does not make the same assumption) was also applied to the data. Regardless of 
which way the data were analysed, the resulting conclusions were the same. 
6.3. Results 
The results from the trial are shown in table 9. 
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Location Horse 10 1
st pre- 2nd pre- Week Week Week Week Week 
trial trial 3 6 10 13 16 
Hapton 1 4 4 4 4 4 4 4 
2 5 4 3 3 4 5 4 
3 4 4 3 3 3 4 5 
4 3 4 X X X X X 
5 2 3 2 3 3 3 3 
6 2 2 1 3 2 3 1 
7 4 3 5 5 2 3 4 
8 4 3 3 3 X X X 
9 3 4 4 4 3 3 3 
10 4 4 4 4 4 3 4 
11 3 3 3 3 3 3 3 
Piggots 12 3 3 4 4 4 4 4 
13 2 2 2 2 2 2 2 
14 3 3 3 3 2 2 3 
15 2 2 3 2 3 3 2 
16 5 5 5 4 4 5 4 
17 4 3 3 4 5 4 3 
18 3 3 3 3 3 2 2 
19 3 3 4 3 4 4 3 
20 3 4 3 3 3 3 3 
21 2 2 2 3 3 3 3 
22 4 4 3 3 4 3 3 
Halnford 23 2 3 3 4 3 3 3 
24 2 3 3 3 3 X 3 
25 X 3 4 3 3 3 4 
26 X 2 3 3 3 2 3 
27 3 3 3 3 4 4 3 
28 3 4 4 3 3 4 3 
29 4 5 5 5 5 5 5 
30 3 4 4 4 4 3 4 
31 3 3 4 4 3 3 4 
32 4 5 4 3 4 4 3 
33 3 3 3 3 4 3 4 
Table 10. Field trial stiffness score results 
Values represent stiffness score (1 = not stiff, 5 = very SI(ff), x = missing value. 
Assessments were done twice before the trial began (lSI pre-trial and 2nd pre-trial), 
midway and at the end of the first period (week 3 and 6), ajier the washout period 
(week 10) and both midway and at the end of the second period (week 13 and 16). 
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All horses started with a stiffness score of between 2 and 5. The median starting 
stiffness score was 4 for the Hapton group and 3 for Piggots and Hainford groups. 
Final group statistics (combining Hapton and Hainford horses as they received both 
treatments) are listed in table 10. Horse 4 has been excluded from the data as she 
was removed from the entire trial. Horse 8 underwent the first period after which he 
was withdrawn from the trial, therefore his data is included in the table. 
Hapton + Halnford Piggots 
Group number 21 11 
Mean age 17 14 
Youngest 9 4 
Oldest 25 23 
Median initial stiffness 3 3 
Lowest initial score 2 2 
Highest initial score 5 5 
Weight <400kg : >400kg 14: 7 7:4 
Ponies: horses (S14.2hh : ~ 1 4 . 3 h h ) ) 18:3 8:3 
Median height (hh) 13 13 
Average height (hh) 13 13 
Smallest pony (hh) 9 10 
Highest horse (hh) 17 16 
Mares: geldings 10: 11 6:5 
Table 11. Vital statistics of horses in the treatment groups (Hapton and 
Hainford) and placebo group (Piggots) 
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Initial analyses found the interaction between treatment and week and the main effect 
of week to be non-significant (p=0.220 and 0.921 respectively), see table 11. 
Source Sum of Df Mean F-Ratio P-Value Sguares Sguare 
Name(Treatment) 38.88 49 0.794 2.275 0.001 
Treatment 6.00 2 3.001 8.605 <0.001 
Week 0.00 1 0.003 0.010 0.921 
Week*Treatment 1.08 2 0.540 1.549 0.220 
Residual 24.41 70 0.349 
Total {corrected} 70.37 124 
Table 12. ANOV A results of trial change from baseline data 
Therefore, the interaction and the effect of week were dropped from the model. 
There were significant differences between treatments, see table 12. 
Source Sum of Of Mean F-Ratio P-Value Sguares Sguare 
N ame(Treatment) 38.89 49 0.79 2.27 <0.001 
Treatment 5.94 2 2.97 8.50 <0.001 
Residual 25.50 73 0.35 
Total {corrected} 70.37 124 
Table 13. ANOVA results of trial change from baseline data, with interaction 
and week removed, showing overall effect of treatment 
There was variation in hindlimb stiffness score as observed in the placebo group but 
the average change in stiffness from baseline was not significant with a 95% 
confidence interval (-0.32, 0.04) (figure 53). There was no significant difference 
between PT and PL (p=0.763). However, the average change in stiffness from 
baseline in CP was significantly increased. i.e. horses became more stiff. when 
compared to both PL and PT (p<0.001 andp=O.OOI respectively). 
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Figure 53. Mean change from baseline stiffness score, with 95% confidence 
intervals, over 6 weeks in the commercial product (CP), plant extract cocktail 
(PT) and placebo (PL) groups 
Positive scores indicate increased stiffness, negative scores show improved mobility. 
Significance compared to PL and PT is indicated by *** (p<=O.OOJ). Bars show 
95% confidence intervals. 
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6.4. Discussion 
The aim of the field trial was to determine whether the feeding the PT would result in 
a detectable clinical improvement in mobility in a group of chronically stiff horses as 
this is how a typical horse owner would assess efficacy of a supplement. In addition, 
the method had to be non-invasive to comply with the wishes of the sanctuary. A 
visibly detectable improvement in stiffness may have been supported by invasive, 
physiological measures of GAG and inflammation in the blood or synovial fluid. For 
example, inflammatory mediators, such as cytokines and peripheral blood 
mononuclear cells (PBMC) increase the release of GAGs in vitro (Mastbergen et al., 
2002), and levels of GAG in the synovial fluid are elevated in horses with OA 
(Alwan et al., 1991) and horses with moderate to severe joint disease and lameness 
(standard grade 1-5) (Palmer et aI., 1995). However, the aim was to detect an 
improvement as would be assessed by an owner. Thus, if the supplement produced a 
visibly detectable improvement in stiffness but did not alter GAG and PGE2 levels, 
then the desired goal would still have been achieved. Consequently, a non-invasive 
determination of hindlimb stiffness in a group of horses with joint mobility issues 
was chosen as the outcome measure of in vivo efficacy, designed with a prior 
estimation ofn numbers for statistical power (Dyson et al., 2001). 
Neither the commercial product nor the formulated cocktail of plant extracts 
significantly improved stiffness in horses under these trial conditions. However, 
despite considerable individual variation between horses as indicated by the placebo 
group, a significant increase in stiffness occurred in the CP group compared to 
placebo and PT groups. Whether this statistical significance reflects a biological 
significance is questionable as it amounted to an average increase of 0.35 in stiffness 
score from baseline. However, when looking at the number of horses out of the total 
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number from both trial periods combined, 35% of horses on CP became worse 
between weeks one and three (i.e. at the end of the loading dose) compared to 10% 
on PT and 18% on PL. By week six, this had changed to 25% for CP, 19% for PT 
and 18% for PL compared to their starting score for the trial period. This trend was 
replicated in the CP groups in both periods. Interestingly 35% of horses improved 
between weeks one and three on the PT, compared to 10% on the CP, and yet after 
six weeks on PT, only 19% were less stiff than they were at the start of the trial 
period, with 15% less stiff on CP. This initial improvement after the first three 
weeks on the loading dose suggests that future trials should consider increasing the 
dosage of PT as the dosage used was based on the CP manufacturer's 
recommendation. Although, it should also be mentioned that 23% of horses 
improved on the placebo between weeks one and three, and after six weeks 36% 
were less stiff than they were at the start of the trial period, thereby highlighting the 
variability within the horse population studied. 
The horses were kept under the same management regimen, in terms of being 
permanently out on pasture, fed their supplement at the same time of day and only 
brought in for the farrier or their assessments. This removed the confounding factor 
of owner variation. 
Other joint supplement studies have assessed efficacy in ridden horses (Clayton et 
al., 2002). However, different intensities and frequencies of work between owners 
can be a confounding variable in lameness/ stiffhess studies. This study used horses 
that were not exercised and so was able to assess the effect on natural (i.e. not 
exercise induced) stiffness of horses at pasture. 
Stiffness was assessed, rather than assessing lameness which has been done in 
previous studies (Hanson et al., 1997). Lameness can be multifactorial in 
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pathogenesis, and is often asymmetric in clinical presentation. By assessing 
stiffness, one can consider the freedom of movement regardless of lameness. Some 
studies have used symmetry as a defining variable of improvement (Clayton et al., 
2002). However, horses with asymmetrical lameness may become more symmetrical 
due to becoming lame on the weight bearing limb, giving a false positive result. In 
addition, false negatives could be introduced by the presence of undetected 
conditions such as hoof abscesses causing lameness, which would not be alleviated 
by a joint supplement. Thus by setting the clearly defined criteria for hindlimb 
stiffness in this study, lameness was not a confounding factor. However, it is 
recognised that the use of a non-validated, non-standardised scoring system is a 
serious limitation to this study. 
This study used a single subjective method of assessment. Studies using either 
mUltiple observers for a sUbjective assessment (Goodrich et al., 2002), objective 
methods such as vertical ground reaction forces (Clayton et al., 2002) and gait 
characterisation software (Forsyth et al., 2006) are possible. In addition, 
physiological measures, such as quantifying potential biomarkers of inflammation in 
the synovium (Pearson et al., 2009) can be used alongside subjective assessments to 
strengthen the conclusions drawn from the data. However, these were not feasible 
options for this study due to ethical, time and location restraints. Consequently, a 
visual assessment of stiffness in two gaits was used. The aim was to represent the 
real life situation to determine whether the supplements caused a detectable change 
without bias. Bias can be introduced by owners who perceive a false benefit due to 
the 'placebo effect', thus an impartial veterinarian was used to assess the horses 
under blinded trial conditions. 
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The use of only one assessor and the stiffness grading criteria could be criticised in 
this study. However, numerical scoring systems are considered more reliable when 
evaluated by a single assessor rather than multiple ones (Fuller et al., 2006). The 
assessor in this study was an equine veterinarian, experienced in assessing lameness 
and stiffness, and who defined the scoring criteria based on her experience. Thus, 
although it was not an established scoring system and may not have been repeatable 
between assessors, the assessor in this trial did not have to overcome the difficulties 
of learning and applying a novel scoring system. Despite this, it is acknowledged 
that experience does not necessarily improve accuracy. A canine study comparing an 
objective lameness measure (force platform gait analysis) with subjective lameness 
scores by experienced veterinary surgeons and novice veterinary students found that 
although the experienced surgeons showed better repeatability in lameness scoring 
than the novice students between viewings, all observers had poor correlation with 
the gait analysis data (Waxman et al., 2008). Therefore, although subjective 
measures with which to compare the scoring system data were not available for the 
trial, future analysis of the assessment videos by multiple observers, multiple times, 
would give an indication of inter- and intra-observer reliability. 
Clinical trials lacking a blinded assessor introduce conscious and! or unconscious 
bias into both attaining and interpreting the results (Bridgman et al., 2003). This trial 
successfully ensured that none of the handlers, farm managers or the assessor knew 
which treatments the horses were receiving. In addition, the assessor was a 
veterinarian impartial to the outcome of the trial. The efforts taken to ensure 
thorough blinding reduces any potential bias in the results. 
Despite efforts to ensure the trial was well-designed, there were limitations, such as 
the placebo group being on one farm. This was requested by the sanctuary to prevent 
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confusion with multiple treatments being administered on each farm and to avoid 
needing to lengthen the trial, which would have interfered with the horses moving to 
summer pastures. The placebo group was only used to monitor changes in stiffness 
in that group of horses over the trial duration and it meant every horse on the trial 
was fed a supplement, thus increasing the blinding of both assessor and staff. The 
placebo group showed that there was variation in hindlimb stiffness score but the 
average change in stiffness from baseline was not significant, indicating that the 
increase in ambient temperature as the horses moved from winter into late spring did 
not have an effect. 
Ideally the study design would have included a positive control group receiving a 
NSAID to reduce stiffness. This group would have indicated whether the horses 
were capable of showing a significant improvement in stiffness and, more 
importantly, whether this was detectable by the assessment method. However, this 
was not a viable option for ethical reasons and the number of animals that would be 
required. In addition, it would have meant increasing the numbers of horses which 
was not possible, as well as increasing the length of the trial which would have 
interfered with them moving onto new pastures. 
As previously mentioned, the trial duration (six weeks on each supplement) was 
determined by the sanctuary's policy of moving the horses off the farms onto their 
summer pastures. Whilst a NSAID may have shown an improvement in this time-
frame, the duration may have been too short to see a detectable reduction in stiffness 
by feeding a cocktail of plants extracts. However, it was relevant to the 'in the field' 
situation where an owner would want to see a benefit relatively quickly. It may be 
that prospective studies of this nature need to be longer, in terms of years rather than 
months, although the potential cost of this may be prohibitive. 
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All horses were kept under the same management regimen in this field trial, but they 
were not located on the same farm, which introduced variation such as different 
assessment areas and days, as well as environmental differences. These differences 
were unavoidable but every effort was made to minimise their impact such as 
ensuring horses were kept on similar flat pastures and assessment areas were on level 
tarmac surfaces. To ensure all horses were assessed at a similar time of day, they 
were assessed on different days. So that all groups were on the trial for the same 
duration, they began their trial on the day on which they were to be assessed. The 
treatment study followed a cross-over design and the same results were found 
regardless of the farm, indicating that the effect of farm was minimal in this study. 
This study fed two joint supplements proven to reduce an indicator of cartilage 
degradation (GAG release) in vitro to horses with joint mobility issues to assess their 
ability in reducing stiffuess. Although in vitro GAG release and in vivo stiffness are 
not closely linked, the field trial sought to discover whether a gross reduction in 
stiffness could be seen in horses fed the PT supplement. Despite convincing anti-
degradative efficacy in the laboratory, neither supplement significantly improved 
stiffness in the horses under the management regimen in this study. However, it 
must be remembered that the in vitro model is a simplified model of early OA, using 
one cytokine to cause an acute effect. This field trial used horses with chronic 
stiffness, of unknown disease stage and aetiologies. Therefore, it is unsurprising that 
the in vitro and in vivo results do not concur. Nevertheless, it does highlight how 
careful manufacturers should be when directly transferring results from in vitro 
studies to the live animal without field trial support or clinical proof. There are many 
intermediate steps needed between the acquisition of meaningful laboratory data and 
the end point of proof of efficacy in vivo. 
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One such issue is bioavailability. Admittedly, many joint health products may have 
systemic benefits such as anti-inflammatory and pro-analgesic effects, which may 
manifest in an overall clinical improvement. However, if bioavailability is low then 
a larger intake is required to be capable of producing any effect. Bioavailability is 
often an issue when discussing nutraceuticals but it is difficult to determine when the 
active ingredient is unknown or when studying cocktails containing multiple actives. 
In addition, care must be taken when transferring data between species, for example, 
the bioavailability of glucosamine in the dog is 12% (Adebowale et al., 2002) 
whereas estimates in the horse are under 6% (Laverty et al., 2005). 
Although this study showed that in vitro models cannot replace in vivo studies, they 
are still useful to help screen nutraceuticals for in vivo testing. They also may aid 
investigation into possible mechanisms of action of nutraceuticals determined to be 
efficacious in vivo. Thus, in vitro models are an important tool in assessing 
nutraceuticals, when used in conjunction with in vivo data. 
In conclusion, although the commercial product and the formulated supplement 
showed significant beneficial effects in vitro in the previous chapter, neither was able 
to significantly improve hindlimb stiffness of horses as evaluated in this study. This 
study was not without its limitations, the outcome measure of a visibly detectable 
improvement in stiffness may have not been sensitive enough to detect a biological 
improvement in reduced inflammation/ degradation. However, it sought to discover 
whether an improvement in stiffness could be detected by a veterinarian blinded to 
the trial, thus trying to mimic a real life situation whilst removing the bias of owner 
SUbjectivity. The lack of improvement in this study highlights the dangers of 
assuming in vitro benefits will translate to the live animal. Thus, manufacturers of 
joint health supplements should carry out rigorous well-designed trials to prove that 
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their product can effectively produce the results that they claim. In addition, 
veterinarians and horse owners should be more aware of the need to critically 
appraise the evidence provided by nutraceutical companies. 
Although the benefits of PT and CP seen in the in vitro model were not reflected in 
the in vivo field trial, it does not necessarily mean that they are ineffective in vivo. It 
may be that the methods employed to detect an improvement in vivo were not 
sensitive enough, or that the results were affected by confounding factors such as 
pain, dosage and trial length. Moreover, the in vitro model mimics early stage OA 
whereas the horses in the field trial were already stiff, showing signs of more 
advanced disease progression. However, the field trial was important, not only to 
experience the difficulties and challenges associated with live animal studies, but 
also to replicate how a joint supplement would be evaluated by a horse owner. A 
beneficial effect in the laboratory, without a visible improvement in the live animal 
would not be of interest to many horse owners. 
Qualitative methods for assessing equine mobility, such as lameness or stiffness 
scoring, are subjective and variable. For example, the designation of mild to 
moderate lameness, even among experienced equine clinicians, is poor (Keegan et 
a/., 1998). In addition, these scoring systems may lack the sensitivity to detect subtle 
improvements. Identifying more objective, quantifiable markers of improvement, 
such as protein levels, could therefore be a valuable clinical tool. Using the in vitro 
explant model could potentially aid the identification of biomarkers in vivo to 
indicate improved joint health. Therefore, adapting the model to identify potential 
markers of structural change in the cartilage secretome highlights how models may 
be used to inform, improve and expand the quality of science in field trial work. 
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CHAPTER 7. GENERAL DISCUSSION 
The aim of the work in this thesis was to develop and test in vitro models of equine 
cartilage to investigate the potential application of nutritional targeting to support 
joint health in equine OA. The studies have shown that the in vitro models of equine 
cartilage can be used to detect cytotoxicity, anti-inflammatory and anti-degradative 
activities of potential joint supplement ingredients alone and in combination. More 
importantly, in using the models, this work found that curcumin at low micromolar 
concentrations (3-12IlM) significantly reduced IL-l p-stimulated GAG and PGE2 
with no adverse effects on cell viability in equine mono layers and explant cultures, 
whereas, these effects were concomitant with cell death at 25-1 OOIlM. This low-dose 
protective effect and high-dose toxic effect suggests that curcumin is hormetic in 
chondrocytes, as it is in other cells. Hormesis is a term used by toxicologists to refer 
to this type of biphasic dose response to an agent, whereas biologists define it is as an 
adaptive response of cells and organisms to a moderate stress (Mattson, 2008). 
Curcumin has been proposed as a hormetic agent, termed hormetin, as low doses of 
curcumin (below IIlM) stimulate proteasome activity in cultured human 
keratinocytes to protect them from ageing, whereas concentrations over 31lM are 
inhibitory (Ali and Rattan, 2006). 
The data presented suggest that curcumin may be of benefit to equine joint health, in 
terms of reducing IL-l p-stimulated GAG, PGE2 and MMP-3 release from cultured 
cartilage explants. This reduction in IL-l p-induced GAG and PGE2 release was also 
observed when curcumin was combined in a cocktail of other plant extracts with 
purported anti-inflammatory activity. However, this was affected by the solvent used 
to dissolve the cocktail. 
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The explant model was adapted for rapid and high-thoughput proteomic analysis of 
the media. This enabled the identification of the ECM components and less 
abundant proteins in the cartilage secretome upon IL-l ~ - s t i m u l a t i o n n in this 
simplified model of mimicking the events in early OA. Some of these markers may 
be used to assess the effects of plant extracts in the model. In addition, further 
refinements to the model may help identify biomarkers in vivo that can aid OA 
detection and prognosis, as well as evaluating therapeutic efficacy of anti-
inflammatory drugs and joint supplements. 
At the same time as the proteomics work was being conducted, an opportunity to 
manage a field trial arose. The plant cocktail, previously tested in vitro, was fed to a 
group of horses with chronic hindlimb stiffness under field trial conditions to 
determine whether it produced a detectable clinical improvement in mobility, as 
would be deemed beneficial by an owner. The plant extract cocktail did not 
significantly reduce stiffness in the horses after six weeks of supplementation. 
Although the results from the field trial suggested that the cocktail was not effective 
in terms of visibly improved mobility, it is likely that any improvement would have 
been masked by confounding factors such as pain, conformation, selected dosage and 
trial duration. It also emphasised the complexities of field trial based work and 
highlighted the need for markers to, firstly, select an appropriate population of horses 
at a similar disease stage for future trials and, secondly, detect improvements in vivo. 
These markers may be potentially found in the secretome of explants in vivo. Thus, 
highlighting the potential value of using the in vitro explant model to study the 
cartilage secretome in order to inform and improve future field trial-based work. 
Despite the positive findings of this thesis, there are several limitations to the work 
described. 
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7.1. Compound Purity 
This work highlighted some of the difficulties and limitations when working with 
extracts rather than pure chemicals. For example, the curcumin tested in chapter 2 
was a commercially available product from Sigma-Aldrich with a reported purity of 
approximately 70%. It could be argued that only pure curcumin should have been 
tested to ensure that the effects seen in the models were from curcumin alone. 
However, the curcumin used for the studies has been used by other researchers to 
determine its effects on other cell types (Ali and Rattan, 2006; Singh et al., 2009), 
and so there was a benefit in using it to enable comparisons with the published 
literature. It should be noted here that many commercially available curcumin 
preparations, including the preparation used in this thesis, are often a mixture of three 
curcuminoids; curcumin (also known as diferuloylmethane), demethoxycurcumin 
and bisdemethoxycurcumin (Yang et al., 2007; Kunnumakkara et al., 2008). Thus, 
the term 'curcuminoid' may be more appropriate to describe curcumin preparations 
of this nature (Quitschke, 2008). However, for comparative purposes with published 
studies that use the term 'curcumin', and in the absence of data determining the 
fractions of the curcuminoid constituents in the specific preparations used for this 
thesis, curcumin was used to describe the preparations. In addition, this 
corresponded with the name of the raw material purchased from Sigma-Aldrich. 
The commercially available curcumin was also used in these studies as it was more 
likely to be contained within a joint supplement than pure curcumin which is 
expensive. Nevertheless, it would be informative to do a study comparing at least 
three different sources of curcumin with differing levels of purity and curcuminoid 
content to determine their effects on cytotoxicity, GAG release and other assays used 
in the models. 
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7.2. Choice of Solvent 
In aqueous solutions, curcumin is insoluble at both a neutral and acidic pH, and 
although it dissolves under alkaline conditions, it rapidly degrades (Tonnesen and 
Karlsen, 1985). Therefore, organic solvents are often used to dissolve curcumin. 
Based upon the published literature, DMSO was used to dissolve the curcumin in the 
studies for this thesis (Shakibaei et al., 2005; Quitschke, 2008). However, previous 
studies have dissolved curcumin in different organic solvents such as ethanol and 
acetone for use in cell culture (Chan et al., 1998; Syng-Ai et al., 2004). Thus, a 
study comparing the effects of curcumin in different organic solvents would also be 
useful. 
Choice of solvent was also an issue when testing the plant extract cocktail and was 
identified as a key variable in affecting the in vitro outcome. The quantities of 
solubilised plant extracts in the final DMSO preparation of the cocktail are unknown. 
Indeed, some extracts such as the water-soluble bromelain may not have dissolved at 
all. Therefore, chromatographic profiling to identify and quantify the active or 
typical constituents in any cocktail tested is an important future direction for this 
work. 
7.3. Storage and Stability 
All the prepared stocks of curcumin and the test materials used in chapter 4 were 
aliquotted and frozen until required. A new aliquot of test material was then 
defrosted for each study so that no sample underwent multiple freeze/ thaw cycles. 
This was done to ensure batch-to-batch consistency and to reduce the risk of 
degradation/ loss of activity that can be associated with repeated freeze thawing. 
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However, it did mean that the length of time being frozen varied from 24 hours to 
several months, and it is not known what effects these may have had on the actives. 
Comparing the effects of curcumin frozen for different lengths of time would be a 
useful addition to the work in this thesis for comparative purposes between studies. 
In addition, it would aid the setting of criteria for future studies so that preparations 
can be discarded after a certain amount of time in the freezer. Although, there is no 
infonnation on the stability of the combined test materials used in chapter 4, previous 
studies have investigated the stability of curcumin and found that it rapidly degrades 
in organic solvents, especially at higher temperatures. For example, after 6 hours at 
37°C only 6% of curcumin remained from the original amount solubilised in 
methanol and PBS (pH 7.4) (Mohanty and Sahoo, 2010). A study comparing 
DMSO-dissolved curcumin in cell culture medium, found that after nine days at 
37°C, the percentage of curcumin had rapidly declined from 100% to less than 20% 
(Quitschke, 2008). Although the rate of decline varies depending on the choice of 
solvent and method of solubilisation, these studies both suggest that researchers 
investigating the effects of curcumin on cells in culture should replace the curcumin-
containing media daily. For consistency, the test material methodology in chapter 4 
was the same as the curcumin methodology in chapter 2, using a single treatment at 
the start of the same 5-day culture period. Future studies should investigate the 
effects of replacing treatments daily to mimic the daily consumption of a dietary 
supplement. 
Despite the solubility of curcumin in organic solutions, it has been reported that 
curcumin degrades rapidly in organic solvents under exposure to light, with traces of 
degradation products being detected after only 15 minutes of light exposure 
(Tonnesen et al., 1986). Although, degradation products were not measured in the 
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studies in this thesis, the curcumin was only exposed to light during dilution and 
addition to the wells, which would have taken about 10 minutes. However, it would 
be beneficial to look at whether curcumin had degraded during this time. 
The presence of serum in cell culture medium has been shown to enhance the 
solubility and stability of DMSO-dissolved curcumin (Wang et al., 1997; Quitschke, 
2008). Therefore, when examining the difference in toxicity threshold between the 
monolayer and explant studies, it may be that as the monolayer cells were cultured 
with FBS, this may have resulted in them being exposed to a higher concentration of 
curcumin for a longer period. The proportions of curcuminoids in solution also vary 
with the method of solubilisation in FBS-containing preparations (Quitschke, 2008). 
Thus, different curcuminoids may have been present in the FBS and non-FBS media 
preparations used for the monolayer and explant studies respectively. Future work 
should look at spectrophotometrically determining the curcumin concentrations in 
media and using reversed phase chromatography to profile the curcuminoids in 
solution when doing studies of this nature. 
There are a variety of methods for improving the solubility and stability of curcumin 
including the use of the aforementioned FBS. Other methods that have been reported 
include forming metallocomplexes of curcumin and zinc (Zebib et al., 2010). 
However, this would mean adding extra ingredients into the medium, which may be 
unsuitable for the model or the assays used. For example, the proteases, growth 
factors, cytokines and their inhibitors present in serum (Childs et al., 1982; 
McKenzie et al., 1990; Knoell et al., 1998). The relatively new concept of 
nanoparticulate curcumin may be a useful alternative method for improving the 
solubility and stability of curcumin. This process uses an emulsifier and a polymer 
to solubilise curcumin, which is then dried to a Iyophilised powder that can be 
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resuspended in aqueous media where it is protected from hydrolytic degradation 
(Mohanty and Sahoo, 2010). This would mean curcumin could be tested in an 
aqueous solution removing the need for an organic solvent. 
7.4. Metabolite Testing 
This thesis also highlighted that the choice of solvent for in vitro testing does not 
take into account the process of digestion in the in vivo situation. Therefore, it could 
be argued that testing the metabolites of curcumin is more relevant to the in vitro 
situation. Some studies have used simulated digests of test supplements to increase 
the relevance of the product to the in vivo situation (Pearson and Lindinger, 2008). 
Although this is still not directly transferrable to the live animal and does not account 
for individual variation, it does attempt to address the digestion issue. However, care 
must be taken to ensure that the method of digestion is appropriate for the species 
being studied. Using a simulated digest of the cocktail in the model would be a 
useful future step, not only for increasing its applicability to the in vivo situation, but 
for comparing the results with those obtained for the DMSO and DMEM-dissolved 
cocktails. 
7.5. The Explant Model 
Although the explant model allows the study of cartilage and OA-like changes by 
using various stimuli under relatively controlled conditions, it does have its 
limitations. As seen in this thesis, the addition of IL-I ~ ~ caused a relatively large 
amount of GAG release from cartilage explants (47.47 ± 1.51 %) compared to 
controls (12.55 ± 0.40%) which is roughly a 35% increase (appendix 10) over 5 days. 
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Thus, the model caused rapid GAG loss over a very short period of time, unlike in 
OA, especially post-traumatic OA which can take years to develop and has a long 
latency period until major structural changes are seen (Lotz, 2010). Thus, the 
suitability of the explant model for OA studies could be questioned. However, 
inflammatory mediator production and cartilage GAG depletion occur in equine 
arthritic joints (Palmer et al., 1995; Bertone et al., 2001) and, as shown by others and 
in this thesis, these are the two factors that may be modulated by nutritional 
intervention in vitro (Pearson et al., 2007; Mathy-Hartert et al., 2009). Thus, the 
model mimics aspects of inflammation and structural change that occur in early OA, 
and does so in a relatively short period of time, which is of considerable benefit in 
the therapeutic evaluation of plant extracts. Whilst these effects may not be directly 
extrapolated to the in vivo situation, the model may be used to identify suitable 
substances for further testing as potential joint health supplements. 
7.6. Additional Models 
The relevance of the chondrocyte model to cytotoxicity could be questioned. 
Although the chondrocyte is the target cell in the joint, other cells such as gut 
epithelial cells may experience greater concentrations, especially as oral curcumin 
has been shown to accumulate in the rat intestine (Ireson et al., 2001). More 
importantly, curcumin is thought to undergo extensive metabolism in the liver, 
therefore its effect on the hepatocytes may be more relevant (Wahlstrom and 
Blennow, 1978). However, this thesis sought to determine whether the 
concentrations of test products that reduced the degenerative effects of IL-l p were 
toxic to chondrocytes. Although curcumin concentrations (25JlM and over) were 
cytotoxic to monolayer chondrocytes after 5 days, concentrations as low as 3JlM 
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effectively reduced IL-I ~ - s t i m u l a t e d d GAG and PGE2 release without any detectable 
signs of toxicity in monolayer cultures or explants. Therefore, although the safety of 
the compounds to other cell types or the live animal cannot be determined from these 
studies, they show that the beneficial effects of low curcumin concentrations 
observed in the explant model were not due to chondrocyte death. 
With regard to culturing conditions, hypoxia and 3-D culture may be more 
appropriate environmental conditions for chondrocyte culture. The chondrocytes are 
dispersed through the ECM of the articular cartilage and are exposed to very low 02 
gradients estimated to be 5-7% at the surface to 1 % in the deepest layers (Silver, 
1975; Zhou et al., 2004). Chondrocytes cultured in mono layers in vitro de-
differentiate and lose their chondrocyte phenotype (8enya et al., 1978; Grundmann 
et al., 1980; Evans and Georgescu, 1983; Stokes et al., 2001). However, de-
differentiated chondrocytes will re-differentiate back to a chondrocyte phenotype 
when cultured in alginate beads in low 02 tensions (5%) (Murphy and Sambanis, 
2001; Domm et al., 2002). Culturing chondrocytes in low 02 also increases cartilage 
anabolism and reduces production of catabolic enzymes; MMP-I and MMP-13 
(Strobel et al., 2010). These effects are mediated by the hypoxic-inducible alpha 
subunit of the hypoxia-inducible factor 1 (HIF-I) transcription factor, known as HIF-
1 a (Strobel et al., 2010). HIF -1 a has also been shown to be a critical factor for 
chondrocyte survival (Schipani et al., 2001). Thus, future studies examining the 
effects of plant extracts on isolated chondrocytes should consider using 3-D cultures 
in low O2 tensions relevant to the joint to increase the physiological relevance when 
studying isolated cells. Low 02 tensions may also be useful for studying cartilage 
explants. Steady rates of proteoglycan synthesis have been reported in bovine 
explants cultured in 6% 02, which were comparable to those in fresh cartilage, and 
250 
differed from the increased synthesis in explants at 24% 02 (Y sart and Mason, 1994). 
All chondrocyte and explants cultures used for the studies in this thesis were 
incubated in 02 tensions around 17% in the primary cell culture incubator. Future 
studies should consider the application of more physiologically relevant 02 tensions 
to the models. 
Culture duration and passage number have also been shown to affect the chondrocyte 
phenotype. Articular chondrocytes grown in mono layers have been shown to de-
differentiate into fibroblast-like cells, significantly reducing collagen type II 
expression and synthesis after one to two passages (Benya et al., 1978; Schnabel et 
at., 2002). The studies in this thesis used first, second and third passage 
chondrocytes, therefore, in addition to the fact the mono layers were incubated in 
normoxic conditions, it must be considered that the chondrocytes may have de-
differentiated. Some markers of chondrocyte de-differentiation include loss of 
collagen type II synthesis, a change in the collagen type I: collagen type II ratio in 
favour of collagen type I (Marlovits et al., 2004), and loss of COMP and collagen 
type IX expression (Zaucke et al., 2001). Future work could include examining 
expression of these markers in order to determine whether the cells are still 
expressing the chondrocyte phenotype. 
Researchers in the OA and cartilage biology field are also using co-culture models. 
Considering OA involves all the joint structures, co-culturing with synoviocytes, the 
cells next to the external surface of the cartilage, or synovial explants could be more 
relevant to the in vivo milieu and could produce different results. Co-culturing 
cartilage explants with synoviocytes has been shown to reduce the degradative 
effects of IL-I ~ ~ compared to culturing cartilage alone, thus suggesting a protective 
role of the synovium (Gregg et al., 2006). Synoviocytes were isolated and cultured 
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during the course of this thesis, but were not characterised or validated with markers, 
and so these data have not been included. However, the co-culture model is a 
relevant model of the joint, and these models are of increasing interest as researchers 
attempt to address the multi-structural nature of OA. 
The studies in this thesis used a single addition of the test material concurrently with 
the addition of IL-I f3. Previous studies using curcumin have pre-treated cartilage 
explants with IL-I ~ ~ for a period of time before adding the test material, to replicate 
the situation of using the supplement once the cartilage is diseased (Schulze-Tanzil et 
al., 2004; Shakibaei et al., 2005). However, joint supplements are often used 
prophylactically. In addition, the purpose of the studies was to use nutritional 
supplementation to improve joint health. Therefore, it could be argued that it would 
be more relevant to pre-treat cartilage with the test substance before adding I L - l ~ . .
This would determine whether using the supplement would protect the cartilage from 
an inflammatory insult. 
A major limitation of the model was that the explants were not subjected to 
mechanical load, which is known to stimulate cartilage turnover. There are many 
published studies that have reported stimulatory effects of cyclic (dynamic) loading 
on the synthesis of aggregating and non-aggregating proteoglycans by chondrocytes 
in cartilage explants (Palmoski and Brandt, 1984; Visser et al., 1994) Thus, low-
level intermittent loading could help replicate the joint environment. Excessive 
(injurious) mechanical load on the other hand causes mechanical failure of the tissue, 
decreases cell viability and stimulates cartilage degradation (Quinn et aI., t 998; 
Loening et al., 2000; Kurz et aI., 200 t). Degradation is also observed when injurious 
mechanical load is used in combination with exogenous cytokines (Patwari et al., 
2003). Therefore, mechanical loading could be another useful addition to the model 
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to either help replicate the biomechanical forces in the joint environment, or as 
another pathophysiological stimulator of cartilage degradation. 
7.7. Additional Assays 
With regard to the assays, using GAG release alone as an indicator of net GAG 
release can be misleading. Ideally, additional measurements of GAG synthesis are 
needed to determine whether any test material can reverse the inhibitory effects of 
cytokines on proteoglycan synthesis. Previously it has been shown that the 
inhibitory effect of I L - l ~ ~ on GAG (namely keratan sulphate) synthesis is mediated, 
in part, by the stimulation of PGE2 production (Fukuda et al., 1995). Consequently, 
when testing curcumin and PT, PGE2 was measured in conjunction with GAG 
release. A reduction in PGE2 in conjunction with GAG release, in the absence of 
toxicity, was therefore determined as being beneficial. However, it is recognised that 
future work should address GAG synthesis as well for completeness. 
In addition, investigating aggrecanase and metalloprotease activity using enzyme 
assays or zymograms, rather than confirming the presence of the protein by 
immunoblotting would provide useful functional information about the model. 
Furthermore, this work could be supported by identifying the products of 
aggrecanase and metalloproteinase activity by western blotting with monoclonal 
antibodies to identify catabolic neoepitopes on proteolytic degradation products, e.g. 
BC-4 and BC-I4 recognise sites of MMP cleavage on aggrecan; BC-3 and BC-I3 
recognise sites of aggrecanase cleavage on aggrecan (Hughes et al., 1995; Little et 
al., 1999). This would provide a greater insight into the mechanisms of GAG release 
in the model and the actions of plant extracts upon them. 
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Further studies into the mechanistic effects of curcumin and the PT on IL-I p-
stimulated cartilage would be useful. It has been shown that curcumin reduces IL-
I ~ - s t i m u l a t e d d MMP-3 release from cartilage because of NF -KB inhibition (Schulze-
Tanzil et al., 2004). However, it would be interesting to determine the effect of 
curcumin on receptors to determine whether curcumin is down-regulating the 
response to IL-I p and/or reducing ability of IL-I ~ ~ to have an effect. F or example, 
does curcumin down-regulate the surface receptors for I L - I ~ , , or increase production 
of its decoy receptor, IL-I RII? 
Similarly, further studies are needed to determine the impact of significantly 
reducing IL-Ip-stimulated PGE2 release. For example, although COX-2 inhibiting 
NSAIDs reduce the pain and inflammation associated with PGE2 production, they 
shift the PGE2:TxA2 ratio in favour of TxA2 (Penglis et al., 2000). TxA2 has been 
shown to increase IL-IP and TNF-a synthesis by monocytes (Caughey et al., 1997). 
Therefore, COX-2 inhibition is not always beneficial, especially in the long term. 
Curcumin has been shown to reduce COX-2 expression in TNF-a and IL-I p-
stimulated chondrocytes via inhibiting NF-KB (Shakibaei et al., 2007). Thus, it 
would be beneficial to determine the effects of curcumin on the synthesis of other 
prostaglandins and TxA2. In addition, COX-2 inhibition could reduce PGH2 
synthesis, from which a variety of prostaglandins are synthesised. Therefore, 
inhibiting PGE2 release further down the eicosanoid pathway downstream of PGH2 
may be more beneficial, especially via inhibiting cytokine-inducible synthases such 
as mPGES-I (Kojima et al., 2004). Further work could examine the effect of 
curcumin and the PT on the expression and production of mPGES-I by IL-1P-
stimulated chondrocytes and cartilage explants. 
254 
With regard to the western blots, no protease inhibitors were added to the samples 
after collection. Although samples were stored at -SOcC, further degradation of ECM 
components may have occurred post-collection, especially considering the increased 
levels of MMP-3 in the IL-l ~ - t r e a t e d d samples. Therefore, future work should 
consider the use of EDT A and protease inhibitors in the samples before they are 
stored for analysis. 
7.8. Biomarker Validation and Quantification 
The use of the in vitro explant model for rapid proteomic analysis of the cartilage 
secretome as documented in chapter 5 may aid biomarker identification. An 
additional technique, stable isotope labelling, has recently been used to determine de 
novo proteins in the secretome of chondrocyte monolayer and cartilage explant 
samples (Polacek et al., 2010). This approach could be expanded to determine 
whether proteins released from IL-l p-treated explants are synthesised and released in 
response to treatment, or are simply leaching out of the cartilage matrix. A 
comparative analysis of the secretome from cartilage treated with different stimuli, 
alone and in combination, would also be useful to determine how each stimulus 
affects the model. Despite the exciting potential of this system, it must be 
remembered that potential biomarkers require extensive validation and qualification. 
Levels in both normal and disease states in a large population need to be evaluated 
and standards must be set to address individual variation as well as other variables. 
For example, the widely discussed potential biomarker COMP has considerable 
diurnal variation and an estimated half life of 7.4 hours (Andersson et al., 2006; 
Kong et al., 2006). Serum COMP levels in humans are raised in response to exercise 
such as 30 minute walking (Mundermann et al., 2005). Therefore, sampling times 
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could significantly affect the results. In addition, COMP is non-cartilage specific, 
e.g. it is elevated in tendons under high load, compared to lower loads (Smith et al., 
1997). This suggest that levels of COMP in the serum and urine may not be specific 
markers of OA, and may be unreliable. However, the state of the molecule, such as 
its molecular weight and its post-translational modifications, or its cleavage and 
fragmentation by proteases may be more important biomarkers of disease rather than 
the intact molecule. Accordingly, COMP fragments have been shown to increase in 
the synovial fluid after joint injury and in early OA (Lohmander et al., 1994). 
Fragments of other matrix associated proteins have been also proposed as biomarkers 
of OA in the synovial fluid, such as collagen type II C-propeptide fragments 
(Lohmander et al., 1996) and proteoglycan fragments (Lohmander et al., 1989). 
Studies of the cartilage secretome will aid the identification of other matrix 
component modifications and fragments released in response to various degradative 
stimuli. 
In addition, although this model may identify potential markers of cartilage 
degradation, future work determining their relevance in vivo may be difficult due to 
the method of sample collection interfering with the results. For example, repeated 
arthrocentesis was shown to significantly increase NO, GAG and PGE2 levels in the 
synovial fluid of exercised and non-exercised horses (van den Boom et al., 2005). 
Despite these considerations, the model provides a simplified overview of the 
complex environment of the joint, as well as the multifaceted nature of OA. Thus, it 
may be a useful tool to reduce the background noise inherent when dealing with 
clinical samples, thereby allowing the identification of potential indicators of ECM 
structural changes. 
256 
7.9. Field Trial Limitations and Improvements 
With regard to the field trial, there were significant but unavoidable limitations with 
the design and methodology of the trial, which were addressed in chapter 5. 
However, the trial was invaluable for gaining experience in this area and cultivating 
new ideas for improving any future trials. 
7.9.1. Animal Selection 
All horses were selected for the trial on the basis that they were chronically stiff but 
did not require medication. Horses were selected by the farm managers and so were 
not randomised, which was a major flaw of the trial. In addition, the population 
selected consisted mainly of ponies (26 ponies:7 horses). Ponies are lighter than 
horses and so would experience lower loading forces on their joints. Although OA 
affects both horses and ponies, and occurs naturally in the joints of wild ponies, it has 
been suggested that the process is hastened by the stresses of heavy work such as 
racing (Cantley et al., 1999). Some of the horses in the trial were ex-police horses 
and ex-racehorses, which would have been more predisposed to joint problems than 
ponies due to their intensive workload history. However, detailed evaluations of the 
joints were not conducted, such as X-rays and magnetic resonance imaging, to 
identify the extent of cartilage damage and possible causes of stiffness, such as bone 
formation limiting movement. Thus, both horses and ponies were classified as being 
clinically stiff of unknown aetiology. This meant that some animals may have been 
more able to respond to the mode of action of the actives than others, which 
increases the variability of the results. Although well-controlled clinical trials can 
reduce the variability associated with field trials, they are expensive and less 
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applicable to the in-the-field situation. Thus, the aim of the trial was to represent 
how supplements are fed to horses in the field where variability in population and 
cause of stiffness are commonly encountered. 
7.9.2. Animal Grouping 
The method of grouping animals by weight (being either under or over 400kg) was 
selected upon the recommendation of the CP manufacturer. However, weights were 
taken from the records at Redwings, so they were not necessarily accurate at the time 
the study began. Future work would ideally weigh, or use a weigh tape, to determine 
the weight of each animal at the start of the trial. Considering the study ran from 
winter to spring, the weights of the animals would have changed, thus some that may 
have been under 400kg at the start may have been over 400kg at the end, yet dosing 
did not change from the start of the trial. Some horses that gained weight were 
placed on restricted diets over the trial. However, the grouping of animals by weight 
is still a problem, as theoretically a 399kg pony would receive half the dose of a 
40lkg pony. Thus, in the future, it would be best to only study animals that qualify 
for the one dose, i.e. only ponies less than 400kg or only horses more than 400kg, or 
to use larger numbers of both groups, each on their set dose, but analyse them 
separately. Ideally, dosages would be individually calculated as weightlkg of 
bodyweight. 
7.9.3. Future Study Design 
Any future trials need to ensure that the treatment groups are spread between farms, 
to remove the farm effect variable. Ideally, all horses would then receive all three 
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treatments and all treatment orders (6 groups) on all fa rms. This would require 18 
horses per farm (3 horses per treatment order) , totall ing 54 horses. The proposed 
tri al design for one farm is shown in tabl e 13. A fourth group receiving a NSAID 
would idea ll y be included as a pos itive control, but thi s would be unlikely if the 
study was carri ed out at the same establishment, and would require more horses and 
a longer tri al durati on. The practi ca liti es of finding even 54 horses may be a 
limitation. Us ing horses in pri vate homes is an option, but the confounding factor of 
environment would be large and therefore the study may require larger numbers of 
horses. In addition, there would be less contro l in the running of the tudy. 
WEEKS d 21 3 41 : 1 61 7 81 91 10 1 I I 121 131 141 15 161 17 1 lsi 19 201 21( 22 1 23 241 25 1 261 27 
PRE-TRIAL PHASE WASHOUT PHA SE WA SHOUT PHA SE WA SHOUT PHASE 1 2 J 
AS SE SSMENT I( I 2 I 31 I ' I sl I 6 I 71 I 8 I 91 I 10 I I d I 12 I 131 I I ' 
PL PT CP 
PL CP PT 
TREATMEN T PT 
ORDER PL 
CP 
(all 'arm s) PT CP PL 
CP PT PL 
CP PL PT 
Table 14. Field trial re-design for a single farm 
Grey columns indicate periods without supplementation, and the phases indicate 
periods with supplementation of either placebo (PL), plant extract cocktail (p rj and 
commercial product (ep) . The six rows represent each combination of treatments, 
which would be given to 3 horses per farm. 
The required loading dose for 2 weeks foll owed by maintenance dose mean that 
future tri als should assess at 2 and 4 weeks rather than 3 and 6 weeks as before. 
However, the loading dose for the plant cocktail and placebo in thi s thes is \-vas 
dictated by the manufacturer of the commercial product. Therefore, more \·vork on 
bioava ilability would probably be needed to determine the appropri ate dose. Desp ite 
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this, if circumstances would allow, then a longer trial duration would be preferential 
as a 6-week trial may be too short to produce a visible improvement. In addition a 
longer washout period may be desirable to reduce the risk of carried-over effects. 
However, extending the trial length would have to be reconciled with parameters that 
are most important to control for, such as the seasonal movement of horse between 
pastures. 
7.9.4. Assessment Method 
The method of assessment is another area that requires improvement in any future 
trials. There are various non-invasive methods available to assess gait, but they all 
have their limitations. For example, stationary force-plate analysis accurately 
quantifies ground reaction forces, but is limited to only one stride thereby not 
accounting for stride to stride variation (Merkens et al., 1988). Force-measuring 
treadmills allow the continuous measurement of ground reaction forces, but are 
expensive and require the horses to be trained to the treadmill beforehand 
(Weishaupt et al., 2002). Force-measuring shoes have been used to collect data on 
ground reaction load from horses at all gaits on the treadmill (Roland et al., 2005). 
Treadmills can also be used with video recorders to perform three dimensional gait 
analysis, which objectively quantifies lameness and stride length (Peloso et al., 
1993). However, treadmill work has been shown to affect gait (lengthened stance 
phase) compared to over ground locomotion (Buchner et al., 1994). Thus, sensor-
based motion analysis provides an alternative option as it is not restricted to a 
treadmill. This method uses sensors located on various parts of the horse to locate 
lameness and provide continuous data as the horse moves (Keegan et al., 2002). 
Although this assesses lameness not stiffness, it can quantify symmetry or 
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asymmetry. However, all these systems are expensive and require docile animals, 
which make them unlikely options for future trials at the sanctuary. Therefore, future 
trials will need to address the stiffness assessment, as it is not an established or 
validated method. 
7.9.5. Stiffness Assessment Validation 
As previously discussed in chapter 5, lameness assessments were not appropriate for 
these trials and the restrictions placed upon the trial by those involved, necessitated 
the development and use of the stiffness scale. In order to validate the scoring 
system, repeatability studies are needed to assess consistency in allocating stiffness 
grade and ability to distinguish between grades, by both the assessor used in the trial 
and other clinicians. Video recordings of each assessment are available for this to be 
done in the future. The advantage of video recordings is that they can be mixed up in 
random order, so all assessments of a single horse can be seen (in random order) one 
after the other, which would assess consistency better than seeing the horse weeks 
apart. All the horses and assessments could also be mixed at random to assess 
repeatability. The main disadvantage is that the video was not in set place each time 
and varied between farms, so the variation in angles at which the horses are viewed 
may affect the results. For both the video footage and future trials, a global scoring 
system would be a more appropriate measure of efficacy, and has been shown to be 
more reliable for a clinical assessment of change in lameness both intra- and inter-
assessor (Fuller et al., 2006). The global scoring system would simply state whether 
the animal improved, declined or stayed the same, rather than categorising degree of 
stiffness. This may be a more accurate method of assessment as, naturally, there is 
considerable individual variation in range of motion. Thus, it may be that some of 
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the horses on the trial were not capable of reaching a score of one due to their 
conformation or the presence of disease limiting movement, e.g. being straight in the 
hock or bone formation especially in the hock. Kinetic data would have detected 
whether each horse had more or less range of motion than before, but this method 
was not possible due to time, location and financial restraints. In addition, the 
disease status of each animal was not known in the trial so differing disease stage 
would have been a confounding factor in the trial. If proven biomarkers for the 
disease stage are discovered in the future, they could be used to ensure that animals 
of the same disease stage are selected for field trials to reduce variability. 
7.9.6. Improving the Stiffness Scoring System 
It may be valuable to regulate the assessment area by drawing a line along which the 
horses have to walk (same length on each farm) so they are assessed at the same set 
distance, with a video camera set up at the exact same distance in front and from the 
side at each assessment. This would enable additional post-assessment analysis 
using the video recordings. In addition, a measure of stride length could be 
incorporated into the assessment, such as marking the floor or walking the subjects 
through a dye or chalk dust. However, factors such as reluctant horses, rain and time 
may make this difficult. Therefore, it can be seen why a quantitative measure of a 
physiological parameter, such as a biomarker, would be of benefit in field trials of 
this nature, where circumstances permit. 
7.10. Summary 
The work in this thesis is summarised in figure 54. 
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Establish the Cartilage Explant Model 
RESULT: EQUINE IL·1 ~ ~ SElECTED AS THE STIMULUS FOR CARTILAGE DEGRADATION 
Assay Development for the Cartilage Explant 
Model Using Curcumln and a NSAID 
RESULT f : CURCUMIN & NSAJD REDUCED GAG. MMP-3 & PGE, RElEASE 
RESULT 2: SUSPECTED CYTOTOXICITY OF CURCUMIN AT 1DOIJM 
CONCLUSION: GAG & PGE, ASSAI'S SELECTED TO MEASURE ANTI·INFLAMMATOfIY t & ANTI·CATABOUC ACTMTY 
Cytotoxicity Testing 
• • Cartilage Explants Monolayer Chondrocytes 
• • RESULT 1: CURCUMIN (1DOIJM) IS TOXIC TO EXPLANTS & MDNDLAYERS 
RESIILT Z: CURCUMIN IS TOXIC AT WWfR CONCENTRATIONS 
IN MONOlAYERS 
CONCWSION: USE MONOlAYER CHONDROCYTES FOR TOXICITY TEST 
t 
UHllse the Cartilage Explant Model to 
Test a Plant Extract Cocktail 
RESULT: REDUCED GAG & PGE, RElEASE AT NON·CYTOTOXIC CONCENTRATIONS 
INDICATING ANTI·INFLAMMATOfIY & ANTI·CATABOUC EFFECTS IN vrmo 
BUT NOT CONCWSNf 
CONCWSION: IDENnFYING PROTEINS IN THE CARnLAGE 
SECRETOME IN THE MODEL MAY INDICATE CANDlCI'ITE MARKERS FOR ASSESSING 
THE EFFECTS OF PLANT EXTRACTS 
t , 
Adapt the Explant Model for Proteomlc 
IdenHflcatlon of Proteins In the 
Cartilage Secretome 
RESULT: PROTEINS RELEVANT TO THE CARTILAGE MATRIX RELEASED 
INTO MEDIA AND SELECTED PROTEINS VAUDATED 
WfTH WESTERN BlDmNG 
CONCWSION: THE MODEL HAS CONSIDERABlE POTENTIAl FOR 
EVALUATING THE EFFECTS OF PLANT EXfRACTS IN VITRO AS 
WEll AS IDENnFYING CANDIDATES FOR BIOMARKER RESEA/ICH IN 11M:) 
FUTURE WORK 
• Use dlff9lent sflmull alone and In combination 
• VallClate more Plotelns 
* Isotope labelUrlQ to measure synthesis & rekKJse 
FUTURE WORK 
• DIfferent stimuli alOne ana In combination 
(mechanical. other cytokines) 
• DIfferent culture condlflans 
(pH. glucose concentrofton. hypoxia) 
• Co-culture model 
• Very culture duration 
FUTURE WORK 
• DIfferent curcumln PleparatiOns/ solvents 
• Use nanapartlculate curcumln with a 1Ong91 h a ~ ~ Ine 
• Quantify curcumJnold content at tlnal soluflons 
• Dally addition of curcumln to cultures 
• Determine GAG synthesis 
• Pre-lTeaftng c a ~ l l a g e e wt1h me sflmulus Of me active 
• Effects of curcumln on the Il· 1 P receptOf 
FUTURE WORK 
* Determine mode of cell death 
• Culture Isolated chondrOCyles In alginate and lOw 
oxygen tension 
• Use a variety of cells (gut epithelial cells. hepatocytes) 
FUTURE WORK 
* Dlff9lent solvents 
* Simulated dlgesflon 
• Test metabolnes 
• ChromatographIC profiling of soIuflons 
(proport1on of octlves In solution ana quanttty) 
Test the Plant Extract Cocktail under Field 
Trial Conditions 
HSULT: NO REDUCTION IN STIFFNESS AFTER 6 WEEKS OF 
SUPPlEMENTATION 
CONCWSION: NEED TO FIND MORE ACCURATE MARKERS FOIl OA 
DIAGNOSIS & EVALUATING RESPONSE TO THERAPY IN ORDER TO SELECT 
HORSES FOR INClUSION IN TRIALS AS WELL AS OBJECTTVELY ASSESSING 
EFFICACY ALONGSIDE VISUAL MEASURES OF IMPflCNEMENT 
FUTURE WORK 
• Ensure all horses receive all Ireotments on each farm 
• Use hOfseS Of ponleS/ or dose by g/kg bodywelght 
• Validate sftffness scoring system 
• Use a more objective. quantItatIve measure of stiffness 
• Use a NSAlD positive contrOl 
Figure 54. Diagrammatic summary of the thesis and potential areas for future 
work 
Red arrows indicate the flow of the studies in the thesis, green arrows highlight 
areas for future work. Abbreviations are as fo llows: glycosaminoglycan (GAG), 
interleukin-1 beta (lL-1 fl), matrix metalloproteinase-3 (MMP-3), nonsteroidal anti-
inflammatory drug (NSA1D), prostaglandin E2 (PGE2). 
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In agreement with the proposed aim, the work in this thesis has shown that it is 
possible to establish in vitro models of cartilage degradation and inflammation, 
consistent with early stage OA, i.e. before collagen degradation occurs in this model. 
In vitro testing of nutritional intervention with plant extracts reduced GAG, MMP-3 
and PG E2 release from IL-l ~ - s t i m u l a t e d d cartilage explants consistent with them 
having the potential to support joint health. In addition, this model can be used to aid 
in the screening of novel compounds or help identify potential modes of action by 
which the ingredients work on chondrocytes in vivo. 
The equine cartilage explant model was then adapted to identify potential biomarkers 
in the secretome of IL-l ~ - s t i m u l a t e d d cartilage with or without an anti-inflammatory 
drug, in comparison to unstimulated controls. This adaptation may aid the 
understanding of the processes involved in OA as well as the identification of OA 
markers for diagnosis, disease progression, prognosis and response to joint 
supplement therapy. The future hope for this work is that it will discover more 
sensitive markers of improvement that can then be detected in vivo. It is unclear 
whether these markers will translate from in vitro to in vivo, but it is an important 
approach for advancing knowledge in this area and improving the scientific quality 
of future field-based trials. 
The modulation of GAG and PGE2 by plant extracts in the model, suggest that the 
model may be useful for nutrigenomic studies. Nutrigenomics studies the influence 
of nutrition on the genome (MOller and Kersten, 2003). The nutrigenomic approach 
can examine the differential transcriptions (e.g. in signalling pathways) between cells 
treated with or without nutritional compounds via studying the transcriptome, 
proteome or metabolome (van Ommen, 2004). Therefore, the anti-inflammatory 
effects observed in the model in response to plant extracts indicate that it will be a 
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useful tool for future nutrigenomic studies investigating the effects of plant-derived 
products on both short-term changes, such as gene expression, and long-term 
changes, such as protein synthesis, in the cartilage. 
The novel findings ofthis project are summarised as follows: 
1. Curcumin reduced IL-I ~ - s t i m u l a t e d d GAG, PGE2 and MMP-3 release in the 
equine cartilage explant model at non-cytotoxic concentrations. 
2. Curcumin (25flM) significantly increased equine chondrocyte death in 
monolayer cultures after 5 days, but not in cartilage explants. 
3. This project was the first to test the effects of a novel plant extract cocktail on 
PGE2 and GAG release from the model. It was also the first to study the 
effects of the commercial joint health supplement, Cortaflex, in the explant 
model. 
4. High-throughput proteomic technology and quantitative western blotting 
enabled the first study of the equine cartilage secretome identifying and 
validating the most abundant proteins present in control, IL-I ~ ~ and NSAID 
treated explants. 
5. Finally, the results from the field trial were the first to suggest that Cortaflex 
does not produce a detectable clinical improvement in mobility, in a group of 
horses with chronic hindlimb stiffness. 
In conclusion, this thesis as a whole suggests that there is considerable potential in 
using in vitro models of equine cartilage to assess nutritional intervention to target 
inflammatory pathways and catabolic mediators to support equine joint health. 
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Appendix 1. 
Cartilage explant harvesting and model set up diagram 
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Appendix 2. 
Glycosaminoglycan (GAG) assay diagram 
Remove 
medium 
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Defrosted 
medium 
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cartilage & medium) 
Appendix 3. 
Prostaglandin E2 (PGE2) assay diagram (high sensitivity method) 
Read at 4S0nm 
sta 
defrosted medium, 
tracer & antibody 
Add stop solution 
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Add substrate solution 
Appendix 4. 
Representative histological images of samples used to show macroscopically intact 
cartilage, plate 1 
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Representative histological images of samples used to show macroscopically intact 
cartilage, plate 2 
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Appendix 5. 
Mean percentage of glycosaminoglycan (GAG) release from control explants from 
14 horses used in chapter 2 (66 values) 
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Appendix 6. 
Mean explant wet weights (mg) from 72 explants 
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Appendix 7. 
Solubilising the plant extract cocktail (PT) and commercial product (CP) in 
Dulbecco' s modified Eagle ' s medium (DMEM) and dimethyl sulfoxide (DMSO) 
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supernatant 
Appendix 8. 
Calculations for determining degree of di ssolution of materi als tested in Chapter 4 
PT in CP in PLin PTin CP in PLin 
DMEM DMEM DMEM DMSO DMSO DMSO 
End material weight 
(mg) 134 120.4 120.8 431 697.3 676 
Start material weight 
(mg) 200 200 200 1000 1000 1000 
Quantity in solution 
(mg) 66 79.6 79.2 569 302.7 324 
Fina l volume of solution 
(ml) 19.3 18.2 18 8.5 7.6 8.1 
Final concentration 
3.42 4.37 4.40 66.94 39.83 40.00 (mg/ml) 
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Appendix 9. 
Nati ve glycosaminoglycan (GAG) content of the ex tracts tested in chapter 4, 
including the plant cockta il (PT), the commercial product (C P) and placebo (PL) 
disso lved in either oulbecco's modi fied Eagle 's medium (OM EM) or dimelhyl 
sul fox ide (OM SO). Max imum concentrati on tes ted on exp lants in chapter 4 was 
400l-lg/ml. All samples were tes ted as run in the GAG assay. Values under I O ~ ~ g / m l l
or above 7 7 ~ ~ g / m l l are off the standard curve and are inaccurate. 
Sample 
Samples 
GAG (1-19) 
PT DMEM 4 0 0 ~ g g 0.0 
PT DMSO 4 0 0 ~ g g 11.4 
CP DMEM 4 0 0 ~ g g 1.0 
CP DMSO 4 0 0 ~ g g 0.0 
PL DMEM 4 0 0 ~ g g 0.0 
PL DMSO 4 0 0 ~ g g 0.0 
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Appendix 10. 
BLAST sequence data for the antibodies llsed in thi s thes is. Peptide sequences of the 
antibodies were checked using the NCBt Basic Loca l Alignment Search Tool 
(Protein BLAST; http ://blast.ncbi .nlm .nih. gov/Blast.cgi ?PAG E=Prolcins). 
Company + Uni Prot % sequence 
Antibody Catalogue Immunogen Antibody accession # for Equus cabal/us identity of Protein equine to # BLAST search human 
R&D Recombinant Sheep 075339 CILP Systems Predicted. CILP 100% 
AF4477 human CILP-l polyclonal 00724-1184 
, 
. '. ' ...... ' \ - , , < - - . . , ~ : , ,
.-'; ""' ":f .. , ~ " ~ . ~ ~ ~ ~ . ' ; p " ' : : r ~ ~ , , : , . : 1 " "
Peptide mapping Pl0909 
CLUS-o Santa Cruz at the C-terminus Goat ao 228-449 (0 Clusterin precursor 100% Sc-6419 of ciusterin-o of polycional subunit CLUS_HORSE 
human origin sequence) 
Predicted: retinal 
clusterin-ilke protein 75% 
CLUL lb 
W.' c' ' ' K \ i . " : , ~ ~ ; . , , , . . " . ; ~ ' , ~ ~ " " I· ... • ..... · ; ,.. .. 1\-"',:.,;., , .. ,'.; .... '!; ';"',,,"',, 
Synthetic peptide P03956 based on the 
ao 284-466 (the Interstitial 
MMP-l Abcam hemopexin Rabbit 4 hemopexin collagenase 100% Ab38929 domain of the polyclonal domain precursor human MMP-l 
sequences) MMPl - HORSE 
sequence 
.... ~ ~ , 
·1'" ,,' , ~ ~ .. I I H·':.·:' .. -:l: .. t'':;' •. : ; : r . ; : ; p ~ ~ ; . , ~ ; ~ : : .. ...;.4' .-,: •.• ; .. , .-'> , - ~ . . ,'N. ' . ' ~ ~ ~ ~ ~ : " " ' ~ ~ . ".,,-< , 
Abcam Recombinant full Goat P08254 Stromelysin- l MMP-3 Ab18898 length protein polyclonal (full sequence) precursor 100% MMP3 HORSE 
Interstllial 
collagenase 95% precursor 
MMPl HORSE 
Predicted: similar to 100% MMP1 2 
l · . ' · ~ , , · · : ~ ; · < ; c c •.• ~ , , I··"'Y(:·:", ..... ""' .. , . ~ ' ; " " · ' J . : ' · I I o V ~ ~ ~ : " ' - ' : ' - - _ " ' ~ ~ ~ ~ ~ ~ ,'-',-.., . " . . , ,
Abcam Reduced and Mouse P07996 Predicted: TSP alkylated form of Thrombospondin 1 99% Ab1823 human TSP-1 monoclonal (full sequence) TSP1 HORSE 
Thrombospond in 2 97% TSP2 HORSE 
Cartilage oligomeric 
matrix protein 53% 
COMP HORSE 
Predicted: similar 
Thrombospondin 3 54% 
TSP3 HORSE 
~ ~.. '/ "", .;. !; :'I'-l' " .... i,.,. , ~ , : ) ! ' ~ ; " ' : ~ ' ' ' ' ' ~ : ' ' ' ! . ..., . ":'':;'. -". ~ ~ 2.':. .. ~ ~
Santa Cruz Reduced and Mouse P07996 Predicted: TSP-l Sc-73158 alkylated form of monoclonal (fu ll sequence) Thrombospondin 1 99% human TSP-1 TSP1 HORSE 
Thrombospondin 2 97% TSP2 HORSE 
Cartilage oligomeric 
matrix protein 53% 
COMP HORSE 
Predicted: similar 
Thrombospondin 3 54% 
TSP3 HORSE 
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Appendix 11. 
Global overview of the mean percentage of glycosaminoglycan (GAG) release from 
cartilage explants incubated in culture medium alone (control), recombinant equine 
IL-I ~ ~ (I Onglml), or recombinant equine IL-J ~ ~ (J Onglml) + Carprofen, a nonsteroidal 
anti-inflammatory drug (NSAID; 100Jlg/ml). Data plots represent results from 
cartilage explants from multiple horses from mUltiple experiments. 
38 horses 22 horses 9 horses 
147 values 64 values 27 values 
Mean GAG ± SEM Mean GAG ± SEM Mean GAG ± SEM 
80- = 12.55 ± 0.40% = 47.47 ± 1.51% = 28.97 ± 1.81% 
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Appendix 12. 
Manufacturer's addresses 
Abeam pic 
330 Cambridge Science Park, 
Cambridge, 
Cambridgeshire 
CB40FL 
UK 
BD Bioseienees 
21 Between Towns Road 
Cowley 
Oxfordshire 
OX43LY 
UK 
Bio-Rad Laboratories 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire 
HP27DX 
UK 
Bruker Daltonies Inc 
40 Manning Road, 
Manning Park, 
Billerica, 
Massachusetts 
01821 
USA 
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Bruker UK Ltd 
Banner Lane, 
Coventry, 
CV49GH 
UK 
Dako UK Ltd 
Cambridge House, 
St Thomas Place, 
Ely, 
Cambridgeshire 
CB74EX 
UK 
Dionex UK Ltd 
4 Albany Court, 
Camberley, 
Surrey 
GU167QL 
UK 
Equine America UK 
7 Lawson Hunt Business Park, 
Broadbridge Heath, 
West Sussex 
RH123JR 
UK 
Fluka 
Fluka Chemie AG 
9471 Buchs 
SWITZERLAND 
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GE Healthcare 
Pollards Wood, 
Nightingales Lane, 
Chalfont St Giles, 
Buckinghamshire 
HP84SP 
UK 
GraphPad Software Inc 
2236 A venida de la Playa, 
La Jolla, 
California 
92037 
USA 
Heraeus-Christ 
Osterode 
GERMANY 
ImageJ 
U. S. National Institutes of Health, 
Bethesda, 
Maryland 
USA 
Invitrogen Ltd 
3 Fountain Drive, 
Inchinnan Business Park, 
Paisley, 
Renfrewshire 
PA49RF 
UK 
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Leica Microsystems UK Ltd 
Davy A venue, 
Knowlhill, 
Milton Keynes, 
Buckinghamshire 
MK58LB 
UK 
MARS Horsecare UK Ltd 
29 Old Wolverton Road, 
Milton Keynes, 
Buckinghamshire 
MKI25PZ 
UK 
National Diagnostics UK Ltd 
Unit 4, 
Fleet Business Park, 
Itlings Lane, 
Hessle, 
East Riding of Yorkshire 
HUI39LX 
UK 
Park Tonks Ltd 
48 North Road, 
Great Abington, 
Cambridge 
CB2I6AS 
UK 
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Pfizer 
Ramsgate Road, 
Sandwich, 
Kent 
CT139NJ 
UK 
Promega UK Ltd 
Delta House, 
Southampton Science Park, 
Southampton, 
Hampshire 
S0167NS 
UK 
R&D Systems Europe Ltd 
19 Barton Lane, 
Abingdon Science Park, 
Abingdon, 
Oxfordshire 
OX143NB 
UK 
Roche Diagnostics Ltd 
Charles A venue, 
Burgess Hill, 
West Sussex 
RH159RY 
UK 
Santa Cruz Biotechnology Inc 
Bergheimer Str. 89-2, 
69115 Heidelberg, 
GERMANY 
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Sigma-Aldrich Company Ltd 
The Old Brickyard, 
New Road, 
Gillingham, 
Dorset 
SP84XT 
UK 
Thermo Fisher Scientific UK Ltd 
Bishop Meadow Road, 
Loughborough, 
Leicestershire 
LE115RG 
UK 
Thermo LabSystems 
St. Georges Court, 
Hanover Business Park, 
Altrincham, 
Cheshire 
WA145TP 
UK 
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